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Abstract 
 
Topoisomerase II (TOP2) is an important anti-cancer drug target.  This 
study demonstrates that proteasomal inhibition by MG132 or PS341 
potentiates the effect of TOP2 poisons on cell growth inhibition.  
Mitoxantrone was potentiated the most.  The presence of the proteasome 
inhibitor MG132 prolonged the half-life of drug-induced DNA-TOP2 
complexes stabilised by mitoxantrone or etoposide.   
Genotoxicity was measured in K562 cells using in vitro micronucleus 
assays for combinations of a proteasome inhibitor (MG132 or PS341) and 
mitoxantrone and for each agent alone.  Combinations that potentiated 
the cytotoxicity reduced the genotoxicity.  This suggests that combining a 
proteasome inhibitor with a TOP2 drug has the potential to reduce late 
toxicities such as therapy related leukaemia.  
The genotoxicity of six TOP2 poisons was determined by high throughput 
in vitro micronucleus assays in three Nalm-6 cell lines with differing TOP2 
levels.  Lower genotoxicity was observed in TOP2B knock-out and TOP2A 
knock-down cells, suggesting both TOP2A and TOP2B have a role in 
genotoxicity triggered by TOP2 poisons.  
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Chapter 1. Introduction 
1.1 DNA topoisomerases  
DNA topoisomerases are enzymes that catalyse changes in DNA topology.  
They transiently break and re-join DNA as part of their reaction 
mechanism.  This involves a covalent intermediate in which the DNA is 
cleaved and covalently linked to the active site tyrosine within the 
topoisomerase (Figure 1.1).  There are two main classes of 
topoisomerases, type I and type II.  Type I enzymes cleave a single 
strand, and type II cleave both strands.  The reactions they catalyse 
include relaxation of DNA supercoils and decatenation of interlinked DNA 
molecules (Figure 1.2).  Biochemical studies have revealed key 
mechanistic details for type II topoisomerases (Figure 1.3).  The 
introduction of protein-bound DNA double strand breaks allows the 
passage of a second DNA helix through the enzyme.  Eukaryotic TOP2 is a 
dimer.  The monomers have three functional domains; an N-terminal 
ATPase domain, a middle “core” domain that houses the catalytic tyrosine 
residue, and a C-terminal domain that has many sites for post-
translational modifications such as phosphorylation.  The core domains for 
yeast TOP2, human TOP2A and human TOP2B have been crystallised and 
the structures solved (Berger et al., 1996; Wu et al., 2011; Wendorff et 
al., 2012).  The work in this thesis focuses on human type II DNA 
topoisomerases.  Vertebrate cells possess two isoforms of topoisomerase 
II, termed alpha (TOP2A) and beta (TOP2B).  TOP2A is essential for cells, 
required for segregation of chromosomes during cell division (Akimitsu et 
al., 2003).  Cells can survive without TOP2B but whole organisms cannot 
(Dereuddre et al., 1997; Yang et al., 2000).  Both isoforms are involved in 
gene regulation (Tiwari et al., 2012; Thakurela et al., 2013; Madabhushi 
et al., 2015). 
20 
 
 
Figure 1.1  DNA cleavage reaction of TOP2. 
TOP2 active site with tyrosine cleaves DNA at the 5’ position, resulting in a DNA double strand 
break with 5’-phosphotyrosyl linkage.   
 
 
Figure 1.2  Schematic of reactions catalysed by TOP2 including decatenation, un-knotting 
DNA and relaxation of supercoiled DNA.  
Adapted with permission from Pommier et al., 2010. 
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Figure 1.3  Catalytic cycle of TOP2. 
The catalytic cycle of TOP2 starts from the binding of the first duplex of DNA to TOP2 (1) and then 
with the binding of ATP and the second duplex of DNA. TOP2 changes to a closed clamp position 
(2).  In the presence of Mg2+, TOP2 breaks the first duplex of DNA and allows the second DNA 
duplex to pass through (3).  Once the second DNA duplex is released, TOP2 re-ligates the first DNA 
duplex (4 and 5).  TOP2 releases the first DNA duplex and returns to the open clamp position by 
ATP-hydrolysis (6).  Adapted with permission from Pommier et al., 2010. 
 
1.2 Drugs targeting human TOP2 
DNA topoisomerase II is an important anti-cancer drug target.  Several 
classes of drug target TOP2, including epipodophyllotoxins (etoposide and 
teniposide), anthracyclines (doxorubicin and epirubicin), anthracenediones 
(mitoxantrone) and acridines (mAMSA) (Figure 1.6).  These drugs can 
target both TOP2A and TOP2B.  TOP2 drugs can act in two ways; TOP2 
poisoning or catalytic inhibition.  Catalytic inhibition is defined as inhibiting 
the TOP2 catalytic cycle but not via the cleaved intermediate (Larsen et al., 
2003; Nitiss, 2009; Pommier et al., 2010).  TOP2 poisoning means 
stabilising the normally transient covalent TOP2-DNA complex whilst the 
DNA is cleaved (Wang, 2002; Pommier et al., 2010).  This results in a 
trapped TOP2 cleavage complex where the DNA has protein-linked strand 
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breaks.  Both types of targeting can kill cells (Wang, 2002).  TOP2 
targeting drugs have been implicated in the initiation of chromosome 
translocations that lead to treatment-related leukaemia (Rowley, 1998; 
Smith et al., 1999; Felix, 2001; Felix et al., 2006; Cowell et al., 2012) 
(Figure 1.4).   
 
Figure 1.4  Schematic of TOP2 reaction cycle and endpoints. 
 
To study the isoform specificity of drug targeting, an isoform-specific 
assay was previously developed here in Newcastle called the trapped in 
agarose DNA immunostaining (TARDIS) assay (Figure 1.7).  This is a 
microscopy-based assay in which TOP2 specific primary antibodies and a 
FITC-labelled secondary antibody are used to detect covalent TOP2-DNA 
complexes formed in cells in response to drugs (Willmore et al., 1998; 
Cowell et al., 2011).  The TARDIS assay can be used to study the rate of 
disappearance of drug-induced DNA-TOP2 complexes from cells (Willmore 
et al., 2004; Sunter et al., 2010) to determine the half-life of the 
complexes under different conditions.  Complexes decrease after removal 
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of the drug.  They can reverse via the normal re-ligation step of the TOP2 
reaction mechanism or they can be repaired by the cellular DNA repair 
machinery. This latter process is essential for “stalled complexes”.  In 
human cells, the main pathway to repair DNA double-strand breaks is 
Non-Homologous End joining (NHEJ).  This requires DNA-dependent 
protein kinase (DNA-PK).  However, activation of DNA-PK requires DNA 
breaks without bound protein (Martensson et al., 2003).  Therefore, TOP2 
must be removed before the double-strand break can be repaired by NHEJ.  
Protein removal is thought to occur by proteases in the proteasome (Lee 
et al., 2016).  This will leave a short peptide attached to the DNA, which 
can be removed by 5’-tyrosyl DNA phosphodiesterase, TDP2 (Cortes 
Ledesma et al., 2009; Zeng et al., 2011; Schellenberg et al., 2012; Gao et 
al., 2014a; Pommier et al., 2014).  Alternatively, the DNA end bearing the 
TOP2 may be cleaved by a nuclease such as MRE11, or an AP lyase 
activity such as KU or APE1 (Ayene et al., 2005; Roberts et al., 2010; Lee 
et al., 2012) (Figure 1.5).  
 
Figure 1.5  Schematic diagram representing possible mechanism(s) of TOP2 protein 
removal.  
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Figure 1.6  Chemical structure of TOP2 poisons. 
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Figure 1.7  Basis of TARDIS analysis. 
A) Schematic diagram of the steps involved in processing cells for TARDIS analysis: (1) cells are 
embedded in agarose on a glass slide; (2) after extraction with SDS and salt, most cellular 
components are removed but genomic DNA and covalent adducts remain; (3) adducts are detected 
by immunofluorescent staining using specific primary antibodies and FITC-labelled secondary 
antibody; (4) areas occupied by genomic DNA are identified by Hoechst fluorescence; (5) FITC 
fluorescence is quantified within the areas defined as containing DNA. (B) Representative images 
recorded for etoposide-treated K562 cells.  Immunofluorescence was carried out with anti-TOP2A 
and FITC-conjugated second antibody. (C) Scattergram representation of the TOP2A signal derived 
from etoposide-treated K562 cells.  Each filled circle represents the integrated fluorescence value 
of a single nucleus.  The horizontal lines represent the median values. This figure was adapted 
from Cowell et al., 2011 with permission.  
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1.3 Proteasome pathway and TOP2 
Proteasomes are important for protein degradation.  Proteins are unfolded 
prior to translocation into the multi-protein barrel shaped proteasome. 
Proteins can be targeted to the proteasome either in a ubiquitin-
dependent or a ubiquitin-independent manner.  The ubiquitin-dependent 
pathway starts with an E1 enzyme to activate ubiquitin and transfer the 
activated ubiquitin to an E2 ubiquitin conjugation enzyme.  The E2 and 
target protein are bound to an E3 ubiquitin ligase and the activated 
ubiquitin is transferred to the target.  This step can be repeated forming 
poly-ubiquitin chain.  Once a ubiquitin chain is formed on the target 
protein it can be targeted to the proteasome.  The proteasome will be 
triggered to degrade the target protein (Ciechanover, 2005; Nalepa et al., 
2006; Goldberg, 2007) (Figure 1.8).   
 
 
Figure 1.8  Ubiquitin-proteasome degradation pathway 
Ubiquitin activated by E1-ubiqutin activation enzyme.  Activated ubiquitin transfers to E2 
conjugation enzyme.  E3 ligase binds to target protein and E2 then E2 labels target protein with 
activated ubiquitin.  This step will be repeated until a poly ubiquitin chain has formed and then the 
proteasome may degrade the target protein.  Adapted with permission from Ciechanover, 2005. 
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Proteasomal degradation is involved in regulating cellular TOP2 levels 
(Salmena et al., 2001).  Also E3 ubiquitin ligases such as BRCA1, FBW7, 
MDM2, BMI1/RING1A and ECV, have been reported to be associated with 
TOP2A (Nayak et al., 2007; Shinagawa et al., 2008; Alchanati et al., 2009; 
Yun et al., 2009; Chen et al., 2011).     
TOP2 poisons appear to alter TOP2 protein levels in a proteasome-
dependent manner (Mao et al., 2001; Xiao and Goodrich, 2005; Zhang et 
al., 2006; Nayak et al., 2007; Alchanati et al., 2009).  To determine if 
proteasomal inhibition can potentiate the effect of TOP2 poisons, cells 
were treated with TOP2 poison alone or in combination with a proteasome 
inhibitor (Figure 1.8 and Figure 1.9).  The effect of proteasome inhibition 
on growth inhibition was determined using an XTT growth inhibition assay 
and by RICC determination.   
Two E3 ligases, Bmi1/Ring1A and HDM2, have been implicated in TOP2A 
degradation after exposure to TOP2 poison (Nayak et al., 2007; Kitagaki 
et al., 2008; Alchanati et al., 2009; Conradt et al., 2013).  To determine 
whether E3 ubiquitin ligase inhibition can potentiate the effect of TOP2 
poisons in cells, two E3 ligase inhibitors of these E3 ligases, PRT4165 and 
HLI373 respectively, were used in combination with TOP2 poisons to study 
potentiation using an XTT growth inhibition assay (Figure 1.8 and Figure 
1.9).  
Proteasomal inhibition and E3 ligases inhibition potentiated the growth 
inhibition of TOP2 poisons.  The biggest effect was seen with mitoxantrone. 
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Figure 1.9  Chemical structure of proteasome inhibitors and E3 ligase inhibitors. 
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1.4 Genotoxicity of TOP2 poisons 
TOP2 poisons are useful anti-cancer drugs.  Their adverse effects include 
the development of secondary malignancies, such as therapy-related 
acute myeloid leukaemia (t-AML) (Felix, 1998; Felix, 2001).  t-AML is 
thought to be caused by chromosome translocations, including those with 
the mixed lineage leukaemia (MLL) gene (Rowley and Olney, 2002).  
TOP2B is implicated in the generation of therapy-related malignancies, for 
example, etoposide (VP16) induced fewer melanomas in a skin-specific 
TOP2B knock-out mice than in the wild type mice (Azarova et al., 2007).  
The absence of TOP2B reduces the levels of VP16-mediated chromosome 
breaks in the MLL gene (Cowell et al., 2012).  In this study, three Nalm-6 
cells line with different levels of TOP2 (wild type, TOP2B knock-out and 
TOP2A knock-down) have been used to determine the role of TOP2 
isoforms in growth inhibition, cytotoxicity and genotoxicity after treatment 
with different TOP2 poisons.  Genotoxicity was determined using the in 
vitro micronucleus assay (Fenech, 2000; Fenech et al., 2011).  The effect 
of proteasome inhibitors on TOP2 poison induced genotoxicity was also 
determined in K562 cells using in vitro micronucleus assays. 
1.5 Aims 
TOP2 poisons are widely used in the treatment of cancers.  These drugs 
are cytotoxic agents that act by stabilising TOP2-DNA complexes.  The 
number of complexes and the longevity of these complexes vary 
depending on which drug is used.  The number of stabilised complexes 
depends upon the rate of formation and the rate of removal of the 
stabilised complexes.  The removal of the stabilised complexes is 
mediated by a range of processes, including reversal when drug is 
removed or repair via one of several pathways.  Repair can be mediated 
by nucleases such as MRE11 (Lee, 2012; Lee et al., 2012) or proteasomal 
degradation removing the drug-induced stabilised TOP2-DNA complexes.  
The role of the proteasome in processing of stabilised TOP2-DNA 
complexes is investigated and reported in this thesis.  TOP2 poison 
induced DNA damage can lead to genotoxicity such as the formation of 
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micronuclei.  There are two human TOP2 isoforms, TOP2A and TOP2B and 
it is possible they contribute differently to the formation of genotoxicity. 
 
 To investigate the effect of proteasome inhibition on TOP2 poison-
induced growth inhibition (Chapter 3). 
 To study the genotoxic effects between mitoxantrone (MTX) alone 
and in combination with a proteasome inhibitor (Chapter 4). 
 To determine the effect of E3 ligase inhibition on TOP2 poison-
induced growth inhibition (Chapter 5). 
 To study the role of TOP2 isoforms in TOP2 poison-induced 
genotoxicity (Chapter 6). 
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Chapter 2. Materials and Methods  
2.1 Chemicals and Reagents 
In this study, chemicals were obtained from Sigma-Aldrich (Gillingham, 
Dorset, UK) unless otherwise stated.  Cell culture reagents were obtained 
from Invitrogen (Paisley, UK) unless otherwise stated.   
2.2 Sterilisation 
Glass and plastic-ware were autoclaved for 15 minutes at 134 °C for 
sterilisation.  Solutions were autoclaved for two hours at 121 °C.  
Solutions were prepared using de-ionised water unless otherwise stated. 
2.3 Cell lines 
Four suspension human cell lines were used in this study; these were 
K562, Nalm-6 WT, Nalm-6TOP2B-/- and Nalm-6TOP2A+/-. 
The K562 cell line was derived from a patient with chronic myelogenous 
leukaemia (CML) in terminal blast phase and its metabolism is therefore 
similar to that of acute myeloid leukaemia (AML) blasts.  K562 is an 
undifferentiated blast cell with a diameter of about 20 µm (Koeffler and 
Golde, 1980).  The cell has a basophilic cytoplasm containing no granules 
and two or more prominent nucleoli.  The K562 cells have an average 
doubling time of 24 hours.   
Nalm-6 is a human pre-B cell line, and Nalm-6TOP2A+/- and Nalm-6TOP2B-/- 
are derivatives of Nalm-6 (Toyoda et al., 2008).  The Nalm-6 cell lines 
have an average doubling time of 24 hours.   
These cell lines were maintained in Roswell Park Memorial Institute (RPMI) 
1640 medium containing 10% (v/v) heat-inactivated foetal bovine serum 
(FBS), 50 U/ml of penicillin and 50 U/ml of streptomycin at 37 °C.  Cells 
were sub-cultured approximately every 2 days and disposed of after 20 
passages.   
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Liquid nitrogen stocks and defrosting cells 
Exponentially growing cells were harvested and centrifuged for 3 minutes 
at 500 RCF.  The supernatant was removed and the cell pellet was re-
suspended with complete media with 10% DMSO.  Re-suspended cells 
were in aliquots kept at -80 °C for 24 to 48 hours.  Finally, the cell stocks 
were stored in liquid nitrogen.  Cells stocks stored in liquid nitrogen 
remain viable for several years.    
To defrost cells, cell stocks were warmed in a water bath at 37 °C and 
mixed with 5 ml of media.  Cells were centrifuged for 3 minutes at 500 
RCF.  After centrifugation, the medium was removed and the cell pellet 
was re-suspended in 10 ml of fresh medium.  Centrifugation and re-
suspension was then repeated.  The re-suspended cells were pipetted into 
a 25 cm2 tissue culture flask (Greiner BioOne, Stonehouse, UK) and 
returned to the incubator.  Defrosted cells were sub-cultured on the 
following day.   
Sub-culturing Cells 
Cells were sub-cultured when 70-90% confluent and transferred to 75 cm2 
or 175 cm2 tissue culture flasks (Greiner BioOne, Stonehouse, UK).  The 
cell number was determined and the culture diluted to 5 x104 cells/ml.  
Cells were incubated in a humid air atmosphere containing 5% CO2.  
During sub-culture, cells were maintained between 5 x 104 to 1 x 106 
cells/ml.   
Determination of cell density 
Cell densities were determined using a TC20 automated cell counter (Bio-
Rad, USA).  Ten microlitres of cell culture were transferred to a cell 
counting slide (Bio-Rad, USA) and inserted into the cell counter.   
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2.4 XTT growth inhibition assay 
Exponentially growing cells were seeded into 96-well plates for 24 hours, 
and then drug(s) were added and incubated for 120 hours.  The growth 
inhibition effects were quantified by using a sodium 3’-[1-
(phenoaminacarbonyl)-3,4,-tetrazolium] bis(4-methoxy-6-nitro)benzene 
sulfonic acid hydrate (XTT) cell proliferation kit (Roche, Lewes, United 
Kingdom).  Fifty microlitres of XTT reagent (50:1 XTT reagent to electron 
coupling reagent, XTT Cell Proliferation kit, Roche, UK) were added per 
well and cells were incubated for a further 4 hours at 37 °C. 
Plates were read on a Bio-Rad iMARK plate reader (Hercules, CA) at 
wavelength 450 nm, and the OD450nm data was analysed using GraphPad 
Prism software version 4.03 (GraphPad Software, USA). 
The OD450nm values of TOP2 poison alone were normalised to 0 nM TOP2 
poison as 100%.  The OD450nm values of TOP2 poison in combination with 
proteasome inhibitor or E3 ligase inhibitor were normalised to 0 nM TOP2 
poison control in the presence of proteasome inhibitor or E3 ligase 
inhibitor as 100%.  The values of media alone were set as 0%.  The 
normalisation method used in this study is the same as Willmore et al., 
2004 (Willmore et al., 2004). 
The 50% inhibitory concentrations (IC50) of TOP2 poison alone and the 
combination were determined using GraphPad Prism.  The effect of the 
combination on TOP2 poison was determined by potentiation factor (Pf50), 
calculated using the below equation. 
𝐼𝐶50𝑜𝑓 𝑇𝑂𝑃2 𝑝𝑜𝑖𝑠𝑜𝑛 𝑎𝑙𝑜𝑛𝑒
𝐼𝐶50𝑜𝑓 𝑡ℎ𝑒 𝑐𝑜𝑚𝑏𝑖𝑛𝑎𝑡𝑖𝑜𝑛 
 
A Pf50 value greater than one means that the combination has potentiated 
the TOP2 poison.  For example, if the Pf50 is two, this means that the 
combination requires half of the concentration of TOP2 poison to inhibit 
cell growth by 50%.  The mean of Pf50 values in the results chapters 
represents the mean of at least three individual Pf50 values. 
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2.5 TARDIS assay—reversal of drug-stabilised TOP2-DNA 
complexes 
Seeding and treating cells 
Exponentially growing K562 cells were seeded at approximately 1 x 105 
cells/ml in 6-well plates for 24 hours, followed by two hours of drug 
treatment.  Cells were centrifuged at 500 RCF for three minutes.  Cell 
pellets were washed with ice-cold phosphate-buffer saline (PBS) and 
centrifuged at 500 RCF for three minutes.  The supernatant was removed 
and replaced with fresh drug-free media, then placed back in the 
incubator.  Samples were collected at different time points after fresh 
drug-free medium was added. 
The collected samples were centrifuged and washed with PBS, then re-
suspended in 50 µl of PBS.  Fifty microlitres of a 2% agarose solution was 
added to the 50 µl PBS cell mixture. 
Embedding slides and cell lysis stage 
Microscopy slides were coated with 0.5% melted agarose (Lonza, USA) 
and allowed to air dry.  The cell cultures mentioned above were mixed 
with 50 µl of a 2% agarose solution and evenly spread on the 0.5% 
agarose.  The slides with cells embedded in agarose were placed on an 
ice-cold surface to set.  Slides were incubated in lysis buffer containing 
80mM potassium phosphate pH 6.5, 1% SDS, 10mM 
ethylenediaminetetraacetic acid (EDTA) and protease inhibitors (1 mM 
benzamidine, 1 mM phenylmethanesulphonylfluoride, 2 ng/ml leupeptin 
and 2 ng/ml pepstatin) for 30 minutes.  After lysis the slides were 
incubated with 1 M sodium chloride (NaCl) with PIs for 30 minutes then 
washed 3 times (30 seconds, 2 x 5 minutes) with PBS containing PIs.   
Immunofluorescent visualisation  
The slides were incubated with an appropriate primary antibody at a 
suitable dilution in 1% BSA-PBS-T [1% (w/v) bovine serum albumin (BSA), 
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PBS and 0.1% (v/v) Tween] for 1.5 hours.   The slides were then washed 
3 times (30 seconds, 2 x 5 minutes) with PBS including PIs and 0.1% v/v 
Tween.  An appropriate secondary antibody, Alexa Fluor® 488 (Life 
technologies, USA) at a suitable dilution in 1% BSA-PBS-T, was incubated 
with the slides in the dark for 90 minutes,  then washed twice (30 seconds 
and 5 minutes) with PBS including PIs and 0.1% v/v Tween, and for a 
further 30 minutes with PBS.  From this point, slides were light sensitive, 
so were stored in the dark and exposure to visible light was minimised. 
Slides were stained with 2 µg/ml Hoechst 33258 (Life technologies, USA) 
in PBS (1:5000) for 5 minutes.  After draining off any surplus Hoechst 
solution, slides were mounted with mounting media Vectashield (without 
DAPI) (Vector laboratories, CA). 
Slides were stored at 4 °C until visualised by microscopy.  Microscopy was 
done within 2 days. 
Microscopy and analysis 
An Olympus IX81 microscope system was used with a Hamamatsu Orca-
AG camera.  Captured microscope images were analysed using Volocity 
6.4 software (Perkin Elmer, Massachusetts, USA).  Statistical analysis was 
carried out using GraphPad Prism software (GraphPad Software, USA).  
The mean integrated fluorescence signal for cells incubated with 100 µM 
VP16 was used as a positive control in each experiment.  
Immunofluorescence levels varied between experiments, so data was 
normalised to enable comparison between experiments. 
The mean integrated fluorescence of the positive control was set as 100% 
and the integrated fluorescence signal from individual cells was 
normalised to it.  The mean of normalised means with standard error from 
at least three individual experiments was plotted unless otherwise stated.   
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2.6 In vitro micronucleus assay—microscopy 
Cells were treated for a designated length of time and the cell density for 
each culture was determined by using a TC20 automated cell counter 
(Bio-Rad, USA).   Relative increase of cell count (RICC) was calculated 
using the equation below:   
𝑅𝐼𝐶𝐶 =
(𝐼𝑛𝑐𝑟𝑒𝑎𝑠𝑒 𝑖𝑛 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑢𝑙𝑡𝑢𝑟𝑒𝑠(𝑓𝑖𝑛𝑖𝑠ℎ − 𝑠𝑡𝑎𝑟𝑡𝑖𝑛𝑔))
(𝐼𝑛𝑐𝑟𝑒𝑎𝑠𝑒 𝑖𝑛 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝑓𝑖𝑛𝑖𝑠ℎ − 𝑠𝑡𝑎𝑟𝑡𝑖𝑛𝑔))
× 100 
After cell counting, a volume containing 5 x 105 cells was transferred to a 
fresh 15 ml centrifuge tube.  Cells were centrifuged at 300 x g for 5 
minutes and supernatants were aspirated.  Three hundred microlitres of 
PBS containing 2 µg/ml ethidium monoazide bromide (EMA) was added 
and the pellet was re-suspended.  Samples were exposed to a cool white 
fluorescent light source for 30 minutes on ice to allow photoactivation of 
EMA.  As the samples were light sensitive, exposure to visible light was 
kept to a minimum.  The samples were centrifuged at 300 x g for 5 
minutes and the supernatant was removed.  2.5 ml media containing 10% 
pluronic solution (Sigma) was added to the samples.  Samples were (100 
µl) spread across a PolysineTM slide (VWR, UK).  Slides were left to air dry 
in the dark. 
Slides were fixed with 100% methanol for 10 minutes then stained with 2 
µg/ml Hoechst 33258 (Life Technologies, USA) in PBS (1:5000) for 5 
minutes.  After draining off any surplus Hoechst dye, slides were mounted 
with Vectashield mounting media (without DAPI) (Vector Laboratories, CA).  
Mounted slides were examined and images were taken using an Olympus 
IX81 microscope system (10x objective) with a Hamamatsu Orca-AG 
camera within 3 days of mounting.  Volocity 6.4 software (Perkin Elmer, 
USA) was used to analyse the microscopy images. 
Microscopy slide scoring  
At least 2000 cells were counted per slide.  Nuclei stained with EMA (red) 
and Hoechst dye (blue) were excluded.  The number of nuclei and 
micronucleated cells were recorded.  
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Criteria for defining micronucleated cells: 
1. The size of a micronucleus should be between 1/16th  and 1/3rd of 
diameter of the main nucleus (Figure 2.1A). 
2. The micronucleus must not be connected to the main nucleus. 
3. The micronucleus/micronuclei may touch but not overlap with the 
main nucleus.  The boundaries should be distinguishable (Figure 
2.1B). 
4. Micronuclei are non-refractile to distinguish them from staining 
artefacts. 
5. The intensity of micronuclei should be the same as the main nucleus 
but occasionally may be more intense.    (Fenech, 2000) 
 
Figure 2.1  Micronucleus scoring. 
(A) A micronucleated cell meeting all the criteria mentioned above. (B) Cell with micronucleus 
touching but not overlapping with the main nucleus. (C) Micronucleus overlapped with the main 
nucleus (this is not classed as a micronucleus).   
 
Average percentage of micronuclei and the fold-increase of micronuclei 
were calculated using the equations shown below: 
Average percentage of micronuclei  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑚𝑖𝑐𝑟𝑜𝑛𝑢𝑐𝑙𝑒𝑖
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
× 100 
 
Fold increase of micronuclei: 
𝐷𝑟𝑢𝑔 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 (𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑚𝑖𝑐𝑟𝑜𝑛𝑢𝑐𝑙𝑒𝑖 %)
𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑚𝑖𝑐𝑟𝑜𝑛𝑢𝑐𝑙𝑒𝑖 %)
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2.7 In vitro micronucleus assay—Flow cytometry 
Exponentially growing cells were seeded at 5 x 104 cells/ml (K562) or 1 x 
105 cells/ml (Nalm-6) for 24 hours prior to drug treatment.   After 
treatment, Relative Increase of Cell Count (RICC) was calculated using an 
automatic cell counter (Bio-Rad, USA).  The flow cytometry method was 
carried out following the “basic” or “high content protocol 1” for 
suspension cells from the instruction manual of the in vitro MicroFlow kit 
(Litron laboratories, USA).  
A consistent volume of cells from each sample was transferred to 15 ml 
centrifuge tubes separately.  The volume used was equivalent to 1 x 106 
cells of the negative control cultures.  The samples were centrifuged at 
300 x g for 5 minutes.  The supernatant was removed carefully by 
aspiration without disturbing the pellet and samples were placed on ice for 
20 minutes.  Three hundred microlitres of nucleic acid dye A working 
solution, containing 1% ethidium monoazide bromide (EMA) and 2% FBS, 
was added to each sample tube.  The samples were exposed to a cool 
white fluorescent light source for 30 minutes on ice, to allow 
photoactivation of EMA.  As the samples were light sensitive, exposure to 
visible light was kept to a minimum.  For the high content protocol, green 
fluorescent beads (Life Technologies, USA) were added to ice-cold 1x 
buffer solution (approximately 1 drop of bead suspension per 10ml).  
Three millilitres of the above solution was added to the samples followed 
by centrifugation at 300 x g for 5 minutes and removal of the supernatant.      
Five hundred microlitres of Complete Lysis Solution 1, containing 0.4% 
nucleic acid dye B (SYTOX green) and 0.5% RNase solution, was added to 
the samples and vortexed on low speed for 5 seconds.  The samples were 
incubated in the dark for an hour at room temperature.  Five hundred 
microlitres of Complete Lysis Solution 2, including 0.4% SYTOX green, 
was added to the samples and then vortexed immediately and incubated 
at room temperature for 30 minutes in dark.  At this stage, the samples 
were stored at 4 °C ready for flow cytometric analysis within 72 hours.   
39 
 
Before analysis, the samples were retrieved from the refrigerator to allow 
them to equilibrate to room temperature.  
Data acquisition was carried out using a BD fluorescence-activated cell 
sorting (FACS) CantoTM II cytometer (BD Biosciences, New Jersey, USA) 
and analysed with BD FACSDiva v8.0 software (BD Biosciences, New 
Jersey, USA).  The samples were excited with a 488 nm laser.  EMA and 
SYTOX Green fluorescence was collected using 585/42 and 530/30 filters 
of the flow cytometer, respectively. 
The positive methyl methanesulfonate (MMS) and negative (DMSO and 
H2O) control samples were used to set up and confirm the parameter 
settings and gating of the system.  The stopping gate was set as 30,000 
nuclei counted.  For each sample, 30,000 nuclei events were counted and 
the number of micronuclei, counting beads and EMA positive events were 
recorded.  The ratio of Nuclei-to-Counting Beads was calculated to 
determine relative survival.  
Data was analysed and presented as relative survival, average percentage 
of micronuclei, fold increase of micronuclei and fold increase of EMA 
events.  The following equations were used.  
 
Relative survival: 
𝑅𝑎𝑡𝑖𝑜 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
𝑅𝑎𝑡𝑖𝑜 𝑜𝑓 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
× 100 
Average percentage of micronuclei: 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑛𝑐𝑢𝑙𝑒𝑖 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 ℎ𝑒𝑎𝑙𝑡ℎ𝑦 𝑛𝑢𝑐𝑙𝑒𝑖 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
× 100 
Fold increase of micronuclei: 
𝐷𝑟𝑢𝑔 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 (𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑚𝑖𝑐𝑟𝑜𝑛𝑢𝑐𝑙𝑒𝑖 %)
𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑚𝑖𝑐𝑟𝑜𝑛𝑢𝑐𝑙𝑒𝑖 %)
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Fold increase of EMA events: 
𝐷𝑟𝑢𝑔 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 (
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐸𝑀𝐴 𝑒𝑣𝑒𝑛𝑡𝑠
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑢𝑐𝑙𝑒𝑖 )
𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐸𝑀𝐴 𝑒𝑣𝑒𝑛𝑡𝑠
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑢𝑐𝑙𝑒𝑖 )
 
DNA content of nuclei provides cell cycle distribution information.  The 
data was plotted as frequency against DNA content histograms and 
analysed by FlowJo v8.1 software (FlowJo, Oregon, USA).    
If the dose or treatment of a sample caused a relative survival lower than 
40%, it was classed as a cytotoxic dose. 
If a sample had more than a two-fold increase in the frequency of the 
micronuclei above the negative control, and the difference was statistically 
significant, it was classed as a genotoxic response.   
MMS was included as a positive control in every experiment.  This positive 
control should induce micronuclei more than two-fold compared to the 
micronuclei of negative control.  If not, the results should be excluded.  
The instruction manual from Litron Laboratories was utilised to determine 
the flow cytometry gating parameters in addition to the micronuclei 
scoring criteria.  An example of the gating and identification of micronuclei 
is shown on figure 2.2 and figure 2.3.  
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Chapter 3. Proteasomal inhibition potentiates growth 
inhibition by TOP2 targeting drugs 
3.1 Introduction 
Topoisomerase II (TOP2) is an important cellular enzyme during 
replication, transcription, chromosome condensation and segregation.  
The catalytic cycle of TOP2 involves cleaving and re-ligating double 
stranded DNA.  A group of chemotherapy agents called “TOP2 poisons” 
target this cycle to stabilise TOP2 while it is covalently bound to the DNA 
double strand break (DSB).  This stabilised cleavable complex is the 
primary damage within the cell.  Repair of this damage may lead to 
genotoxicity, resulting in secondary cancer (Cowell et al., 2012). 
The stabilised TOP2 needs to be removed before DNA double-strand break 
(DSB) repair can occur by NHEJ.  DSBs with stabilised TOP2 do not 
activate DNA-PK in vitro (Martensson et al., 2003) and a number of lines 
of evidence suggest cellular processing is required to remove stabilised 
TOP2 prior to triggering a DNA damage response.   
A number of potential mechanisms exist to remove stabilised TOP2 
complexes.  One mechanism involves a multi-step process that starts with 
proteasome degradation to break down the poisoned TOP2, leaving a 
peptide fragment on the 5’ end of the DNA double strand break.  Then 
TDP2 removes the 5’- adduct to allow the DSB to be repaired (Cortes 
Ledesma et al., 2009; Zeng et al., 2011; Gao et al., 2012; Schellenberg et 
al., 2012; Shi et al., 2012; Gao et al., 2014a; Gao et al., 2014b; Pommier 
et al., 2014).   
To address the question of whether proteasomal inhibition increase 
(potentiates) the growth inhibition of TOP2 poisons, the XTT assay was 
used.  The XTT assay is a growth inhibition assay widely used in drug 
testing.  Sodium 3’-[1-(phenoaminacarbonyl)-3,4,-tetrazolium] bis(4-
methoxy-6-nitro)benzene sulfonic acid hydrate (XTT) is a yellow 
tetrazolium salt.  This is cleaved by metabolically active cells to form an 
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orange formazan dye.  Importantly, the formazan dye formed is soluble in 
aqueous solutions. The intensity of this dye can be measured by a 
microplate reader and the optical density indirectly represents the number 
of viable cells.  
In order to determine whether proteasomal inhibition alters the kinetics of 
formation and removal of covalent TOP2-DNA complexes, the Trapped in 
Agarose DNA immunostaining (TARDIS) assay was used to measure the 
removal rate of drug-induced DNA-TOP2 complexes in K562 cells with or 
without MG132 proteasome inhibitor.  
3.2 Growth curve of K562 cells (XTT assay to determine optimal 
cell density for potentiation experiments) 
The K562 cell line was used to study the effect of proteasome inhibitors on 
the growth inhibitory effects of TOP2 poisons.  Cell growth and growth 
inhibition of K562 cells were determined by XTT assay.   
To determine an optimal cell density for the potentiation study, K562 cells 
were seeded at a range of cell densities in 96-well plates and incubated 
for up to 144 hours (6 days).  96-well plates were stained and read every 
24 hours after seeding.  After seeding, K562 cells grew exponentially from 
one to five days.  As shown in figure 3.1, cells seeded at approximately 2 
x 103 cells per well demonstrated exponential growth over days 1-5 with 
the absorbance remaining fairly constant at day 6 (144 hours).  A cell 
density of 2 x 103 cells per well was used in all XTT potentiation studies 
including 120 hours incubation for the K562 cell line.  
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Figure 3.1  Growth curve of K562 cell line.   
K562 cells were seeded at approximately 0, 0.75, 1, 2, 3, 4 and 5 x103 cells/well in 96-well plates.  
Plates were stained with XTT and the OD450nm was determined every 24 hours after seeding up to 6 
days (144 hours).   
 
3.3 Proteasome inhibition and the effect of MTX on K562 cell line 
Proteasome inhibitor MG132 effects on growth inhibition 
MG132 is a low molecular weight proteasome inhibitor.  It can enter cells 
and selectively inhibit protein degradation (Lee and Goldberg, 1998).   
MG132 dose-response for growth inhibition in K562 cells was determined 
by XTT assay.  K562 cells were seeded for 24 hours followed by 120 hour 
exposure to a range of concentrations of MG132 (0 -200 nM).  Absorbance 
of non-treated cells was set as 100% and all the readings were normalised 
to it. 
Willmore et al. demonstrated that a low level of DNA-PK inhibitor 
potentiates the cytotoxicity of TOP2 poisons (20% growth inhibition) 
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(Willmore et al., 2004).  Based on the above experimental setup, the 
results showed that 95 nM MG132 inhibited cell growth by 20% (figure 
3.2).  This concentration was used in combination with TOP2 poisons to 
study potentiation. 
Proteasomal inhibition potentiates MTX 
Mitoxantrone (MTX) is an anthracenedione TOP2 poison which is 
commonly used to treat breast cancer, prostate cancer, lymphoma and 
leukaemia.  K562 cells were seeded at 2 x 103 cells per well in 96-well 
plates for 24 hours, then treated with a range of concentrations of MTX 
alone or in the presence of a fixed concentration of 95 nM MG132 for 120 
hours.  After drug treatment, growth inhibition was detected by XTT assay.  
The OD450nm values of MTX alone were normalised to 0 nM MTX as 100%, 
and OD450nm values of MTX in combination with MG132 were normalised to 
0 nM MTX control in the presence of 95 nM MG132 as 100%. 
IC50 refers to the dose which exhibited 50% growth inhibition.  The 
difference between the IC50 of MTX alone and the IC50 in the presence of 
MG132 was determined by unpaired t-test.  The potentiation of MTX by 
MG132 was presented as potentiation factors (Pf50).  It was calculated 
using the IC50 value of MTX alone over the IC50 value of MTX in 
combination with MG132.    
Figure 3.3 shows K562 cell growth inhibition by MTX.  When combined 
with MG132 cell growth inhibition was increased.  The potentiation factor 
(Pf50) of MTX and MG132 was 4.58 (Table 3.1).  The IC50 of MTX alone and 
in the presence of MG132 was statistically significant (p≤0.0001).  This 
suggests inhibition of the proteasome potentiates the growth inhibition 
effects of MTX. 
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Figure 3.2  Growth inhibition curve of proteasome inhibitor MG132 in K562 cells. 
K562 cells were seeded at approximately 2x103 cells/well in 96-well plates for 24 hours prior to 
MG132 drug treatment.  After 120 hours of drug exposure, cells were stained with XTT and OD450nm 
was quantified.  Results are means of four experiments ± standard error of the mean.  
 
Figure 3.3  Potentiation of MTX by MG132 in K562 cells. 
Cells were treated with increasing concentrations of MTX alone or in combination with 95 nM 
MG132 for 5 days followed by XTT staining.  Dose–response curves were used to estimate the IC50 
of MTX alone or in combination with MG132.  Error bars represent the mean ± SEM of at least 3 
separate experiments for both + and - MG132 conditions. Values were normalised to the 0 nM MTX 
value (100%). 
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Proteasome inhibitor PS341 (bortezomib, Velcade) effects on 
growth inhibition 
PS341 (bortezomib, Velcade) is a proteasome inhibitor used successfully 
in the treatment for multiple myeloma.  The dose response curve of PS341 
in K562 cells was determined by XTT assay.  K562 cells were seeded at 2 
x 103 cells per well for 24 hours prior to the exposure to a range of 
concentrations of PS341.  The absorbance of untreated cells was set as 
100% and all the readings were normalised to it.  
The dose demonstrating 20% growth inhibition was 5.2 nM and this dose 
was used in the potentiation assay (Figure 3.4). 
PS341 potentiates the growth inhibitory effects of MTX 
K562 cells were treated with MTX alone or in the presence of 5.2 nM 
PS341.  After 120 hours of incubation, XTT assays were used to determine 
growth inhibition.  The OD450nm values were normalised as described for 
the combination with MG132.  Potentiation was presented as Pf50 and 
statistical significance determined by unpaired t-test.  The presence of 5.2 
nM PS341 significantly potentiated MTX (Pf50=2.95) (Figure 3.5 and Table 
3.1).  The results show the proteasome inhibitor currently used in 
treatment can potentiate the growth inhibitory effect of MTX.   
 
Mitoxantrone + Mean of Pf50 SEM p-value 
MG132 4.58 0.54 <0.0001 
PS341 2.95 0.11 0.002 
Table 3.1  Potentiation factor (Pf50) summary of mitoxantrone (MTX) in combination with 
proteasome inhibitors.   
Statistical significance between IC50 values of MTX alone and in combination with proteasome 
inhibitors by unpaired t-test (p-value).    
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Figure 3.4  Growth inhibition curve of proteasome inhibitor PS341 in K562 cells. 
K562 cells were seeded at approximately 2x103 cells/well in 96-well plate for 24 hours prior to 
PS341 drug treatment.  After 120 hours of drug exposure, cells were stained with XTT and OD450nm 
was quantified.  Results are means of four experiments ± standard error of the mean.  
 
 
Figure 3.5  Potentiation of MTX by PS341 in K562 cells. 
Cells were treated with increasing concentrations of MTX alone or in combination with 5.2 nM 
PS341 for 5 days followed by XTT staining.  Dose–response curves were used to estimate the IC50 of 
MTX alone or in combination with PS341.  Error bars represent the mean ± SEM of at least 3 
separate experiments for both + and – PS341 conditions, values were normalised to the 0 nM MTX 
value (100%). 
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Investigating the effect of proteasome inhibition on the stability of 
MTX-induced TOP2-DNA complexes 
MTX is a TOP2 poison.  It stabilises TOP2-DNA complexes formed with 
both TOP2 isoforms in the cell.  Drug-stabilised TOP2 complexes are 
reversible upon removal of the TOP2 poison as seen in TARDIS reversal 
assays (Errington et al., 2004).  The rate of reversal differs, depending on 
the drug used.   
The effect of proteasome inhibition on MTX-induced TOP2 complex 
stability was determined using the Trapped in Agarose DNA 
immunostaining (TARDIS) assay, which involves embedding cells in 
agarose on microscopy slides followed by sodium dodecyl sulphate (SDS) 
and salt extraction to remove cellular components.  Immunofluorescent 
staining with a specific primary antibody and FITC labelled secondary 
antibody is then used to detect covalent DNA-TOP2 adducts on the 
genomic DNA on the slide.  FITC fluorescence of TOP2 complexes is then 
quantified and represents the TOP2 complex levels in individual cells 
(Cowell et al., 2011).   
K562 cells were seeded at approximately 1 x 105 cells per ml for 24 hours, 
followed by a 2 hour exposure to either 5 µM MTX alone or in combination 
with 50 µM MG132.  Cells were then washed and placed in fresh media.  
For both the MG132-treated control and the combination cells, 50 µM 
MG132 was added back into the media.  Cells were reincubated and 
samples were taken at 0, 1, 3, 6 (and 24, TOP2A only) hours later.  Cells 
were processed on TARDIS microscopy slides with lysis and probed with 
TOP2A or TOP2B-specific antibodies.  TOP2-DNA complex levels were 
determined by quantifying the intensity of integrated fluorescence (FITC).  
The mean FITC values of 5 µM MTX treated cells were set as 100% and all 
of the single cell values were normalised to this.  The unpaired t-test was 
used to calculate the differences between cells treated with MTX alone and 
cells treated with MTX and MG132.  Trypan blue exclusion was performed 
at 0 and 6 hours after drug treatment, which confirmed no major cell 
viability decrease within the duration of the experiment (Figure 3.6 C).    
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The results confirm that MTX alone induces TOP2-DNA complexes 
significantly above untreated control.  The TOP2-DNA complex levels in 
MG132 treated cells were similar to untreated cells; MG132 alone did not 
stabilise TOP2-DNA complexes in K562 cells. This confirmed that the 
induction of TOP2-DNA complexes was specific to MTX.  TOP2-DNA 
complex levels in MTX treated cells reduced with time after drug wash out.  
TOP2A-DNA complex levels reduced more slowly than TOP2B complexes.  
About 75% of TOP2A-DNA complexes remained 6 hours after drug wash-
out, and reduced further to 30% after 24 hours.  TOP2B-DNA complexes 
were significantly reduced within 6 hours.  The half-life of TOP2A- and 
TOP2B- DNA complexes were estimated to be between 6 and 24 hours 
and 3 hours, respectively (Figure 3.6A and B). 
The presence of MG132 slowed down the complex removal for both 
isoforms.  For TOP2A, the complex levels remained at or above 100% 24 
hours after drug wash-out, which was significantly higher than MTX alone 
at 24 hours (Figure 3.6A).  Similarly, TOP2B complex levels showed a 
significant difference with and without MG132 at 3 and 6 hours.  At one 
hour and six hours after drug wash out, 60% and 40% of TOP2B-DNA 
complexes remained in MTX alone treated cells, respectively.  In the 
presence of MG132, TOP2B-DNA complex levels were 122% after a two-
hour drug treatment and 118% remained at six hours after drug wash-out.   
MTX induced TOP2-DNA complexes with both isoforms and the reversal 
times were different.  This is analogous to Errington et al., 2004, who 
measured the stability of MTX induced TOP2-DNA complexes of both 
isoforms in mouse embryonic fibroblasts (MEF).  After removal of MTX, 
TOP2-DNA complex levels were reduced and this decline was slower for 
TOP2A than TOP2B.  Half-lives of the TOP2-DNA complexes were about 12 
and 6 hours for TOP2A and TOP2B, respectively (Errington et al., 2004).  
These results suggest that proteasomal inhibition could prolong the 
stability of TOP2 complexes in the cell.  This might be related to the 
potentiation of MTX with proteasome inhibitors.   
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Figure 3.6  MG132 inhibits the reversal of MTX-induced TOP2A- and TOP2B-DNA 
complexes.  
(A) and (B) K562 cells were incubated with solvent, MTX (5 µM), MG132 (50 µM) or were co-
incubated with 50 µM MG132 and 5 µM MTX for 2 h. After 2 h MTX was removed, but MG132 was 
maintained in cell incubations that initially contained it. Levels of TOP2A and TOP2B DNA 
complexes at 0, 1, 3, 6 h after MTX removal (wash-out) were determined using the TARDIS assay, 
with an additional time point of 24 h for TOP2A. Statistical comparisons were made between the 
levels of TOP2-DNA complexes in the presence or absence of MG132 by unpaired t-test.  (C) cell 
viability (trypan blue exclusion) under the cell treatment conditions used: ‘‘0” refers to the time at 
which MTX wash-out was performed and ‘‘6 h” refers to time post drug wash-out. 
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3.4 Proteasome inhibition and the effect of epipodophyllotoxins in 
the K562 cell line  
Proteasomal inhibition potentiates etoposide and teniposide 
VP16 and teniposide (VM26) are epipodophyllotoxins.  These compounds 
are used in the treatment of non-Hodgkins lymphoma, leukaemia and lung 
cancer.   
K562 cells were treated with epipodophyllotoxin alone or in combination 
with 95 nM MG132.  Potentiation effects were detected by XTT assay after 
120 hours incubation.  The OD450nm values for epipodophyllotoxin alone 
were normalised to 0 nM epipodophyllotoxin as 100%, and OD450nm values 
of epipodophyllotoxin in combination with MG132 were normalised to 0 nM 
epipodophyllotoxin control in the presence of 95 nM MG132 as 100%. 
The potentiation effect is presented as Pf50.  VP16 and VM26 significantly 
inhibited K562 cell growth.  In combination with MG132, IC50 values of 
both drugs were reduced.  Pf50 values for VP16 and VM26 were 1.65 and 
2.62, respectively (Figure 3.7).  The results suggest that the proteasome 
inhibitor MG132 potentiated the inhibitory effect of VP16 and VM26 on cell 
growth.  The level of potentiation was higher with VM26.   
PS341 potentiates the growth inhibitory effects of VP16 and VM26  
The same potentiation assay setup and analysis which was used in the 
MG132 experiment was used here.  The IC50 values of VP16 and VM26 
were both reduced in the presence of PS341.  The mean IC50 values of 
VM26 alone was around 60 nM, however, in the presence of PS341 it fell 
to around 22 nM (p<0.0001).  The level of potentiation was greater with 
VM26 (Pf50=2.71) than with VP16 (Pf50=1.24) (Figure 3.8).  The results 
show that proteasome inhibition by either MG132 or PS341 potentiates 
the effect of epipodophyllotoxins.   
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Figure 3.7  Potentiation of VP16 or VM26 by MG132 in K562 cells. 
Cells were treated with increasing concentrations of VP16 (A) or teniposide (VM-26) (B) alone or in 
combination with 95 nM MG132 for 5 days followed by XTT staining. Dose–response curves were 
used to estimate the IC50 of epipodophyllotoxin alone or in combination with MG132. Error bars 
represent the mean ± SEM of at least 3 separate experiments for both + and - MG132 conditions, 
values were normalised to the 0 nM epipodophyllotoxin value (100%). 
 
Etoposide + Mean of 
Pf50 
SEM p-value  
MG132 1.65 0.25 0.0261 
PS341 1.24 0.32 0.769 
Table 3.2  Potentiation factor (Pf50) summary of etoposide (VP16) in combination with 
proteasome inhibitors.  
Statistical significance between IC50 values of VP16 alone and in combination with proteasome 
inhibitors by unpaired t-test (p-value).    
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Figure 3.8  Potentiation of VP16 or VM26 by PS341 in K562 cells. 
Cells were treated with increasing concentrations of VP16 (A) or VM26 (B) alone/ or in combination 
with 5.2 nM PS341 for 5 days followed by XTT staining. Dose–response curves were used to 
estimate the IC50 of epipodophyllotoxin alone or in combination with PS341. Error bars represent 
the mean ± SEM of at least 3 separate experiments for both + and – PS341 conditions. Values 
were normalised to the 0 nM epipodophyllotoxin value (100%). 
 
Teniposide + Mean of 
Pf50 
SEM p-value  
MG132 2.62 0.15 <0.0001 
PS341 2.71 0.04 <0.0001 
Table 3.3  Potentiation factor (Pf50) summary of teniposide (VM26) in combination with 
proteasome inhibitors.   
Statistical significance between IC50 values of VM26 alone and in combination with proteasome 
inhibitors by unpaired t-test (p-value). 
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Proteasome inhibition prolonged the half-life of VP16 induced 
TOP2-DNA complexes  
VP16 is a TOP2 poison targeting both TOP2 isoforms to induce stabilised 
TOP2-DNA complexes.  Errington et al,. 2004 have previously shown that 
VP16 stabilised TOP2-DNA complexes dissociate shortly after drug 
removal (Errington et al., 2004).  TOP2-DNA complexes are covalently 
bound to DNA therefore the levels of complex formation and dissociation 
can be observed by TARDIS.   
K562 cells were seeded at approximately 1 x 105 cells per ml in a 6-well 
plate for 24 hours, and then treated with either 100 µM VP16 alone or in 
combination with 50 µM MG132.  After a two-hour treatment, the media 
containing drugs was removed and replaced with fresh media.  For the 
combination experiment, 50 µM MG132 was retained in the media.  Cells 
were incubated for another two hours in fresh media.  Samples were 
taken at 0, 15, 30, 60, and 120 minutes after drug removal for the 
TARDIS assay.  TARDIS slides were probed with TOP2A (4566) or TOP2B 
(4555) specific antibodies for the study of TOP2-DNA complex levels.  
Integrated FITC readings for 100 µM VP16 treated cells were set as 100% 
and all the cells were normalised to this value. 
The level of TOP2-DNA complexes was significantly higher in cells exposed 
to VP16 compared with untreated cells after exposure to VP16.  In cells 
exposed to MG132 alone, TOP2-DNA complex levels remained at 
background level (no difference from untreated cells) at all time points 
tested, showing that MG132 does not induce a significant amount of 
TOP2-DNA complexes within the length of exposure time tested.  Levels of 
both TOP2A- and TOP2B-DNA complexes were reduced after VP16 removal.  
After 120 minutes, TOP2-DNA complexes were reduced to the levels seen 
in the untreated controls. 
The half-lives of TOP2A- and TOP2B-DNA complexes were about 30 and 
15 minutes, respectively.  In the presence of MG132, TOP2A-DNA complex 
levels remained elevated.  77% remained 30 minutes after drug removal, 
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and 54% remained 60 minutes after drug wash-out.  In the presence of 
MG132, higher levels of TOP2B-DNA complexes (153%) were induced and 
the reversal of TOP2B-DNA complexes were slower than VP16 alone.  After 
15 minutes of drug wash-out, TOP2B-DNA complex levels in the absence 
and presence of MG132 were 20% and 86%, respectively.  In the 
presence of MG132, the complex reversal rates were significantly 
prolonged (Figure 3.9A and B).  These data are reported in Lee et al. 2016 
(Lee et al., 2016).   
Trypan blue exclusion was used to determine cell viability throughout the 
VP16 exposure and drug free incubation.  Cell viability was above 90% for 
all treatments and time points.  This suggests a 2-hour exposure to 100 
µM VP16 plus a 2-hour of recovery incubation did not increase membrane 
permeability of cells (Figure 3.9C).    
The half-lives of VP16-induced TOP2A- and TOP2B- complexes are 30 and 
15 minutes, respectively (Lee et al., 2016).  In the presence of MG132 
and VP16, TOP2B complex levels were higher than seen with VP16 alone.  
The presence of MG132 slowed the TOP2A and B complex reversal rate in 
K562.  
Cytotoxicity and cell cycle analysis of VP16 and MG132 in K562 
Following drug wash out, VP16-stabilised TOP2-DNA complexes reversed 
in cells.  This finding is in line with Errington et al., 2004 who reported 
that stabilised TOP2A- and TOP2B-DNA complexes in VP16-treated MEF 
cells dissociated after the VP16 was washed out. The half-life of TOP2A- 
and TOP2B-DNA complexes were approximately 40 and 20 minutes, 
respectively (Errington et al., 2004).  Proteasome inhibition significantly 
slowed down VP16-induced TOP2-DNA complex reversal rate (Figure 3.9 A 
and B).  Trypan blue exclusion and flow cytometry data show that this 
observation was not due to a drop in cell viability or disturbed cell cycle 
distribution (Figure 3.9C and Figure 3.10). 
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Figure 3.9  MG132 slows the reversal of VP16-induced TOP2A- and TOP2B-DNA 
complexes. 
K562 cells were incubated with solvent, VP16 (100 µM), MG132 (50 µM) or were co-incubated with 
50 µM MG132 and 100 µM VP16 for 2 h. After 2 h VP16 was removed, but MG132 was maintained 
in cell incubations that initially contained MG132. Levels of TOP2A (A) and TOP2B (B) DNA 
complexes at 0, 15, 30, 60 and 120 min after VP16 removal (wash-out) were determined using the 
TARDIS assay.  Statistical comparisons were made between the levels of TOP2-DNA complexes in 
the presence or absence of MG132 by unpaired t-test. (C) cell viability (trypan blue exclusion) 
under the cell treatment conditions used: ‘‘-120 min” refers to the time at which drugs were first 
added to cells, ‘‘0” refers to the time at which VP16 wash-out was performed and ‘‘120 min” refers 
to 2 h post drug wash-out.  
 
 
Figure 3.10  Cell cycle distribution at time of VP16 wash-out. 
Cell cycle distribution at time of VP16 wash-out (‘‘0”) and 2 h after VP16 removal (‘‘120”) of cells 
treated with solvent (DMSO), VP16, MG132,or VP16 and MG132. 
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3.5 Proteasome inhibition and effect of amsacrine in the K562 
cells  
Proteasomal inhibition potentiates mAMSA 
Amsacrine (mAMSA) is an aminoacridine, which intercalates into DNA and 
inhibits TOP2.  Amsacrine is used to treat lymphoma and leukaemia. 
K562 cells were treated with different concentrations of mAMSA alone or 
in combination with a fixed concentration of proteasome inhibitor (95 nM 
MG132) for 120 hours.  Growth inhibition was measured by XTT assay.  
The OD450nm values of mAMSA alone were normalised to 0 µM mAMSA 
(100%), and OD450nm values of mAMSA in combination with proteasome 
inhibitor were normalised to 0 µM mAMSA control in the presence of 95 
nM MG132 (100%) (Figure 3.11).  mAMSA inhibited K562 cell growth 
significantly on its own.  The IC50 value was approximately 50 nM.  The 
IC50 value dropped to approximately 15 nM in the presence of MG132 
(Figure 3.11).  The Pf50 value was 2.68, therefore the growth inhibition 
effect of mAMSA is significantly potentiated by MG132 (Table 3.4).   
PS341 potentiates the growth inhibitory effects of mAMSA 
Another proteasome inhibitor (PS341) was used in combination with 
mAMSA to study the potentiation effect.  The results show PS341 
potentiated the growth inhibition effect of mAMSA. The IC50 value of 
mAMSA alone was approximately 50 nM, however, in the presence of 
PS341 it dropped to approximately 23 nM (Figure 3.12).  The potentiation 
effect was statistically significant by unpaired t-test (Pf50=1.7) (Table 3.4).  
mAMSA showed potentiation in combination with two different proteasome 
inhibitors.   
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Figure 3.11  Potentiation of mAMSA by MG132 in K562 cells. 
Cells were treated with increasing concentrations of mAMSA alone or in combination with 95 nM 
MG132 for 5 days followed by XTT staining. Dose–response curves were used to estimate the IC50 
of mAMSA alone or in combination with MG132. Error bars represent the mean ± SEM of at least 3 
separate experiments for both + and - MG132 conditions. Values were normalised to the 0 nM 
mAMSA value (100%). 
   
Figure 3.12  Potentiation of mAMSA by PS341 in K562 cells. 
Cells were treated with increasing concentrations of mAMSA alone or in combination with 5.2 nM 
PS341 for 5 days followed by XTT staining. Dose–response curves were used to estimate the IC50 of 
mAMSA alone or in combination with PS341. Error bars represent the mean ± SEM of at least 3 
separate experiments for both + and – PS341 conditions. Values were normalised to the 0 nM 
mAMSA value (100%). 
 
mAMSA + Mean of Pf50 SEM p-value  
MG132 2.68 0.3 0.0005 
PS341 1.7 0.35 0.0259 
Table 3.4  Potentiation factor (Pf50) summary of amsacrine (mAMSA) in combination with 
proteasome inhibitors.   
Statistical significance between IC50 values of mAMSA alone and in combination with proteasome 
inhibitors by unpaired t-test (p-value). 
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Effect of proteasomal inhibition on mAMSA stabilised TOP2 
complex stability (TARDIS reversal) 
To investigate the effect of proteasomal inhibition on mAMSA stabilised 
TOP2 complex stability, K562 cells were seeded at approximately 1 x 105 
cells per ml for 24 hours, and then treated with 25 µM mAMSA alone or in 
combination of 50 µM MG132 for 2 hours.  After treatment, the drug(s) 
were removed by spinning down the cells, and was replaced with fresh 
media for further 2 hours incubation.  For the cells also treated with 
MG132, MG132 was maintained in the fresh media.  Samples were taken 
at 0, 15, 30, 60, and 120 minutes after drug wash out.  Samples were 
processed onto TARDIS slides after lysis and then probed with TOP2A or 
TOP2B specific antibody (4566 and 4555).  The mean integrated 
fluorescence of 25 µM mAMSA treated cells from individual experiments 
was set as 100% and all values of individual cells were normalised to it. 
Trypan blue exclusion was used to determine cell viability before cells 
were treated with mAMSA (-120minute), after 2 hours mAMSA treatment 
(0 minute) and 2 hours (120minute) after mAMSA removal.  The results 
showed that cell viability did not drop significantly during the period of the 
experiment (Figure 3.13 C).   
mAMSA-stabilised TOP2-DNA complexes show a time-dependent reduction 
upon mAMSA removal.  This was observed for both TOP2A and TOP2B.   
The half-lives of TOP2A- and TOP2B-DNA complexes were approximately 
15 and 10 minutes, respectively.  TOP2B complex levels were slightly 
increased in MG132 treated cells at 30, 60 and 120 minutes time points.  
For TOP2B, this experiment was only repeated twice, therefore unpaired t-
test could not be used to determine statistical significance.  According to 
the error bars the increase is unlikely to be significant (Figure 3.13 A and 
B).   
In the presence of MG132, mAMSA stabilised higher levels of TOP2-DNA 
complexes than mAMSA alone at time point zero.  After drug removal, the 
complex dissociation rate was similar to mAMSA alone treated cells.  The 
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difference between the presence and absence of MG132 did not reach 
statistical significance by unpaired t-test at 15 mins, 30 mins, 60 mins and 
120 mins.  Therefore the presence of MG132 did not affect complex 
reversal rate (Figure 3.13 A and B).    
mAMSA stabilised both isoforms of TOP2 in the cell, and the complexes 
decreased in a time-dependent manner upon removal of mAMSA.  This 
finding is in line with Errington et al,. 2004, as mAMSA stabilised both 
TOP2A- and TOP2B-DNA complexes in MEF cells.  The complex levels 
decreased after drug removal and half-life of both TOP2A and TOP2B 
complexes were approximately 15 minutes (Errington et al., 2004), 
consistent with the results shown below (Figure 3.13). 
 
 
Figure 3.13  MG132 did not significantly affect the reversal of mAMSA-induced TOP2A- 
and TOP2B-DNA complexes.  
K562 cells were incubated with solvent, mAMSA (25 µM), MG132 (50 µM) or were co-incubated 
with 50 µM MG132 and 25 µM mAMSA for 2 h. After 2 h mAMSA was removed, but MG132 was 
maintained in cell incubations that initially contained MG132. Levels of (A) TOP2A and (B) TOP2B 
DNA complexes at 0, 15, 30, 60, and 120 min after mAMSA removal (wash-out) were determined 
using the TARDIS assay. Statistical comparisons were made between the levels of TOP2-DNA 
complexes in the presence or absence of MG132 by unpaired t-test.  (C)Cell viability (trypan blue 
exclusion) under the cell treatment conditions used: ‘‘-120 min” refers to the time, at which drugs 
were first added to cells, ‘‘0” refers to the time at which mAMSA wash-out was performed and ‘’15, 
30, 60, and 120” refers to time (minutes) post drug wash-out. 
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3.6 Proteasomal inhibition and the effect of anthracyclines in the 
K562 cells 
Proteasomal inhibition potentiates anthracyclines 
Daunorubicin (Dau), doxorubicin (Dox), epirubicin (Epi) and idarubicin 
(Ida) are anthracyclines.  All of these target TOP2 as a poison.  These 
drugs are clinically used to treat leukaemia, lymphoma and breast cancer.  
The XTT assay was used to investigate the effect of proteasome inhibition 
on the growth inhibitory effects of anthracyclines. 
K562 cells were seeded and treated with anthracycline alone or in 
combination with 95 nM MG132 for 120 hours.  The OD450nm values of 
anthracycline alone were normalised to 0 nM anthracycline, and OD450nm 
values of anthracycline in combination with proteasome inhibitor were 
normalised to 0 nM anthracycline control in the presence of 95 nM MG132.  
The results show that all anthracyclines tested were potentiated 
significantly by MG132 (Figure 3.14).  All Pf50 values were above 1.9, and 
Dau had the highest Pf50 value (Pf50= 2.95) (Table 3.5 to Table 3.8).    
PS341 potentiates the growth inhibitory effects of anthracyclines 
To study the effect of PS341 on anthracycline-induced growth inhibition, 
the same experimental setup was used as for MG132.  The Pf50 values 
were between 1.37 (Ida) to 1.67(Dau) (Figure 3.15 and Table 3.5 to Table 
3.8).   
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Figure 3.14  Potentiation of anthracyclines (Dau, Dox, Epi and Ida) by MG132 in K562 
cells. 
Cells were treated with increasing concentrations of anthracycline (A) Dau, (B) Dox, (C) Epi, and 
(D) Ida alone or in combination with 95 nM MG132 for 5 days followed by XTT staining. Dose–
response curves were used to estimate the IC50 of anthracycline alone or in combination with 
MG132. Error bars represent the mean ± SEM of at least 3 separate experiments for both + and - 
MG132 conditions. Values were normalised to the 0 nM anthracycline value (100%). 
 
Daunorubicin + Mean of 
Pf50 
SEM p-value  
MG132 2.95 0.99 0.0115 
PS341 1.67 0.07 0.0088 
Table 3.5  Potentiation factor (Pf50) summary of daunorubicin (Dau) in combination with 
proteasome inhibitors.   
Statistical significance between IC50 values of Dau alone and in combination with proteasome 
inhibitors by unpaired t-test (p-value).   
Doxorubicin + Mean of 
Pf50 
SEM p-value  
MG132 1.93 0.31 0.0155 
PS341 1.44 0.23 0.1826 
Table 3.6  Potentiation factor (Pf50) summary of doxorubicin (Dox) in combination with 
proteasome inhibitors. 
Statistical significance between IC50 values of Dox alone and in combination with proteasome 
inhibitors by unpaired t-test (p-value).   
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Figure 3.15  Potentiation of anthracyclines (Dau, Dox, Epi and Ida) by PS341 in K562 
cells. 
Cells were treated with increasing concentrations of anthracycline (A) Dau, (B) Dox, (C) Epi, and 
(D) Ida alone or in combination with 5.2 nM PS341 for 5 days followed by XTT staining. Dose–
response curves were used to estimate the IC50 of anthracycline alone or in combination with PS341. 
Error bars represent the mean ± SEM of at least 3 separate experiments for both + and – PS341 
conditions. Values were normalised to the 0 nM anthracycline value (100%). 
 
Epirubicin + Mean of 
Pf50 
SEM p-value  
MG132 1.93 0.24 0.0018 
PS341 1.63 0.05 0.0056 
Table 3.7  Potentiation factor (Pf50) summary of epirubicin (Epi) in combination with 
proteasome inhibitors.   
Statistical significance between IC50 values of Epi alone and in combination with proteasome 
inhibitors by unpaired t-test (p-value).   
Idarubicin + Mean of 
Pf50 
SEM p-value  
MG132 1.92 0.09 0.0018 
PS341 1.37 0.02 0.089 
Table 3.8  Potentiation factor (Pf50) summary of idarubicin (Ida) in combination with 
proteasome inhibitors.   
Statistical significance between IC50 values of Ida alone and in combination with proteasome 
inhibitors by unpaired t-test (p-value).   
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A 
 
B 
 
Table 3.9  Summary of Pf50 (A) MG132 and (B) PS341. 
 
3.7 Conclusion and discussion 
Eight TOP2 poisons were tested in combination with two proteasome 
inhibitors.  The presence of proteasome inhibitors potentiated the growth 
inhibition of TOP2 poison determined by XTT assay in the K562 cell line.  
The proteasome inhibitor MG132 potentiated all TOP2 poisons tested and 
PS341 potentiated five TOP2 poisons (Table 3.9).  MTX demonstrated the 
highest level of potentiation.  The results demonstrate that proteasomal 
inhibition can increase (potentiate) the growth inhibition of TOP2 poisons 
in K562 cells. 
One possible explanation for the observed growth inhibition is that 
inhibiting the proteasome may increase the cellular protein level of TOP2.  
TOP2A and B protein quantitation in K562 cells treated with MG132 or 
PS341 was reported by Lee at al., 2016.  These immuno-fluorescence data 
showed PS341 treatment of K562 increased the levels of TOP2A protein 
but not TOP2B protein.  There were no changes in TOP2 protein levels 
MG132 + Mean of Pf50 SEM p -value 
Mitoxantrone 4.58 0.54 <0.0001
Etoposide 1.65 0.25 0.0261
Teniposide 2.62 0.15 <0.0001
mAMSA 2.68 0.3 0.0005
Daunorubicin 2.95 0.99 0.0115
Doxorubicin 1.93 0.31 0.0155
Epirubicin 1.93 0.24 0.0018
Idarubicin 1.92 0.09 0.0018
PS341 + Mean of Pf50 SEM p -value 
Mitoxantrone 2.95 0.11 0.0020
Etoposide 1.24 0.32 0.7690
Teniposide 2.71 0.04 <0.0001
mAMSA 1.7 0.35 0.0259
Daunorubicin 1.67 0.07 0.0088
Doxorubicin 1.44 0.23 0.1826
Epirubicin 1.63 0.05 0.0056
Idarubicin 1.37 0.02 0.0890
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after MG132 treatment (Lee et al., 2016).  Thus, the potentiation by 
PS341 may be due to increased TOP2A protein target levels in the cells.  
Congdon et al., 2008 showed that treatment with PS341 increased TOP2A 
protein levels in a drug-resistant human multiple myeloma cell line, and 
the presence of PS341 potentiated the effects of TOP2 poisons (Congdon 
et al., 2008).     
The TARDIS assay was used to address the question of whether 
proteasome inhibition alters the kinetics of formation and removal of 
covalent TOP2-DNA complexes.  The TARDIS assay results showed that 
the presence of 50 µM MG132 prolonged the half-life of VP16 or MTX 
stabilised covalent DNA-TOP2 complexes in cells.  This was observed for 
complexes with both isoforms.  In contrast the presence of MG132 did not 
alter the half-life of mAMSA stabilised DNA-TOP2 complexes in cells.  
These findings suggest that covalent DNA-TOP2 complex removal involves 
the proteasome.  Increasing the half-life of the DNA-TOP2 complex 
provides one mechanism for MG132 to potentiate the growth inhibitory 
effects of MTX and VP16. 
MG132 also potentiated the effects of mAMSA but the presence of MG132 
did not alter the clearance rate of DNA-TOP2 complexes.  This observation 
suggests mAMSA stabilised DNA-TOP2 complexes may be removed by 
other mechanism(s).  Multiple pathways are involved in the removal of 
drug stabilised DNA-TOP2 complexes.  Lee et al., 2012 previously found 
that the nuclease MRE11 can facilitate TOP2 complex removal (Lee et al., 
2012).  Furthermore, the AP lyases, Ku70/80 and APE1, can remove TOP2 
adducts in vitro (Lee, MPhil 2012).  Therefore, further work is required to 
determine the mechanism by which MG132 potentiates growth inhibition 
by mAMSA. 
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Chapter 4. Genotoxicity of MTX alone or in 
combination with a proteasome inhibitor 
4.1 Introduction 
In the previous chapter (Chapter 3), I demonstrated that the growth 
inhibition by TOP2 poisons was potentiated by proteasome inhibitors 
(MG132 and PS341).  The highest level of potentiation was seen with MTX.   
Drugs targeting DNA topoisomerase II are genotoxic and produce 
micronuclei.  In this chapter, I investigated whether the combination of a 
proteasome inhibitor and MTX was more or less genotoxic than MTX alone.  
To detect in vitro micronuclei accurately, a two-colour assay system was 
used. 
Micronuclei are lagging chromosome fragments or whole chromosomes 
that fail to attach to the spindle during the segregation process in 
anaphase (Figure 4.1).  After cell separation, a nuclear envelope forms 
around these lagging chromosomes to form micronuclei (Fenech, 2000; 
Fenech et al., 2011).  Unrepaired DNA double-stranded breaks can lead to 
the formation of chromatid and chromosome fragments which may 
become micronuclei. Therefore, micronuclei can be observed in cells after 
exposure to radiation or DNA damaging agents as a biomarker of 
genotoxicity (Bryce et al., 2007; Hartlerode and Scully, 2009; O'Donovan 
and Livingston, 2010).  Applications such as Fluorescence in situ 
hybridization (FISH) or live-cell imaging can also be used to further study 
the micronucleus’ contents and the details of formation (Norppa and Falck, 
2003; Lindberg et al., 2008; Huang et al., 2011).   
Initially, micronuclei are usually scored manually under a microscope or 
on microscopy images.  However, manual micronuclei scoring can be time 
consuming.  Automated methods have been developed, such as the use of 
software to analyse microscopy images and a specific type of flow 
cytometry termed fluorescence activated cell sorting (FACS) (Nusse et al., 
1994; Avlasevich et al., 2006; Bryce et al., 2007; Diaz et al., 2007; 
Shibai-Ogata et al., 2011). 
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In this study, manual scoring microscopy and FACS methods are used to 
study micronucleus formation after drug treatment. 
The principle of the micronucleus assay used in this study involves 
staining the DNA content of nuclei and identifying micronucleated cells by 
the size of the micronuclei.  Two different nucleic acid dyes were used.  
First, a cell-impermeable dye (EMA) was used to stain cells with damaged 
cell membranes such as apoptotic and necrotic cells staining them red.  
After fixation or lysis, another dye SYTOX Green or Hoechst used to stain 
all nuclei blue or green.  The cells stained with both dyes are identified as 
apoptotic cells and excluded for micronucleus counting (Figure 4.2).  
The criteria for identifying micronuclei manually under a microscope are 
based on Fenech, 2000, and are defined as small micronuclei located near 
to the main nucleus without overlapping each other.  The size of a 
micronucleus is between 1/16 and 1/3 of the main nucleus.  The DNA 
fluorescence intensity of a micronucleus and the main nucleus needs to be 
similar (Fenech, 2000).  
The aim of this chapter was to investigate whether proteasomal inhibition 
potentiates cytotoxicity and reduces genotoxicity of MTX.   
 
 
Figure 4.1  Micronucleus formation in cells undergoing nuclear division.  
Adapted with permission from Fenech, 2000. 
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Figure 4.2  Flow chart of micronucleus assay with the use of two colour nucleic acid dyes 
to identify different types of cells. 
 
4.2 Two-Colour Micronucleus (MN) assay 
Early studies used acridine orange staining to detect nuclei and 
micronuclei.  However, with this assay it is hard to distinguish between 
micronuclei and apoptotic blebbing. A different staining method was 
developed to enable exclusion of apoptotic cells from the counting process. 
After drug exposure, the cells were counted prior to incubation with 2 
µg/ml ethidium monoazide bromide (EMA) under a cool white light source 
for 30 minutes.  EMA is a cell membrane impermeable nucleic acid dye 
which enters cells with damaged membranes, such as apoptotic or 
necrotic cells, and becomes covalently bound to DNA after photo-
activation.  Samples were then applied to microscope slides prior to 
fixation with methanol.  Fixed cells were stained with Hoechst.  Hoechst 
and EMA have different emission wavelengths which are detected in two 
different channels; 461 nm for Hoechst (blue) and 600 nm for EMA (red).  
Microscopy images were taken and analysed using Volocity software 
(Perkin-Elmer, USA).  Figure 4.3 shows representative microscopy images.  
Figure 4.3A shows Hoechst-stained nuclei.  Apoptotic cells are stained with 
both EMA and Hoechst, (e.g. cell marked with “X33”).  Figure 4.3B and C 
show cells with micronuclei marked with “X1”.  On each slide at least 2000 
cells were counted.  The number of “healthy” cells, the number of 
micronucleated cells, and the total number of cells counted was recorded. 
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Figure 4.3  Microscopy images of cells in the micronucleus assay. 
Cells were treated with 5 nM MTX for 120 hours.  Apoptotic cells are stained red by EMA, and all 
nuclei were stained blue with Hoechst.  Images are taken with magnification (x10).  (A)  A mixed 
population of cells.  (B) Two zoomed in images showing cells with micronuclei.   
 
4.3 Micronucleus assay: MTX alone or in combination with MG132 
(120 hours) 
Relative Increase in Cell Count (RICC) 
For in vitro micronuclei detection, Relative Increase in Cell Count is a 
cytotoxicity measurement recommended in the Organisation for Economic 
Co-operation and Development  (OECD) guidelines (Oecd).  RICC is 
calculated using the equation shown below: 
𝑅𝐼𝐶𝐶 =
(𝐼𝑛𝑐𝑟𝑒𝑎𝑠𝑒 𝑖𝑛 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑢𝑙𝑡𝑢𝑟𝑒𝑠(𝑓𝑖𝑛𝑖𝑠ℎ − 𝑠𝑡𝑎𝑟𝑡𝑖𝑛𝑔))
(𝐼𝑛𝑐𝑟𝑒𝑎𝑠𝑒 𝑖𝑛 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝑓𝑖𝑛𝑖𝑠ℎ − 𝑠𝑡𝑎𝑟𝑡𝑖𝑛𝑔))
× 100 
K562 cells were treated with MTX either alone or in combination with 95 
nM MG132 for 120 hours, at the concentrations determined in Chapter 3.  
Cell counts for each sample were taken to calculate the RICC.  For 
micronuclei assays, an RICC lower than 40% is classed as cytotoxic.  
Results from cytotoxic samples need to be interpreted with caution.   
Figure 4.4A shows the 120-hour RICC values.  These were 82% for 95 nM 
MG132 alone, 52% for 5 nM MTX alone, and 25% for 5 nM MTX plus 95 
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nM MG132.  The RICC for the combination was significantly lower than the 
RICC for MG132 alone (p=0.0012) or MTX alone (p=0.0046) (Figure 4.4A).  
The RICC for cells treated with 22.5 nM MTX alone was 14%.   
Micronuclei formation assessed by microscopy (Average 
micronuclei) 
Average percentage of micronuclei was calculated using the equation 
shown below: 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑚𝑖𝑐𝑟𝑜𝑛𝑢𝑐𝑙𝑒𝑖
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
× 100 
At least 2000 cells were counted in each sample.   Of the untreated 
control cells 0.3% had micronuclei. Cells treated with 95 nM MG132 alone 
were comparable to the untreated control (Figure 4.4B).  MTX exposure is 
genotoxic; cells incubated with 5 nM MTX or 22.5 nM MTX produced 
significantly higher levels of micronuclei than untreated controls, 3.3% 
(p=0.0082) and 3.8% (p<0.0001), respectively.  The combination of 5 nM 
MTX and 95 nM MG132 was significantly less genotoxic (0.9%) than 5 nM 
MTX alone (**, p=0.0054) (Figure 4.4B).    
Micronucleus formation (Fold change) assessed by microscopy 
Micronucleus formation is often reported as fold increase over the 
untreated control.  A two-fold increase over the untreated control is 
classed as genotoxic.  The equation used to calculate this is shown below: 
𝐷𝑟𝑢𝑔 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 (𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑚𝑖𝑐𝑟𝑜𝑛𝑢𝑐𝑙𝑒𝑖 %)
𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑚𝑖𝑐𝑟𝑜𝑛𝑢𝑐𝑙𝑒𝑖 %)
 
MTX treatment was genotoxic.  5 nM MTX produced an eleven-fold 
increase in micronuclei and 22.5 nM MTX produced a twelve-fold increase 
in micronuclei. A combination of 5 nM MTX and 95 nM MG132 produced 
only a 3.5-fold increase over the untreated control. It was higher than 
MG132 alone (1.3-fold), but significantly lower than 5 nM MTX alone (11-
fold) (p=0.0197) (Figure 4.4C), suggesting the combination was less 
genotoxic.  
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Summary 
After a 120 hours exposure, by RICC the 22.5 nM MTX was most cytotoxic, 
followed by the combination of 5 nM MTX and 95 nM MG132.  5 nM MTX 
alone was the least cytotoxic of the three combinations tested.  This is 
consistent with the growth inhibition assay results shown in the previous 
chapter.  For both the % micronuclei and the fold change over the 
untreated control, the combination was less genotoxic than MTX alone (5 
nM or 22.5 nM) when determined in vitro by microscopy counting at least 
2000 cells per sample.   
 
 
Table 4.1  Mean values with standard error for RICC, average (%) micronuclei and fold 
change show on figure 4.4.   
 
% ±SEM % ±SEM
Fold 
change ±SEM
Untreated 100.0 0.0 0.3 0.1 1.0 0.0
95 nM MG132 82.3 10.9 0.3 0.1 1.3 0.3
5 nM MTX 52.4 4.4 3.3 0.7 13.5 3.8
22.5 nM MTX 13.8 1.3 3.8 0.4 11.6 5.2
95 nM MG132+ 
5 nM MTX
25.2 4.7 0.9 0.1 3.5 0.7
RICC
Average 
micronuclei (%)
Micronuclei          
fold change
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Figure 4.4  K562 cells after 120 hours treatment of MTX with or without 95 nM MG132. 
(A) Relative increase in cell count (RICC), (B) Average (%) micronuclei and (C) micronucleus 
induction (fold change over control) determined by microscopy. (*p≤0.05, **p≤0.01, and 
***p≤0.005) 
 
4.4 In vitro micronucleus assay using FACS for MTX alone and in 
combination with MG132 (120 hours) 
FACS provides an effective and robust way to determine micronuclei in a 
population of cells; it enables use of higher cell numbers. At least 30,000 
“healthy” nuclei were counted per sample and the number of micronuclei 
was recorded.  Genotoxicity data is presented as average micronuclei or 
as fold induction over untreated control.  In addition, data on apoptosis 
(EMA positive events) and cell cycle distribution is presented. 
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RICC 
The 120-hour RICC values were 92% for 95 nM MG132 alone, 50% for 5 
nM MTX alone, and 46% in combination.  The RICC for the combination 
was significantly lower than the RICC for MG132 alone (p=0.012) but not 
for 5 nM MTX alone (Figure 4.5A).  The RICC for cells treated with 22.5 nM 
MTX alone was 24%.   
The RICC means for this set of experiments were generally higher than 
the values shown in figure 4.4A, but these differences were not 
statistically significant.   
Average % Micronucleus  
The results of the flow cytometric analysis are presented as an average 
micronuclei percentage.  In each sample at least 30,000 “healthy” nuclei 
were counted.  Average micronuclei were calculated using the equation 
shown below: 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑛𝑐𝑢𝑙𝑒𝑖 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 ℎ𝑒𝑎𝑙𝑡ℎ𝑦 𝑛𝑢𝑐𝑙𝑒𝑖 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
× 100 
The average percentage of micronuclei in the untreated control was 3.9%. 
High levels of micronuclei were induced by 5 nM MTX (51%) or 22.5 nM 
MTX (174%).  The average micronuclei for MTX alone or in combination 
with MG132 (27%) were significantly higher than the untreated control 
(Figure 4.5B).  Cells treated with 22.5 nM MTX had an RICC lower than 
40%, which is classed as a cytotoxic dose.  The genotoxicity data 
therefore needs to be viewed with caution. This dose induced a very high 
level of micronuclei.  Similar observations were reported in Bryce et al., 
2007 and Avlasevich et al., 2006 which demonstrated that a large number 
of micronuclei were induced when cells were treated with cytotoxic doses 
of drug.  After the cytotoxic treatment, FACS determined a higher level of 
micronuclei than determined by microscopy (Avlasevich et al., 2006; 
Bryce et al., 2007).   
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Micronucleus fold change over untreated control (120 hours) 
Micronucleus formation results are presented as fold increase over 
untreated control.  The ratio of micronuclei to healthy nuclei in the 
untreated control is set a base.  Using the equation shown below: 
 
𝐷𝑟𝑢𝑔 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 (𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑚𝑖𝑐𝑟𝑜𝑛𝑢𝑐𝑙𝑒𝑖 %)
𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑚𝑖𝑐𝑟𝑜𝑛𝑢𝑐𝑙𝑒𝑖 %)
 
 
MTX was genotoxic.  5 nM induced 13-fold higher micronuclei than the 
untreated control and 22.5 nM MTX induced 46-fold higher micronuclei 
than the control.  The combination of 95 nM MG132 and 5 nM MTX only 
induced 7.2-fold more micronuclei than the untreated control.  These 
results (Figure 4.5C) are consistent with the observations from the 
microscopy micronucleus assay shown in section 4.3 (Figure 4.4).  The 
combination produced fewer micronuclei.   
 
 
Table 4.2  Mean values with standard error for RICC, average (%) micronuclei and 
micronucleus induction show on figure 4.5. 
 
% ±SEM % ±SEM Fold ±SEM Fold ±SEM
Untreated 100.0 0.0 3.9 1.0 1.0 0.0 1.0 0.0
95 nM MG132 91.7 6.1 2.9 0.7 0.8 0.0 0.9 0.1
5 nM MTX 49.5 5.9 50.8 16.5 13.0 2.9 16.3 7.9
22.5 nM MTX 23.9 7.4 173.6 42.5 46.0 5.0 18.4 8.3
95 nM MG132+ 
5 nM MTX
46.0 8.3 26.6 4.4 7.2 0.7 6.2 8.3
RICC
Average 
micronuclei 
Micronuclei          
(Fold change)
EMA increase      
(Fold change)
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Figure 4.5  Data from K562 cells after a 120-hour treatment determined by FACS.  
(A) RICC (B)  Average (%) micronuclei and (C) micronucleus induction (fold change) (D) apoptosis 
(*p≤0.05, **p≤0.01, and ***p≤0.005) 
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Apoptotic measurement  
The number of EMA positive events reflects the number of apoptotic cells 
in the sample.  The ratio of healthy nuclei compared to the EMA positive 
events can be used to determine the level of apoptosis in each sample 
(Bryce et al., 2007).  The equation used is: 
𝐷𝑟𝑢𝑔 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 (
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐸𝑀𝐴 𝑒𝑣𝑒𝑛𝑡𝑠
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑢𝑐𝑙𝑒𝑖 )
𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐸𝑀𝐴 𝑒𝑣𝑒𝑛𝑡𝑠
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑢𝑐𝑙𝑒𝑖 )
 
MG132 alone had no significant induction of apoptosis compared to 
untreated control.  MTX induces apoptosis, which is consistent with the 
RICC data.  
Cell cycle distribution: MTX alone or in combination with MG132 
for 120 hours 
FACS can detect DNA content in cells.  This feature enables the cell cycle 
distribution within samples to be determined.  K562 cells were treated 
with MTX alone or in combination with MG132 for 120 hours.  SYTOX 
green was used to stain the nuclei and the fluorescence intensity of this 
represented DNA content. This was recorded by the FACS and was plotted 
as a frequency against DNA content intensity on a histogram.  The 
frequencies of each G1, S and G2/M phases were calculated using 
specialised software FlowJo (FlowJo, USA).   
In the untreated control, the distribution of G1, S and G2/M phases were 
31%, 53% and 15%, respectively.  After treatment with MG132 alone, the 
pattern was similar to untreated control (Figure 4.6).  Cells treated with 5 
nM MTX alone or the combination of 5 nM MTX and 95 nM MG132 for 120 
hours showed a significant reduction of S phase cells with p-values of 
0.0274 and 0.0088, respectively (Figure 4.6).  Cells treated with 22.5 nM 
MTX alone accumulated in G2/M phase and had fewer S phase cells than 
the untreated control (0.0012) (Figure 4.6).   
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Figure 4.6  Cell cycle distribution of cells treated with MTX alone or in combination with 
MG132 for 120 hours.  
Each plot represents at least three individual experiments.  
 
 
Table 4.3  Cell cycle distribution—Percentage of G1, S and G2/M phase cells in K562 cells. 
Data shown on figure 4.6 is the mean of at least three experiments analysed by Flow Jo.   
   
% ±SEM % ±SEM % ±SEM
Untreated 31.4 4.9 52.8 2.7 14.5 0.6
95 nM MG132 29.4 4.5 52.6 2.7 14.6 0.9
5 nM MTX 27.0 4.4 37.0 3.8 14.9 1.5
22.5 nM MTX 13.4 4.0 23.2 2.4 21.6 2.5
95 nM MG132 
+ 5 nM MTX
29.4 3.4 38.0 1.5 16.4 1.6
G1 S G2/M
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Summary 
Cytotoxicity determined by RICC after a 120-hour exposure to the 
combination of 5 nM MTX plus 95 nM MG132 or 5 nM MTX or 22.5 nM MTX 
alone is consistent with the growth inhibition assay results shown in the 
previous chapter.  For both the % micronuclei and the fold change over 
the untreated control the combination was less genotoxic than MTX alone 
(5 nM or 22.5 nM).  This was true, when determined in vitro by 
microscopy counting of at least 2000 cells per sample or by FACS.  There 
RICC between the combination, 5 nM and 22.5 nM MTX alone were not 
significantly different.  The % micronuclei of the combination was lower 
than 22.5 nM MTX alone.   However, the micronuclei levels were incredibly 
high by FACS.  The RICC below 40% raise a concern that some of the 
small objects measured by FACS may not be micronuclei.  Therefore, a 
48-hour drug exposure was carried out using the same drug 
concentrations.   
In vitro micronucleus assay by flow cytometric analysis: MTX 
alone or in combination with MG132 (48 hours) 
In the previous section the 22.5 nM MTX for 120 hours was very cytotoxic 
and produced extremely high levels of micronuclei by FACS. The 
incubation time was reduced to 48 hours then FACS analysis for 
micronuclei was carried out.  Cytotoxicity was determined in two ways: 
relative survival determined by FACS and RICC by cell counting.  These 
experiments were carried out in triplicate four times (once where only 
RICC was determined and three times where both RICC and relative 
survival were determined).  During the nucleic acid staining step 6-micron 
latex counting beads were added to each sample as an internal control 
(Avlasevich et al., 2006; Bryce et al., 2007).  In the FACS analysis, at 
least 30,000 healthy nuclei were counted.  The system also records the 
number of beads counted.  The relative survival was calculated using the 
ratio of healthy nuclei to beads, taking the untreated control as 100% and 
normalising each sample to it. The major difference between the relative 
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survival and the RICC is the exclusion of the apoptotic cell population in 
the relative survival dataset.     
Equation below: 
𝐷𝑟𝑢𝑔 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 (
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑎𝑑𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 ℎ𝑒𝑎𝑙𝑡ℎ𝑦 𝑛𝑢𝑐𝑙𝑒𝑖 𝑐𝑜𝑢𝑛𝑡𝑒𝑑)
𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑎𝑑𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 ℎ𝑒𝑎𝑙𝑡ℎ𝑦 𝑛𝑢𝑐𝑙𝑒𝑖 𝑐𝑜𝑢𝑛𝑡𝑒𝑑)
× 100 
In figure 4.7A, cytotoxicity results are presented as means with standard 
error of the mean for at least three experiments (relative survival as grey 
bars and RICC as black bars).  Statistical significance was determined 
using the unpaired t-test.  The cytotoxicity determined by relative survival 
and RICC were very similar after 48-hour drug treatments.  The cytotoxic 
effect of MTX was dose-dependent.  The relative survival of 5 nM MTX was 
54%, and reduced to 23% with 22.5 nM MTX (Figure 4.7A).  The relative 
survival values of the combination (53%) were significantly (p=0.0002) 
lower than MG132 alone (90%), but not significantly different from the 5 
nM MTX alone.    
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Figure 4.7  K562 cells after a 48-hour treatment of MTX with or without MG132. 
(A) Relative Increase in Cell Count (RICC) black bars, relative survival – grey bars (B) Average (%) 
micronuclei, (C) micronucleus fold change and (D) apoptosis determined by FACS. (*p≤0.05, 
**p≤0.01, and ***p≤0.005) 
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Average micronucleus formation (%) induced by MTX alone or in 
combination with MG132 after a 48-hour incubation 
At least 30,000 “healthy” nuclei were counted in each sample.  The 
untreated control population had an average of 3.4% micronuclei.  MTX 
induced micronuclei significantly above background.  22.5 nM MTX 
induced 43% micronuclei (Figure 4.7B).  The combination of 5 nM MTX 
and 95 nM MG132 induced 17% micronuclei, significantly above 
background (p<0.0001), and similar to 5 nM MTX (20 % micronuclei) 
(Figure 4.7B and Table 4.4).   
Micronucleus formation presented as fold change over untreated 
control (48 hours)  
Fold change data had the same trend as the average micronuclei data.  95 
nM MG132 alone had similar levels to the untreated control.  Following 
treatment with 5 nM MTX there was a 6.4-fold increase in micronuclei 
above the control.  The combination showed a 5.8-fold increase but this 
was not significantly lower than 5 nM MTX alone. Incubation with 22.5 nM 
MTX induced a 18-fold increase in micronuclei over the untreated control, 
significantly higher than the combination (p=0.0008) (Figure 4.7C) 
Apoptotic measurement  
Apoptosis induced by MTX was dose-dependent.  The combination had 
comparable levels of apoptosis to 5 nM and 22.5 nM MTX alone (Figure 
4.7D). 
Cell cycle distribution: MTX alone or in combination with MG132 
for 48 hours 
The cell cycle distribution determined by FACS is displayed in figure 4.8.  
In the untreated control, the distribution of G1, S and G2/M phases were 
37%, 50% and 15%, respectively.   MTX altered the cell cycle distribution.  
The combination of 5 nM MTX and 95 nM MG132 produced a similar cell 
cycle distribution pattern as the 5 nM MTX, G1 (26%), S (42%) and G2/M 
(31%).  The combination of 5 nM MTX and 95 nM MG132 had a 
85 
 
significantly higher population of cells at G2/M phase than untreated 
control (p<0.0001) or 95 nM MG132 (p=0.0003) (Figure 4.8 and Table 
4.5).   
Summary 
After a 48-hour exposure, the combination of 95 nM MG132 and 5 nM MTX 
had a lower cytotoxicity than 22.5 nM MTX.  The cytotoxicity of the 
combination was similar as 5 nM MTX alone.  The presence of 95 nM 
MG132 did not potentiate the cytotoxicity 5 nM MTX. 
The combination of 95 nM MG132 and 5 nM MTX had lower micronuclei 
levels than 22.5 nM MTX alone.  This might be related to the levels of 
cytotoxicity were differing. 
There was no significant difference in cytotoxicity or genotoxicity between 
5 nM MTX and 5 nM MTX plus MG132. 
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Figure 4.8  Cell cycle distribution of cells treated with MTX or MTX in combination with 
MG132 for 48 hours. 
 
 
 
Table 4.5  Cell cycle distribution—Percentage of G1, S and G2/M phase cells in K562 cells. 
Data shown on figure 4.8 analysed by Flow Jo.  
 
  
% ±SEM % ±SEM % ±SEM
Untreated 37.0 2.2 49.8 1.6 14.5 0.6
95 nM MG132 31.3 3.3 54.9 2.3 16.2 0.5
5 nM MTX 27.0 1.3 44.3 0.8 29.3 1.5
6 nM MTX 23.4 1.4 43.4 2.4 29.3 3.0
7.5 nM MTX 23.4 2.0 35.9 1.6 40.1 2.2
10 nM MTX 15.3 1.5 32.8 2.2 44.1 5.3
22.5 nM MTX 11.8 1.8 21.8 1.1 67.1 3.5
95 nM MG132 
+ 5 nM MTX
25.8 0.5 42.4 1.5 31.0 1.5
G1 S G2/M
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4.5 In vitro micronucleus assay with flow cytometric analysis: 
MTX alone and in combination with PS341 (120 hours) 
Chapter 3 demonstrated that 5.2 nM PS341 potentiated the growth 
inhibition of MTX after a 120-hour incubation.  In the XTT growth 
inhibition assays the IC50 of MTX alone was 22.5 nM, and the 
concentration of MTX that produced a comparable IC50 in combination with 
5.2 nM PS341 was 7.5 nM.  To determine if the PS341 combination altered 
genotoxicity in vitro, micronuclei assays by FACS were carried out.  K562 
cells were exposed to the drug doses used in the XTT growth inhibition 
assays in chapter 3.   
Cytotoxicity determined by relative survival and RICC for K562 
cells treated with MTX alone or in combination with PS341 for 120 
hours 
The RICC determinations have bigger error bars and higher survival rates 
than the relative survival determinations.  Differences between the two 
measurements are statistically significant for 7.5 nM, 22.5 nM MTX and 
the combination of 7.5 nM MTX and 5.2 nM PS341 (Figure 4.9).  All of the 
doses tested were classed as cytotoxic as the relative survival is lower 
than 40% (Figure 4.9). The relative survival of 5.2 nM PS341 alone, 7.5 
nM MTX alone and 22.5 nM MTX alone were 19%, 30% and 10%, 
respectively.  The combination of 5.2 nM PS341 and 7.5 nM MTX had 
relative survival of 3.3%, significantly lower than 22.5 nM MTX 
(p<0.0001).  Thus the PS341 potentiated the effect of MTX after 120 
hours, consistent with the data in chapter 3.  
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Figure 4.9  K562 cells after 120 hours treatment determined by FACS.   
(A) Relative Increase in Cell Count (RICC), (B) Average (%) micronuclei and (C) micronucleus 
induction (fold change) and (D) apoptosis determined by FACS.   (*p≤0.05, **p≤0.01, and 
***p≤0.005)
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Micronucleus formation for MTX alone or in combination with 
PS341 presented as average micronuclei (%) (120 hours 
incubation) 
MTX induced micronuclei significantly above the untreated control levels.  
In cells treated with 5.2 nM PS341 alone the percent of micronuclei 
recorded was 32%.  This was lower than when 7.5 nM or 22.5 nM MTX 
was used alone,  where the average micronuclei were 67% and 107%, 
respectively (Figure 4.9B and Table 4.6).  The combination resulted in 
more micronuclei (120%) than 7.5 nM MTX alone and 13% more than 
22.5 nM MTX alone.  The levels of micronuclei increase with increasing 
cytotoxicity.  
Micronucleus formation (PS341 + MTX) Fold change 
5.2 nM PS341 alone was genotoxic, as it induced 3-fold more micronuclei 
than the untreated control.  7.5 nM MTX alone resulted in 6-fold increase 
in micronuclei and the combination caused a 12.6-fold increase, more 
micronuclei than either the PS341 or MTX alone.  The micronuclei levels 
increased as the cytotoxicity level increased. 
Apoptotic measurement (EMA positive events increase over 
untreated control) 
The combination produced the highest levels of apoptosis; 18-fold over 
the untreated control, and significantly higher than 5.2 nM PS341, 7.5 nM 
MTX, or 22.5 nM MTX (p<0.0001) (Figure 4.9D).  In these experiments 
both 5.2 nM PS341 and 7.5 nM MTX alone induced similar levels of 
apoptosis in K562, ~ 5-fold over untreated control.   
Cell cycle distribution: MTX alone or in combination with PS341 for 
120 hours 
Figure 4.10 shows the cell cycle distribution of cells after 120 hours drug 
treatments.   
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The majority of cells in the untreated control were in S phase (60%), with 
fewer in G1 (24%) and G2/M (19%) phases respectively (Table 4.7). The 
5.2 nM PS341 treated sample had more cells in G1 phase and fewer cells 
in S phase (41%; p=0.0071) compared to the untreated control.   
The 7.5 nM MTX treated sample had similar levels of cells in  G1 phase  as 
the untreated control, but fewer cells in S phase (46%; p=0.0176) and 
more cells in G2/M phase (26%; p=0.0203) when compared to the 
untreated control.  Cells treated with 22.5 nM MTX or the combination of 
7.5 nM MTX and 95 nM MG132 looked similar to each other with most cells 
in G2/M phase.   
Summary 
These doses produced very high levels of cytotoxicity after 120 hours; too 
high for reliable micronuclei determination by FACS.  To address this lower 
concentrations of PS341 and MTX were used for 48 hours. 
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Figure 4.10  Cell cycle distribution of cells treated with MTX alone or in combination with 
PS341 for 120 hours. 
 
 
 
Table 4.7  Cell cycle distribution—Percentage of G1, S and G2/M phase cells in K562 cells.   
Data shown on figure 4.10 analysed by Flow Jo.  Each value is the mean of at least three 
experiments displayed in table with standard error.  
% ±SEM % ±SEM % ±SEM
Untreated 24.1 3.0 60.2 3.5 19.1 2.0
5.2 nM PS341 36.9 0.7 40.6 1.7 17.7 1.1
7.5 nM MTX 25.0 1.1 46.2 0.8 26.5 0.3
22.5 nM MTX 15.5 0.9 25.2 0.9 60.4 3.0
5.2 nM PS341 
+ 7.5 nM MTX
20.6 0.3 26.9 1.4 45.7 1.8
G1 S G2/M
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4.6 In vitro micronucleus assay with flow cytometric analysis: 
MTX alone and in combination with lower doses of PS341 (48 
hours) 
The PS341 concentration was reduced from 5.2 nM to 2.5 nM or 3 nM and 
a range of MTX concentrations were tested to determine a dose-
dependent response.  The incubation time was also reduced to 48 hours.    
Cytotoxicity was determined by both relative survival and RICC  
Data for relative survival (grey) and RICC (black) are plotted on a graph 
shown in figure 4.11A.  The values for relative survival and RICC were 
comparable in all samples tested.  The 2.5 nM and 3 nM PS341 alone had 
70% and 60% relative survival (Figure 4.11A).  MTX reduced relative 
survival of K562 in a dose-dependent manner; 55% with 5 nM MTX and 
23% with 22.5 nM MTX (Figure 4.11A).  2.5 nM PS341 in combination with 
5 nM MTX reduced the relative survival to 47%.  It was significantly lower 
than 5 nM MTX alone (p=0.0073) (Figure 4.11A).  The relative survival of 
the combination with 3 nM PS341 was 36% and was significantly lower 
than combination with 2.5 nM (p=0.0053).  It was also lower than 7.5 nM 
(41%) and 10 nM (37%) MTX alone, but the differences were not 
statistically significant (Figure 4.11). 22.5 nM MTX was most cytotoxic.  
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Figure 4.11  Data of K562 cells after 48 hours treatment of MTX with or without PS341. 
(A) Relative Increase in Cell Count (RICC), (B) Average (%) micronuclei and (C) micronucleus 
induction (fold change) and (D) apoptosis determined by FACS.   (*p≤0.05, **p≤0.01, and 
***p≤0.005) 
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Micronucleus formation with MTX alone or in combination with 
PS341 presented as average micronuclei (%) following a 48-hour 
incubation 
The average level of micronuclei in the untreated control cells was 3.3%.  
Micronucleus levels of cells exposed to 2.5 nM or 3 nM PS341 alone were 
7.3% and 7.0%, respectively, and significantly higher than untreated 
controls (p=0.0007 and p=0.0012, respectively) (Figure 4.11B).   
MTX induced micronuclei significantly above background, and it was dose-
dependent (Figure 4.11B). 
The combination of 5 nM MTX with 2.5 nM PS341 generated 19% average 
micronuclei, higher than 2.5 nM PS341, 5 nM or 6 nM MTX alone (7.3, 15 
and 16.6%, respectively) but the differences were not statistically 
significant (Figure 4.11B and Table 4.8).  22.5 nM MTX alone generated 
53% average micronuclei. Figure 4.11A shows 5 nM and 6 nM MTX alone 
had comparable cytotoxicity to the combination with 2.5 nM PS341.   
The combination of 5 nM MTX with 3 nM PS341 generated 17.7% average 
micronuclei which was similar to the combination with 2.5 nM PS341 
(18.5%).  Figure 4.11A shows this combination had similar cytotoxicity to 
7.5 nM or 10 nM MTX alone.  The average micronuclei induced by the 
combinations were significantly lower than that generated by 7.5 nM MTX 
(p=0.045) or 10 nM MTX (p=0.005) alone (Figure 4.11B). 
22.5 nM MTX alone resulted in 53% average micronuclei.  The 
combination with 2.5 nM (p=0.0043) or 3 nM PS341 (p=0.0037) had 
significantly lower levels of micronuclei than 22.5 nM MTX (Figure 4.11B).   
Micronucleus formation in fold change over untreated control after 
48 hours treatment 
Figure 4.11C micronucleus formation is presented as fold increase over 
untreated control.   
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PS341 alone induced micronuclei above background but the induction was 
lower than two-fold over untreated control (Figure 4.11C).  The 
micronucleus induction by MTX alone was dose-dependent which is shown 
by average micronuclei and fold change on figure 4.11B and C.   
The combination of 5 nM MTX with 2.5 nM or 3 nM PS341 had 4.4 and 4.2 
fold increase in micronuclei.  The micronuclei induced by the combination 
of 5 nM MTX with 2.5 nM (p=0.0002) or 3 nM (p<0.0001) PS341 were 
significantly lower than any of the concentrations of MTX tested (Figure 
4.11C).  This demonstrates that the combination induced fewer 
micronuclei than cells treated with MTX alone.  
Apoptotic measurement (EMA positive events increase over 
untreated control) after a 48-hour incubation 
Apoptotic cells increased by 2.8-fold or 3.6-fold over the control after 
treatment with 2.5 nM or 3 nM PS341 alone.  MTX produced a dose-
dependent increase in apoptotic cells.  With 5 nM MTX alone the increase 
was 2.9-fold, similar to 2.5 nM PS341 alone (Figure 4.11D and Table 4.8). 
The combination of 3 nM PS341 and 5 nM MTX increased apoptosis to 6.6-
fold above the untreated control, which was significantly higher than 3 nM 
PS341 alone (p=0.0323) or 5 nM MTX alone (p=0.002) (Figure 4.11D).  
The combination of 3 nM PS341 and 5 nM MTX had similar cytotoxicity 
(36.3%) to 7.5 nM or 10 nM MTX alone (41% and 37.4%) (Figure 4.11A).  
The apoptotic cell level of this combination was significantly higher than 
7.5 nM MTX (p=0.0107), but not significantly different to 10 nM MTX 
alone (Figure 4.11D).    
Cell cycle distribution: MTX alone or in combination with PS341 for 
48 hours 
DNA content of each “healthy” nucleus was recorded by FACS.  The data 
was plotted against DNA content, displayed in figure 4.12.  Cell cycle 
distributions were analysed by FlowJo, and statistical significances were 
determined using the unpaired t-test.   
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In the untreated control, 50% of cells were in S phase, 37% in G1 (37%) 
and 15% in G2/M.  This pattern was observed in cells treated with 2.5 nM 
or 3 nM PS341 alone (Figure 4.12 and Table 4.9).  MTX reduced the 
proportion of cells at G1 and S phases.  A bigger population of cells 
accumulated at G2/M phase.  This observation was more distinctive when 
MTX concentration increased (Figure 4.12).  Cycle distribution of the 
combination with both 2.5 nM and 3 nM PS341 were similar to 5 nM or 6 
nM MTX.  The majority of cells were in S phase and an increased 
proportion of cells were in the G2/M phase.  The rise in cells in G2/M phase 
was significantly higher than in the untreated control (p<0.0001) (Figure 
4.12) but significantly lower than MTX alone.   
Summary 
A high level of micronuclei was observed in cells treated with high 
concentrations of MTX (7.5 nM -22.5 nM).  The cytotoxicity, micronucleus 
formation and G2/M accumulation of MTX alone were found to be dose- 
dependent.   
MTX in combination with PS341 showed higher cytotoxicity, lower 
micronucleus formation and lower level of G2/M phase accumulation than 
5 nM MTX alone.  These results suggest micronucleus formation might be 
related to the cell cycle distribution.   
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Figure 4.12 Cell cycle distribution of cells treated with MTX or in combination with 
PS341 for 48 hours. 
 
 
Table 4.9  Cell cycle distribution—Percentage of G1, S and G2/M phase cells in K562 cells.   
Data shown on figure 4.12 analysed by Flow Jo.  Each value is the mean of at least three 
experiments, displayed in table with standard error.   
% ±SEM % ±SEM % ±SEM
Untreated 37.0 2.2 49.8 1.6 14.5 0.6
2.5 nM PS341 31.5 0.5 51.6 0.4 14.5 0.6
3 nM PS341 29.5 1.5 47.3 1.1 14.4 0.6
5 nM MTX 27.0 1.3 44.3 0.8 29.3 1.5
6 nM MTX 23.4 1.4 43.4 2.4 29.3 3.0
7.5 nM MTX 23.4 2.0 35.9 1.6 40.1 2.2
10 nM MTX 15.3 0.9 32.8 2.2 44.1 3.3
22.5 nM MTX 11.8 1.8 21.8 1.1 67.1 3.5
2.5 nM PS341 
+ 5 nM MTX
28.0 0.7 44.7 1.2 22.4 1.2
3 nM PS341 + 
5 nM MTX
28.0 2.3 37.4 1.0 25.1 1.1
G1 S G2/M
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4.7 Conclusion and discussion 
The aim of this chapter was to address the question of whether 
proteasomal inhibition potentiated cytotoxicity and reduced genotoxicity of 
MTX.   
Micronucleus assays have been carried out in two ways by microscopy and 
by FACS to compare the combination of 95 nM MG132 and 5 nM MTX with 
5 nM MTX or 22.5 nM MTX alone.  Using both methods the combination 
induced less micronuclei than 5 nM or 22.5 nM MTX alone.  The 
percentage of micronuclei detected by FACS was much higher than by 
microscopy.  For example the average percentages of micronuclei 
detected in untreated cells by microscopy and FACS were 0.3% and 3.9%, 
respectively (Table 4.10).     
The proteasome inhibitor PS341 potentiated the cytotoxic effect of MTX 
after treatment for 120 hours.  However, cells exposed to these doses and 
combinations have a relative survival lower than 30%, too low for reliable 
use in FACS.  Therefore the dose of PS341 was reduced from 5.2 nM to 
2.5 nM or 3 nM with 5 nM MTX and cells were treated for 48 hours.  PS341 
potentiated 5 nM MTX.  The combination of 2.5 nM or 3 nM PS341 with 5 
nM MTX showed comparable cytotoxicity to 7.5 nM or 10 nM MTX.  
Moreover the combination produced lower genotoxicity than MTX alone.  
Exposure to 2.5 nM or 3 nM proteasome inhibitor alone for 48 hours was 
not genotoxic to K562 cells.  The relative survival dropped when PS341 
was combined with 5 nM MTX, and the percentage of micronuclei 
increased to a level similar to 5 nM or 6 nM MTX.  Micronucleus induction 
was MTX dose-dependent.  This showed that proteasomal inhibition by 
PS341 potentiated the cytotoxicity of MTX using two cytotoxicity assays 
(RICC and relative survival).  The combination of 3 nM PS341 with 5 nM 
MTX produced fewer micronuclei than 7.5 nM, 10 nM or 22.5 nM MTX 
alone, and even fewer than with 5 nM and 6 nM MTX alone by fold change.   
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Table 4.10  Summary of micronucleus data (A) Microscopy and (B) FACS. 
 
 
   
  
% ±SEM % ±SEM
Fold 
change ±SEM
Untreated 100.0 0.0 0.3 0.1 1.0 0.0
95 nM MG132 82.3 10.9 0.3 0.1 1.3 0.3
5 nM MTX 52.4 4.4 3.3 0.7 13.5 3.8
22.5 nM MTX 13.8 1.3 3.8 0.4 11.6 5.2
95 nM MG132+ 
5 nM MTX
25.2 4.7 0.9 0.1 3.5 0.7
RICC
Average 
micronuclei (%)
Micronuclei          
fold change
% ±SEM % ±SEM Fold ±SEM Fold ±SEM
Untreated 100.0 0.0 3.9 1.0 1.0 0.0 1.0 0.0
95 nM MG132 91.7 6.1 2.9 0.7 0.8 0.0 0.9 0.1
5 nM MTX 49.5 5.9 50.8 16.5 13.0 2.9 16.3 7.9
22.5 nM MTX 23.9 7.4 173.6 42.5 46.0 5.0 18.4 8.3
95 nM MG132+ 
5 nM MTX
46.0 8.3 26.6 4.4 7.2 0.7 6.2 8.3
RICC
Average 
micronuclei 
Micronuclei          
(Fold change)
EMA increase      
(Fold change)
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Chapter 5. E3 ligase inhibition and the growth 
inhibitory effects of TOP2 poisons  
5.1 Introduction 
This investigation used two E3 ligase inhibitors (PRT4165 and HLI373) in 
combination with different groups of TOP2 poisons (MTX, 
epipodophyllotoxins, mAMSA and anthracyclines) to determine the effect 
on cell growth inhibition by XTT assay.   
The ubiquitin-proteasome system (UPS) is a major protein degradation 
pathway in cells.  Ubiquitin acts as a meditator to trigger the proteasome 
to degrade the target protein.  The system starts with ubiquitin activation 
by an E1 ubiquitin activator which is then transferred to an E2 ubiquitin 
conjugating enzyme.  Both E2 and the target protein are bound to an E3 
ligase.  The activated ubiquitin is transferred to the target protein.  This 
step is repeated until a ubiquitin chain is formed on the target protein.  
The ubiquitin chain acts as a trigger to activate proteasome degradation 
(Ciechanover, 2005; Goldberg, 2007).   
Cells have more than 600 different E3 ligases which largely determine 
substrate specificity. Therefore E3 ligase inhibition would be more specific 
than proteasome inhibition.  Two E3 ligases, Bmi1/Ring and HDM2, have 
been implicated in TOP2A degradation after exposure to a TOP2 poison.     
Bmi1/Ring1A is an E3 ubiquitin ligase involved in drug-induced TOP2A 
degradation (Alchanati et al., 2009).  PRT4165 was reported as a small-
molecule inhibitor of Bmi1/Ring1A.  It inhibits the Bmi1/Ring1A-induced 
ubiquitination of TOP2A and the TOP2A degradation induced by VM26 
(Alchanati et al., 2009).   
HDM2 (called mdm2 in mouse) is an E3 ligase which interacts with and 
regulates the degradation of p53.  HDM2 also interacts with TOP2A in the 
cell and is involved in VP16-induced TOP2A degradation (Nayak et al., 
2007).  In mdm2 knockdown MEF cells, TOP2A was not degraded after 
VP16 exposure (Nayak et al., 2007).  This suggests that inhibition of 
103 
 
HDM2 might prevent TOP2A degradation after exposure to VP16 (Conradt 
et al., 2013). HLI373 is an E3 ligase inhibitor targeting HDM2 (Kitagaki et 
al., 2008).   
The aim of this chapter was to test whether inhibiting an E3 ligase 
reported to inhibit TOP2A degradation potentiated growth inhibition by 
TOP2 poisons in K562 cells. 
5.2 E3 ligase inhibition and the effect of MTX on the K562 cell line 
Growth inhibition by a Bmi1/Ring1A inhibitor (PRT4165) in K562 
cells 
For the potentiation assay, a dose of PRT4165 which inhibits K562 cell 
growth by 20% is needed.  The XTT assay was used to determine the IC20 
of PRT4165.  K562 cells were seeded at approximately 2 x 103 cells per 
well in 96-well plates for 24 hours and then treated with increasing 
concentrations of PRT4165 for 120 hours.  According to figure 5.1, 95 µM 
of PRT4165 inhibited K562 cell growth by 20%.  This dose was used in 
potentiation assays with TOP2 poisons.   
Bmi1/Ring1A inhibitor (PRT4165) potentiates growth inhibition by 
MTX in K562 cells 
The potentiation effect was examined by XTT assay.  K562 cells were 
treated with increasing concentrations of the TOP2 poison MTX, alone or in 
combination with a fixed concentration of PRT4165 (95 µM).  The OD450nm 
values of MTX alone were normalised to 0 nM MTX as 100%, and OD450nm 
values of MTX in combination with PRT4165 were normalised to 0 nM MTX 
control in the presence of 95 µM PRT4165 as 100%.  Figure 5.2 shows the 
presence of PRT4165 significantly increased growth inhibition by MTX 
(Pf50= 3.73).   This shows that MTX can be potentiated by E3 ligase 
inhibition in K562 cells.   
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Figure 5.1  Growth inhibition curve of E3 ligase (Bmi1/Ring1A) inhibitor PRT 4165 in 
K562 cells.  
K562 cells were seeded at approximately 2x103 cells per well in a 96-well plates for 24 hours prior 
to PRT 4165 drug treatment.  After 120 hours of drug exposure, cells were stained with XTT and 
OD450nm was quantified.  Results are means of four experiments ± standard error of the mean. 
 
Figure 5.2  Potentiation of MTX by PRT4165 in K562 cells. 
Cells were treated with increasing concentrations of MTX alone or in combination with 95 µM 
PRT4165 for 5 days followed by XTT staining.  Dose–response curves were used to estimate the 
IC50 of MTX alone or in combination with PRT4165.  Error bars represent the mean ± SEM of at 
least 3 separate experiments for both + and – PRT4165 conditions. Values were normalised to the 
0 nM MTX value (100%). 
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HLI373 growth curve 
For the potentiation study, the IC20 of HLI373 in K562 cells was required.  
Growth inhibition was determined by XTT assay.  K562 cells were seeded 
and treated with HLI373 for 120 hours, followed by XTT staining.  The 
absorbance readings of untreated cells were set at 100% and all the 
readings were normalised to it.  The data shows approximately 3.75 µM 
HLI373 inhibited 20% of K562 cell growth (Figure 5.3).  This 
concentration of HLI373 was used in combination with the TOP2 poison 
MTX to study whether HDM2 inhibition increases the growth inhibitory 
effects of MTX. 
HLI373 potentiates MTX-induced growth inhibition 
K562 cells were seeded and treated with a range of concentrations of MTX 
alone or in combination with a fixed concentration of 3.75 µM HLI373 for 
120 hours.  The OD450nm values of MTX alone were normalised to 0 nM 
MTX as 100%, and OD450nm values of MTX in combination with HLI373 
were normalised to 0 nM MTX control in the presence of 3.75 µM HLI373 
as 100%.  The results show the presence of HLI373 significantly 
potentiated the growth inhibitory effect of MTX (Pf50=4.38) (Figure 5.4).  
The difference between the IC50 values of MTX alone and in combination 
with HLI373 were statistically significant by unpaired t-test (p=0.0003) 
(Figure 5.4).  This result suggests inhibition of HDM2 can potentiate the 
effect of MTX in cells. 
Mitoxantrone + Mean of Pf50 SEM p-value 
PRT4165 3.73 0.035 0.002 
HLI373 4.38 0.45 0.0003 
Table 5.1 Potentiation factor (Pf50) summary of mitoxantrone (MTX) in combination 
with E3 ligase inhibitors. 
Statistical significance between IC50 values of MTX alone and in combination with E3 ligase 
inhibitors by unpaired t-test (p-value).   
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Figure 5.3  Growth inhibition curve of E3 ligase (HDM2) inhibitor HLI373 in K562 cells.  
K562 cells were seeded at approximately 2x103 cells/well in a 96-well plate for 24 hours prior to 
HLI-373 drug treatment.  After 120 hours of drug exposure, cells were stained with XTT and 
OD450nm was quantified.  Results are means of four experiments ± standard error of the mean. 
 
Figure 5.4  Potentiation of MTX by HLI373 in K562 cells. 
Cells were treated with increasing concentrations of TOP2 poison alone or in combination with 3.75 
µM HLI 373 for 5 days followed by XTT staining. Dose–response curves were used to estimate the 
IC50 of TOP2 poison alone or in combination with HLI373. Error bars represent the mean ± SEM of 
at least 3 separate experiments for both + and – HLI373 conditions, and values were normalised to 
the 0 nM of TOP2 poison value (100%). 
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5.3 E3 ligase inhibition and the effect of epipodophyllotoxins on 
the K562 cell line 
Bmi1/Ring1A inhibition potentiates growth inhibition by 
epipodophyllotoxins 
VP16 and VM26 were used to study the potentiation of 
epipodophyllotoxins in combination with PRT4165.  Alchanati et al., 2009 
demonstrated that silencing Bmi1 increased the sensitivity of HeLa cells 
and A549 lung cancer cells to VM26.  Moreover, the cytotoxicity of VM26 
was increased by PRT4165 in a synergistic manner (Alchanati et al., 2009).  
Potentiation assays were performed to investigate the effect of PRT4165 
on epipodophyllotoxin-induced growth inhibition. 
K562 cells were treated with epipodophyllotoxin alone or in combination 
with a fixed concentration of PRT4165 (95 µM).  VP16 and VM26-induced 
growth inhibition was potentiated by PRT4165, with both IC50 values 
reduced in the presence of PRT4165 (Figure 5.5).  The effect with VM26 
(Pf50 =2.84) was greater than with VP16 (Pf50 =1.76).  These results show 
that Bmi1/Ring1A inhibition potentiates the growth inhibitory effects of 
epipodophyllotoxins. 
HDM2 inhibition and the effect of epipodophyllotoxins in K562 
cells  
To investigate whether epipodophyllotoxins could also be potentiated by 
HDM2 inhibition, potentiation assays were performed with VP16 and VM26 
in the presence of HLI373.  VP16 and VM26 were used alone or in 
combination with the HDM2 inhibitor (HLI373) to treat K562 cells for 120 
hours.  Epipodophyllotoxin-induced growth inhibition was potentiated by 
HLI373.  The potentiation factors (Pf50) of VP16 and VM26 were 1.49 and 
1.75, respectively.  The potentiation effect toward VM26 was greater than 
VP16.   
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Figure 5.5  Potentiation of epipodophyllotoxins (VP16 and VM26) by PRT4165 in K562 
cells. 
Cells were treated with increasing concentrations of VP16 (A) or VM26 (B) alone or in combination 
with 95 µM PRT4165 for 5 days followed by XTT staining.  Dose–response curves were used to 
estimate the IC50 of epipodophyllotoxin alone or in combination with PRT4165. Error bars represent 
the mean ± SEM of at least 3 separate experiments for both + and – PRT4165 conditions. Values 
were normalised to the 0 nM epipodophyllotoxin value (100%). 
 
Etoposide + Mean of Pf50 SEM p-value  
PRT4165 1.75 0.16 0.0494 
HLI373 1.49 0.13 0.022 
Table 5.2  Potentiation factor (Pf50) summary of VP16 in combination with E3 ligase 
inhibitors.   
Statistical significance between IC50 values of etoposide (VP16) alone and in combination with E3 
ligase inhibitors by unpaired t-test (p-value).   
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Figure 5.6  Potentiation of epipodophyllotoxins (VP16 and VM26) by HLI373 in K562 cells. 
Cells were treated with increasing concentrations of VP16 (A) or VM26 (B) alone or in combination 
with 3.75 µM HLI373 for 5 days followed by XTT staining. Dose–response curves were used to 
estimate the IC50 of epipodophyllotoxin alone or in combination with HLI373. Error bars represent 
the mean ± SEM of at least 3 separate experiments for both + and – HLI373 conditions. Values 
were normalised to the 0 nM epipodophyllotoxin value (100%). 
 
Teniposide + Mean of Pf50 SEM p-value  
PRT4165 2.84 0.59 0.015 
HLI373 1.76 0.12 0.0026 
Table 5.3  Potentiation factor (Pf50) summary of VM26 in combination with E3 ligase 
inhibitors.   
Statistical significance between IC50 values of teniposide (VM26) alone and in combination with E3 
ligase inhibitors by unpaired t-test (p-value). 
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5.4 E3 ligase inhibition and the effect of amsacrine on the K562 
cell line 
Bmi1/Ring1A inhibition and the growth inhibitory effect of mAMSA 
in K562 cells 
The effect of Bmi1/Ring1A inhibition on mAMSA-induced growth inhibition 
was determined by XTT assay.  K562 cells were treated with mAMSA alone 
or in combination with a fixed concentration of PRT4165 (95 µM) for 120 
hours.  The OD450nm values of mAMSA alone were normalised to 0 nM 
mAMSA (100%), and OD450nm values of mAMSA in combination with 
PRT4165 were normalised to 0 nM mAMSA control in the presence of 95 
µM PRT4165 (100%).  Figure 5.7 shows that the presence of PRT4165 
potentiated the growth inhibitory effect of mAMSA (Pf50=1.48) (Table 5.4).   
HDM2 inhibition and the growth inhibitory effect of mAMSA in 
K562 cells 
The effect of HLI373 treatment on mAMSA-induced growth inhibition was 
studied by XTT assay.  K562 cells were treated with mAMSA alone or in 
combination with 3.75 µM HLI373 for 120 hours. The OD450nm values of 
mAMSA alone were normalised to 0 nM mAMSA (100%), and OD450nm 
values of mAMSA in combination with HLI373 were normalised to 0 nM 
mAMSA control in the presence of 3.7 µM HLI373 (100%).  In the 
presence of HLI373, the IC50 of mAMSA was about 65 nM (p=0.0345) 
(Figure 5.8).  The Pf50 was 1.39 (Table 5.4).  
 
mAMSA + Mean of Pf50 SEM p-value  
PRT4165 1.48 0.04 0.0026 
HLI373 1.39 0.04 0.0345 
Table 5.4  Potentiation factor (Pf50) summary of mAMSA in combination with E3 ligase 
inhibitors.   
Statistical significance between IC50 values of mAMSA alone and in combination with E3 ligase 
inhibitors by unpaired t-test (p-value). 
 
111 
 
 
Figure 5.7  Potentiation of mAMSA by PRT4165 in K562 cells. 
Cells were treated with increasing concentrations of mAMSA alone or in combination with 95 µM 
PRT4165 for 5 days followed by XTT staining.  Dose–response curves were used to estimate the 
IC50 of mAMSA alone or in combination with PRT4165. Error bars represent the mean ± SEM of at 
least 3 separate experiments for both + and – PRT4165 conditions. Values were normalised to the 
0 nM mAMSA value (100%). 
 
Figure 5.8  Potentiation of mAMSA by HLI373 in K562 cells. 
Cells were treated with increasing concentrations of mAMSA alone or in combination with 3.75 µM 
HLI373 for 5 days followed by XTT staining.  Dose–response curves were used to estimate the IC50 
of mAMSA alone or in combination with HLI373. Error bars represent the mean ± SEM of at least 3 
separate experiments for both + and – HLI373 conditions. Values were normalised to the 0 nM 
mAMSA value (100%). 
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5.5 E3 ligase inhibition and effect of anthracyclines in the K562 
cell line 
Bmi1/Ring1A inhibition and the growth inhibitory effect of 
anthracyclines in K562 cells 
The effect of PRT4165 on anthracycline-induced growth inhibition was 
determined by XTT assay.  Four anthracyclines (Dau, Dox, Epi, and Ida) 
were tested in this study.  K562 cells were seeded and then treated with 
anthracyclines alone or in combination with a fixed concentration of 
PRT4165 (95 µM) for 120 hours.  The OD450nm values of 0 nM of 
anthracycline and 95 µM PRT4165 were set as 100%, and all values were 
normalised to it.  The presence of PRT4165 reduced the IC50 of all 
anthracyclines tested (Figure 5.9).  Epi had the greatest potentiation (Pf50 
1.91) and Dox had the lowest (Pf50 1.16) (Table 5.6 and Table 5.7).  The 
results suggest that inhibition of Bmi1/Ring1A potentiates the effect of 
anthracyclines in cells. 
HDM2 inhibition and the growth inhibitory effect of anthracyclines 
in K562 cells  
Four anthracyclines (Dau, Dox, Epi and Ida) were used to treat K562 cells 
alone or in combination with a fixed concentration (3.75 µM) of HLI373.  
After 120 hours treatment the XTT assay was used to determine the effect 
on growth inhibition.  The results show that HLI373 potentiates the effect 
of anthracyclines (Figure 5.10).  Epi had the highest potentiation effect 
(Pf50=1.72) and Dox had the lowest (Pf50 =1.22) (Table 5.6 and Table 5.7).  
The results show that HDM2 inhibition potentiates the growth inhibition 
effect of anthracyclines.  The level of potentiation varies depending on the 
drug used. 
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Figure 5.9  Potentiation of anthracyclines (Dau, Dox, Epi and Ida) by PRT4165 in K562 
cells. 
Cells were treated with increasing concentrations of anthracycline (A) Dau, (B) Dox, (C) Epi and (D) 
Ida alone or in combination with 95 µM PRT4165 for 5 days followed by XTT staining. Dose–
response curves were used to estimate the IC50 of anthracycline alone or in combination with 
PRT4165. Error bars represent the mean ± SEM of at least 3 separate experiments for both + and 
– PRT4165 conditions. Values were normalised to the 0 nM anthracycline value (100%). 
 
Daunorubicin + Mean of Pf50 SEM p-value  
PRT4165 1.74 0.09 0.0067 
HLI373 1.41 0.04 0.0071 
Table 5.5  Potentiation factor (Pf50) summary of daurubicin (Dau) in combination with E3 
ligase inhibitors.   
Statistical significance between IC50 values of Dau alone and in combination with E3 ligase 
inhibitors by unpaired t-test (p-value).   
 
Doxorubicin + Mean of Pf50 SEM p-value  
PRT4165 1.16 0.05 0.0257 
HLI373 1.22 0.03 0.0024 
Table 5.6  Potentiation factor (Pf50) summary of Dox in combination with E3 ligase 
inhibitors.   
Statistical significance between IC50 values of Dox alone and in combination with E3 ligase 
inhibitors by unpaired t-test (p-value).   
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Figure 5.10  Potentiation of anthracyclines (Dau, Dox, Epi and Ida) by HLI 373 in K562 
cells. 
Cells were treated with increasing concentrations of anthracycline (A) Dau, (B) Dox, (C) Epi and (D) 
Ida alone or in combination with 3.75 µM HLI373 for 5 days followed by XTT staining. Dose–
response curves were used to estimate the IC50 of anthracycline alone or in combination with 
HLI373. Error bars represent the mean ± SEM of at least 3 separate experiments for both + and – 
HLI373 conditions. Values were normalised to the 0 nM anthracycline value (100%). 
 
Epirubicin + Mean of Pf50 SEM p-value  
PRT4165 1.91 0.07 0.0169 
HLI373 1.72 0.02 0.0001 
Table 5.7  Potentiation factor (Pf50) summary of epirubicin (Epi) in combination with E3 
ligase inhibitors.   
Statistical significance between IC50 values of Epi alone and in combination with E3 ligase inhibitors 
by unpaired t-test (p-value).   
 
Idarubicin + Mean of Pf50 SEM p-value  
PRT4165 1.25 0.08 0.035 
HLI373 1.44 0.09 0.0328 
Table 5.8  Potentiation factor (Pf50) summary of idarubicin (Ida) in combination with E3 
ligase inhibitors.   
Statistical significance between IC50 values of Ida alone and in combination with E3 ligase inhibitors 
by unpaired t-test (p-value).   
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5.6 Conclusion and discussion 
Two E3 ligase inhibitors were studied in combination with different TOP2 
poisons.  The potentiation was determined by XTT growth inhibition assay.  
The results show inhibition of the E3 ligase Bmi1/Ring1A potentiated all 
the TOP2 poisons tested.  In the presence of the Bmi1/Ring1A inhibitor, 
PRT4165, the IC50 of TOP2 poisons were significantly reduced.  The levels 
of potentiation were different for each TOP2 poison.  MTX showed the 
greatest potentiation (Pf50=3.73), followed by VM26 (Pf50=2.84) (Table 
5.9A).  Of the four anthracyclines tested, only Epi was potentiated 
significantly (Pf50>1.5) (Table 5.9A).  The XTT assay results are consistent 
with a previous study which showed siRNA silencing of Bmi1 increased cell 
sensitivity to TOP2 poisons (Alchanati et al., 2009).  The siRNA silencing 
of Bmi1 inhibited drug-induced TOP2A degradation (Alchanati et al., 2009).  
These results support the idea that Bmi1 facilitates TOP2A degradation 
after TOP2 drug exposure. 
The presence of HLI373, an HDM2 inhibitor, significantly reduced the IC50 
of all TOP2 poisons tested.  The level of potentiation was different for each 
TOP2 poison.  MTX had the greatest potentiation (Pf50=4.38) followed by 
VM26 (Pf50=1.76).  Of the anthracyclines tested, Epi was potentiated the 
most (Pf50=1.72) (Table 5.9B).  The results of the potentiation assays are 
consistent with previous studies which showed that inhibition of HDM2 
sensitised cells to VP16 in a p53 independent manner, and prevented 
TOP2A degradation after exposure to VP16 (Nayak et al., 2007; Conradt 
et al., 2013).  HDM2 regulates p53, however K562 cells do not express 
p53 (Prokocimer et al., 1986).  The potentiation by HLI373 may be via 
regulation of TOP2A levels or by altering HDM2 interactions with other 
protein(s).   
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Table 5.9  Summary of Pf50 (A) PRT4165 and (B) HLI373 in combination with TOP2 
poisons. 
 
 
 
 
 
 
 
 
 
 
 
PRT4165+ Mean of Pf50 SEM p -value 
Mitoxantrone 3.73 0.035 0.002
Etoposide 1.75 0.16 0.0494
Teniposide 2.84 0.59 0.015
mAMSA 1.48 0.04 0.0026
Daunorubicin 1.74 0.09 0.0067
Doxorubicin 1.16 0.05 0.0257
Epirubicin 1.91 0.07 0.0169
Idarubicin 1.25 0.08 0.035
HLI373+ Mean of Pf50 SEM p -value 
Mitoxantrone 4.38 0.45 0.0003
Etoposide 1.49 0.13 0.022
Teniposide 1.76 0.12 0.0026
mAMSA 1.39 0.04 0.0345
Daunorubicin 1.41 0.04 0.0071
Doxorubicin 1.22 0.03 0.0024
Epirubicin 1.72 0.02 0.0001
Idarubicin 1.44 0.09 0.0328
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Chapter 6. Cytotoxic and genotoxic effects of TOP2 
poisons on Nalm-6 cell lines 
6.1 Introduction 
TOP2 poisons are used clinically for the treatment of cancer.  However, 
TOP2 poisons are genotoxic in cells.  TOP2 poisons are linked to serious 
adverse effects such as treatment-related secondary cancer and 
cardiotoxicity (Azarova et al., 2007; Cowell et al., 2012; Zhang et al., 
2012; Vejpongsa and Yeh, 2014). 
Two TOP2 isoforms, TOP2A and TOP2B, exist in human cells.  They have a 
similar reaction mechanism and are similar in structure. However, TOP2A 
and TOP2B differ in some of their biological functions.  TOP2A is highly 
expressed in rapidly growing cells and is essential for cell division.   Both 
are involved in transcription and TOP2B plays a role in ligand-mediated 
transcription.  Evidence suggests that poisoning of TOP2B is related to 
secondary cancer development (Azarova et al., 2007; Cowell et al., 2012).  
Therefore, TOP2B inhibition might contribute more to TOP2 poison 
genotoxicity than TOP2A. 
Three Nalm-6 cell lines with different expression levels for TOP2 isoforms 
were treated with TOP2 poisons in order to determine the contribution of 
each isoform to cytotoxicity and genotoxicity. This study used the human 
pre-B cell line Nalm-6 (wild-type) and the two derivatives of Nalm-6 to 
investigate the role of TOP2A and TOP2B in the growth inhibitory effect of 
TOP2 poisons.  Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cell lines have reduced 
expression of type II topoisomerases.  TOP2A is reduced by 50% in Nalm-
6TOP2A+/-  and Nalm-6TOP2B-/-  lack TOP2B.  How this affects growth 
inhibition, cytotoxicity and genotoxicity has been determined.   
The micronucleus assay is one of the preferred methods for studying 
chromosome damage.  In mitosis, dividing cells contain chromosome 
fragments lacking centromeres and/or whole chromosomes that are 
unable to travel to the spindle poles.  A nuclear envelope will form around 
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the lagging chromosome or fragment, forming a “micronucleus”. The 
number of cells with micronuclei after drug treatment is used as a 
measure of chromosome damage (Fenech, 2000; Norppa and Falck, 2003).  
Flow cytometry is a robust and fast way to measure micronuclei in cells 
(Avlasevich et al., 2006; Bryce et al., 2007).  Drugs which induce 
micronuclei levels two-fold higher than the untreated control are classed 
as genotoxic.   
The aim of the work described in this chapter to study the role of TOP2 
isoforms in TOP2 poison-induced growth inhibition, cytotoxicity and 
genotoxicity.  
6.2 MTX 
MTX- effect on Nalm-6 cell line growth 
MTX is a TOP2 poison which stabilises TOP2-DNA complexes with both 
isoforms in human and mouse cell lines (Errington et al., 2004; Lee et al., 
2016).  Cells were incubated with increasing concentrations of MTX for 
120 hours and growth inhibition was determined by XTT assay, as 
described in chapter 3.  The OD450nm values of 0 nM MTX treated cells 
were set as 100%, and all other values were normalised relative to the 0 
nM MTX control values. The results are shown in figure 6.1A and table 
6.1A. The growth inhibitory effect of MTX is greater in Nalm-6 WT cells 
than in Nalm-6TOP2A+/- or Nalm-6TOP2B-/- cells.  The IC50 of Nalm-6 WT, 
Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells were approximately 4 nM, 8.5 nM 
and 17.4 nM, respectively.  The Nalm-6TOP2B-/- cells were most resistant to 
MTX demonstrating that TOP2B plays a large role in the growth inhibitory 
effects of MTX (Figure 1.1A and Table 6.1A).  These results are consistent 
with Toyoda et al 2008 and Errington et al 1999 who used clonogenic 
assays on human Nalm-6 or transgenic murine cell lines, respectively 
(Errington et al., 1999; Toyoda et al., 2008).   
Cytotoxicity was determined by Relative Increase in Cell Count (RICC) and 
Relative survival; both methods were described in chapter 4.  Cells were 
119 
 
treated with increasing concentrations of MTX for 48 hours, followed by 
cell counting to obtain the RICC.  After that, cells were prepared for 
micronucleus assays.  Relative survival data was obtained during the flow 
cytometric analysis. The data for RICC and relative survival were plotted 
to obtain IC50 values as a measure of cytotoxicity.   
Figure 6.1 and Table 6.1B and C show RICC and relative survival 
determined during FACS, respectively.  The RICC IC50 values were 
approximately 1 nM in Nalm-6 WT, 1.7 nM in Nalm-6TOP2A+/- and 2.8 nM in 
Nalm-6TOP2B-/- cells.  The IC50 values from relative survival were 
approximately 1.2 nM in Nalm-6 WT, 2.5 nM in Nalm-6TOP2A+/- and 3.8 nM 
in Nalm-6TOP2B-/- cells.  The relative survival rate of Nalm-6 WT cells was 
the lowest of the three Nalm-6 cell lines.  It was significantly lower than 
that of Nalm-6TOP2B-/- cells at all doses tested (0.75 nM; p=0.0059, 1.5 nM; 
p=0.0056 and 3 nM; p=0.0004). 
The cytotoxic effect of MTX in Nalm-6 cell lines was highest in Nalm-6 WT 
cells and lowest in Nalm-6TOP2B-/- cells (Nalm-6 WT > Nalm-6TOP2A+/- > 
Nalm-6TOP2B-/-).  This trend was the same whether determined by relative 
survival or RICC and similar to the growth inhibition trend. The increased 
resistance in the Nalm-6TOP2B-/- cell line reflects the importance of TOP2B 
in the growth inhibitory and cytotoxic effects of MTX.   
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Table 6.1 Summary of relative survival after treatment of MTX. 
Determined by (A) XTT, (B) RICC, and (C) FACS in Nalm-6 WT, Nalm-6TOP2A+/- and Nalm-6TOP2B-/- 
cell lines after 48 hours of MTX treatment.  
  
MTX (nM) Mean SEM Mean SEM Mean SEM
0.0 100.0 0.0 100.0 0.0 101.1 1.1
1.0 111.4 10.3 92.1 14.5 82.3 5.3
1.5 118.9 12.4 122.4 25.5 101.1 5.5
2.0 118.4 8.1 124.6 29.8 89.2 2.2
2.5 101.9 6.1 114.4 24.5 102.6 7.7
5.0 17.6 5.8 96.0 10.1 83.5 0.7
7.5 -10.0 1.4 112.3 12.1 61.9 1.8
10.0 -9.5 1.7 95.0 7.5 30.9 8.9
15.0 - - 63.3 4.1 - -
20.0 -9.3 1.5 46.2 9.6 -6.9 0.5
25.0 - - 11.3 2.4 - -
30.0 - - 2.1 2.8 - -
40.0 -4.3 0.9 -4.7 2.0 -9.4 0.7
50.0 - - -2.9 2.7 - -
Growth inhibition (XTT)
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
MTX (nM) Mean SEM Mean SEM Mean SEM
0.00 100.0 0.0 100.0 0.0 100.0 0.0
0.75 62.4 5.7 78.7 6.4 79.6 9.4
1.50 32.4 4.3 72.7 8.7 47.9 4.8
3.00 10.8 2.5 45.9 1.1 25.5 4.0
4.50 6.3 2.2 - - - -
6.00 - - 31.9 0.9 10.8 3.5
12.00 - - 14.7 0.0 - -
RICC (%)
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
MTX (nM) Mean SEM Mean SEM Mean SEM
0.00 100.0 0.0 100.0 0.0 100.0 0.0
0.75 68.7 2.6 98.6 6.9 90.5 15.4
1.50 39.3 4.7 84.1 9.5 63.6 8.6
3.00 16.2 4.2 55.0 3.4 37.8 4.1
4.50 8.4 2.8 - - - -
6.00 - - 29.7 0.7 14.3 0.6
12.00 - - 19.5 0.0 - -
Relative survival (%) (FACS)
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
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Figure 6.1 MTX-induced growth inhibition and cytotoxicity in Nalm-6 WT, Nalm-
6TOP2A+/- and Nalm-6TOP2B-/- cells. 
(A) Cells were treated with increasing concentrations of MTX for 120 hours and growth was 
determined by XTT assay (where % is inhibition of growth in relation to untreated controls). (B & C) 
Cells were treated with increasing concentrations of MTX for 48 hours followed by the estimation of 
(B) relative increase in cell count (RICC) and (C) relative survival by FACS.  The value of untreated 
cells was set as 100% and all values normalised to it.  Dose-response curves were plotted to obtain 
the IC50 of MTX in each cell line.  Error bars represent the mean ± SEM of at least 3 separate 
experiments. 
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Genotoxicity of MTX in nalm6 cell lines 
From this cytotoxicity data, dose ranges between 0 nM -3 nM (Nalm-6 
WT), 0 nM -6 nM (Nalm-6TOP2A+/-) and 0 nM -12 nM (Nalm-6TOP2B-/-) were 
used in subsequent micronucleus assays to determine MTX genotoxicity in 
cell lines with differing levels of TOP2.  Cells were seeded at 
approximately 5 x 104 cells per ml for 24 hours prior to incubation with 
MTX for 48 hours.  Cells were harvested and processed for the in vitro 
micronucleus assay.  Figure 6.2 shows micronucleus assay results for the 
three Nalm-6 cell lines in response to three different doses of MTX.  This is 
presented as average micronuclei and micronuclei induced over untreated 
control.  The histograms represent averages of three individual 
experiments.  Unpaired t-tests were used to determine the statistical 
difference between cell lines at each dose. 
In general, the levels of micronuclei in cells increased with dose of MTX.  
The average micronucleus (%) present in the Nalm-6 WT untreated 
control was 1.3%.  The percentage went up to 3.8% or 8.3% after 
treatment with 0.75 nM or 1.5 nM MTX (Figure 6.2B), respectively. This 
increase was statistically significant as determined by t-test (p<0.0001 
and p<0.0001, respectively).   For Nalm-6 WT cells treated with 0.75 nM 
MTX, micronuclei were induced 3.2-fold over the untreated control (Figure 
6.2C), confirming that MTX is genotoxic to Nalm-6 WT cells.   
In Nalm-6TOP2B-/- cells, the average micronuclei without MTX treatment 
was 1.9%.  Levels of micronuclei increased with MTX concentration.  At 
0.75 nM, 1.5 nM and 3 nM MTX, the percentage micronuclei increased to 
2.2%, 3.8% and 5.9%, respectively (Figure 6.2B and Table 6.2B). At 1.5 
nM and 3 nM MTX, the average micronuclei were significantly higher than 
the untreated control (p=0.0003 and p=0.0002, respectively).  
According to the fold change data, there was no significant difference 
between 0.75 nM MTX and untreated Nalm-6TOP2B-/- cells (1.4-fold).  
Exposure to 1.5 nM and 3 nM MTX induced 2.3-fold and 3.2-fold higher 
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micronuclei than untreated cells.  Thus at 1.5 nM and 3 nM MTX is 
genotoxic to Nalm-6TOP2B-/- cells. 
In untreated Nalm-6TOP2A+/- cells the average micronuclei was 1.7%. This 
was increased to 3.3 (p=0.0042), 4.8 (p=0.0002) or 8.4% (p<0.0001) 
after treatment with 0.75 nM, 1.5 nM and 3nM MTX.  The fold changes of 
micronuclei over control were 1.9-fold, 2.8-fold and 5.0-fold at 0.75 nM, 
1.5 nM and 3 nM MTX, respectively.  Thus, MTX is also genotoxic to Nalm-
6TOP2A+/- cells.  
Comparisons of the micronuclei levels between cell types show that the 
average micronuclei present in untreated Nalm-6TOP2B-/- cells (1.9%) was 
significantly higher than in untreated Nalm-6 WT cells (1.2%).  However, 
after exposure to 0.75 nM MTX, the average micronuclei in Nalm-6 WT 
cells (3.8%) were significantly higher than in Nalm-6TOP2B-/- (2.2%; 
p=0.0018) and Nalm-6TOP2A+/- cells (3.3%; p=0.0039) (Figure 6.2B).  
More micronuclei were induced in Nalm-6 WT at all doses tested.  The 
Nalm-6TOP2B-/- and Nalm-6TOP2A+/- cells produced comparable levels of 
micronuclei, with no significant difference between the two cell lines. 
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Table 6.2 Summary of micronucleus assay data after MTX treatment.  
(A) mean of relative survival, (B) average percentage of micronuclei, (C) micronucleus induction by 
fold change and (D) p-values by unpaired t-test in Nalm-6 cell lines after 48 hours of MTX 
treatment.    
% ±SEM % ±SEM % ±SEM
0 100.0 0.0 100.0 0.0 100.0 0.0
0.75 68.7 2.6 98.6 6.9 90.5 15.4
1.5 39.3 4.7 84.1 9.5 63.6 8.6
3 16.2 4.2 55.0 3.4 37.8 4.1
Relative survival
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-Mitoxantrone     
(nM)
% ±SEM % ±SEM % ±SEM
0 1.3 0.1 1.9 0.2 1.7 0.3
0.75 3.8 0.2 2.2 0.1 3.3 0.1
1.5 8.3 0.9 3.8 0.2 4.8 0.1
3 16.0 2.5 5.9 0.6 8.4 0.4
Average micronuclei (%)
Mitoxantrone     
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Fold ±SEM Fold ±SEM Fold ±SEM
0.75 3.2 0.4 1.4 0.1 1.9 0.3
1.5 7.0 0.8 2.3 0.2 2.8 0.4
3 10.7 1.7 3.2 0.4 5.0 0.8
Micronucleus induction (Fold change)
Mitoxantrone     
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Conc. Sig. p -value Conc. Sig. p -value Conc. Sig. p -value
0.75 WT vs. B-/- ** 0.0059 0 WT vs. B-/- ** 0.0088 0.75 WT vs. B-/- ** 0.009
1.5 WT vs. B-/- ** 0.0056 0.75 WT vs. B-/- ** 0.0018 0.75 WT vs. A+/- * 0.0486
1.5 WT vs. A+/- * 0.0439 0.75 WT vs. A+/- ** 0.0039 1.5 WT vs. B-/- ** 0.0049
3 WT vs. B-/- *** 0.0004 1.5 WT vs. B-/- ** 0.0088 1.5 WT vs. A+/- ** 0.0098
3 WT vs. A+/- * 0.0211 1.5 WT vs. A+/- * 0.0223 3 WT vs. B-/- ** 0.0013
3 B-/- vs. A+/- * 0.0193 1.5 B-/- vs. A+/- * 0.0123 3 WT vs. A+/- * 0.0363
3 WT vs. B-/- ** 0.0022
3 WT vs. A+/- * 0.0259
3 B-/- vs. A+/- * 0.0390
0 vs. 0.75 WT *** <0.0001
0 vs. 1.5 WT *** <0.0001
0 vs. 3 WT *** <0.0001
0 vs. 1.5 B-/- *** 0.0003
0 vs. 3 B-/- *** 0.0002
0 vs. 0.75 A+/- ** 0.0042
0 vs. 1.5 A+/- *** 0.0002
0 vs. 3 A+/- *** <0.0001
Relative survival Average micronuclei (%)
Micronucleus induction               
(Fold change)
Mitoxantrone (nM)
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Figure 6.2  Micronucleus assay data showing cytotoxic and genotoxic effect of MTX in 
Nalm-6 cell lines. 
Nalm-6 WT, Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells were treated with 0 nM, 0.75 nM, 1.5 nM or 3 
nM MTX for 48 hours followed by micronucleus assay by FACS, (A) relative survival (%), (B) 
average micronuclei (%) and (C) micronuclei induced over untreated control cells (fold change).   
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6.3 mAMSA 
Effect of mAMSA on Nalm-6 cell line growth 
mAMSA is a TOP2 poison which stabilises both isoforms of TOP2 in human 
and mouse cell lines (Errington et al., 2004).  Nalm-6 cell lines were 
treated with increasing concentrations of mAMSA for 120 hours, and 
growth inhibition was detected by XTT assay.  The OD450nm values of the 
untreated control for each cell line was set as 100% and all values were 
normalised to the relevant control.  The results are plotted on figure 6.3A. 
The results show that, like MTX, Nalm-6TOP2B-/- cells are more tolerant to 
mAMSA than Nalm-6 WT or Nalm-6TOP2A+/- cells. The IC50 of Nalm-6 WT, 
Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells were approximately 45 nM, 33 nM 
and 125 nM, respectively (Figure 6.3A).  This suggests that TOP2B is 
important in the growth inhibitory effects of mAMSA and consistent with 
previous studies (Errington et al., 1999; Toyoda et al., 2008). 
Nalm-6 cells were treated with increasing concentrations of mAMSA for 48 
hours followed by cytotoxicity estimation.  Cytotoxicity estimation (by 
relative survival and RICC) was used to determine a suitable dose range 
for mAMSA in Nalm-6 cell lines for use in micronucleus assays.  The 
results for both relative survival and RICC show the cell line sensitivities to 
mAMSA are Nalm-6 WT> Nalm-6TOP2A+/- > Nalm-6TOP2B-/-.  The dose range 
between 0 nM and 50 nM mAMSA was carried forward in micronucleus 
assays for all three cell lines, and was extended to 100 nM mAMSA for 
Nalm-6TOP2B-/- cells.    
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Table 6.3  Summary of relative survival after mAMSA treatment. 
Determined by (A) XTT, (B) RICC, and (C) FACS in Nalm-6 WT, Nalm-6TOP2A+/- and Nalm-6TOP2B-/- 
cell lines after 48 hours of mAMSA treatment. 
mAMSA (nM) Mean SEM Mean SEM Mean SEM
0.0 100.0 0.0 100.0 0.0 100.0 0.0
10.0 86.9 2.3 97.3 1.1 90.3 3.8
20.0 75.8 4.5 96.0 2.4 73.7 2.5
30.0 64.0 8.5 88.5 4.7 55.0 1.4
40.0 54.6 10.5 89.3 1.7 40.1 2.2
50.0 45.1 11.3 84.8 1.1 27.5 2.7
60.0 34.5 10.3 80.2 2.0 19.6 2.5
70.0 29.6 10.5 74.6 4.8 12.9 1.6
80.0 - - 78.2 1.5 - -
100.0 11.9 4.8 62.0 3.6 7.1 1.8
150.0 - - 54.3 1.7 - -
175.0 - - 48.8 1.1 - -
200.0 - - 40.2 0.7 - -
Growth inhibition (XTT)
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
mAMSA (nM) Mean SEM Mean SEM Mean SEM
0.0 100.0 0.0 100.0 0.0 100.0 0.0
8.0 66.8 6.3 86.2 5.2 74.2 4.9
16.0 44.6 4.8 67.8 3.7 60.4 10.3
33.0 - - - - 43.0 6.0
50.0 13.4 3.9 46.3 1.4 21.8 2.2
64.0 - - 33.2 5.8 - -
100.0 - - 18.5 0.6 - -
RICC (%)
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
mAMSA (nM) Mean SEM Mean SEM Mean SEM
0.0 100.0 0.0 100.0 0.0 100.0 0.0
8.0 67.7 4.1 84.0 2.6 86.3 8.3
16.0 42.7 2.3 67.5 2.4 66.4 2.0
33.0 - - - - 37.8 0.6
50.0 10.3 1.2 36.5 2.2 21.8 1.3
64.0 - - 28.3 1.5 - -
100.0 - - 15.9 0.3 - -
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
Relative survival (%) (FACS)
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Figure 6.3  mAMSA-induced growth inhibition and cytotoxicity in Nalm-6 WT, Nalm-
6TOP2A+/- and Nalm-6TOP2B-/- cells. 
(A) Cells were treated with increasing concentrations of mAMSA for 120 hours and growth 
inhibition determined by XTT assay (where % is inhibition of growth in relation to untreated 
controls). Cells were treated with increasing concentrations of mAMSA for 48 hours followed by the 
estimation of (B) relative increase in cell count (RICC) and (C) relative survival by FACS.  The value 
of untreated cells was set as 100% and all values normalised to it.  Dose-response curves were 
plotted to obtain the IC50 of mAMSA in each cell line.  Error bars represent the mean ± SEM from 
at least 3 separate experiments. 
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Genotoxicity of mAMSA  
Cells were treated continuously with mAMSA for 48 hours prior to nucleic 
acid staining, lysis and FACS.  Data are presented as relative survival, 
average micronucleus levels (%) and micronuclei induction over untreated 
control (fold change).  Unpaired t-tests were used to determine the 
statistical significance in the average micronucleus levels between drug-
treated and untreated controls.  
Average micronucleus percentage in the Nalm-6 WT untreated control was 
1.8%.  Micronuclei increased significantly in a dose-related manner after 
treatment with mAMSA (Figure 6.4).  At 8 nM the average micronuclei and 
fold change were 5.0% (p=0.0005 versus untreated cells) and 3.3-fold, 
respectively.  This shows that mAMSA is genotoxic to Nalm-6 WT cells at 
the lowest dose tested. 
The background micronuclei level for untreated Nalm-6TOP2B-/- cells was 
2.6%.  Micronuclei were significantly induced after treatment with 8 nM 
(4.6%; p=0.0342) or 16 nM (5.8%; p=0.0273) mAMSA (Figure 6.4B). 
The fold change was above 2 at 16 nM, confirming that at this dose 
mAMSA was genotoxic in the Nalm-6TOP2B-/- cells (Figure 6.4C).  The levels 
of micronuclei increased with dose at 50 nM, 66 nM and 100 nM.  However, 
relative survival was reduced below 40% above 50 nM, and FACS 
micronuclei determinations need to be viewed with caution when the 
survival drops below 40% (please see appendix figure 2). 
Micronuclei levels in untreated Nalm-6TOP2A+/- cells were 2.4%.  Micronuclei 
were induced significantly after treatment with mAMSA.  At 8 nM and 16 
nM, micronuclei levels increased to 4.3% (p=0.0226) and 7.5% 
(p=0.0005), respectively (Figure 6.4B).  Fold change over the untreated 
control was 1.8-fold and 3.2-fold at 8 nM and 16 nM (Figure 6.4C).  
Therefore 16 nM mAMSA is genotoxic to Nalm-6TOP2A+/- cells at 16 nM and 
above.  The level of micronuclei increased further to 16.5-fold at 50 nM 
mAMSA. By 50 nM the relative survival had dropped below 40%.    
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When comparing micronuclei levels between cell lines, untreated Nalm-
6TOP2B-/- cells had higher levels of micronuclei than untreated Nalm-6 WT 
cells (p=0.0410) .   
However, after treatment with 16 nM or 50 nM mAMSA, micronucleus 
levels in Nalm-6TOP2B-/- cells were lower than the other two cell lines 
(Figure 6.4B). This observation was more apparent when measured in fold 
change; micronuclei levels in Nalm-6TOP2B-/- cells were significantly lower 
than in Nalm-6 WT at 8n M (1.7 vs. 3.3; p=0.0013 and 16 nM (2.1 vs. 4.9; 
p=0.0004).  The difference between Nalm-6 WT and Nalm-6TOP2A+/- cells 
was also significant (p<0.05). 
In conclusion, mAMSA significantly induced micronuclei in all three cell 
lines, but higher doses were needed to reach two-fold above the untreated 
control significance for both Nalm-6TOP2B-/- and Nalm-6TOP2A+/- cells.  This 
confirmed that the level of TOP2 is important for micronuclei formation, 
and that both isoforms are involved in the formation of micronuclei.  
 
 
  
131 
 
A 
 
B 
 
C 
 
D 
 
Table 6.4  Summary of micronucleus assay data after mAMSA treatment. 
(A) mean of relative survival, (B) average percentage of micronuclei, (C) micronucleus induction by 
fold change and (D) p-values by unpaired t-test in Nalm-6 cell lines after 48 hours of mAMSA 
treatment.    
% ±SEM % ±SEM % ±SEM
0 100.0 0.0 100.0 0.0 100.0 0.0
8 67.7 4.1 84.0 2.6 86.3 8.3
16 42.7 2.3 67.5 2.4 66.4 2.0
50 10.3 1.2 36.5 2.2 21.8 1.3
mAMSA (nM)
Relative survival
Nalm-6
TOP2A+/-
Nalm-6
TOP2B-/-Nalm-6 WT 
% ±SEM % ±SEM % ±SEM
0 1.9 0.2 2.6 0.2 2.4 0.2
8 5.0 0.6 4.6 1.0 4.3 0.6
16 9.1 0.8 5.8 1.5 7.5 0.7
50 17.4 1.6 10.8 2.3 16.5 0.7
mAMSA (nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Average micronuclei (%)
Fold ±SEM Fold ±SEM Fold ±SEM
8 3.3 0.3 1.7 0.3 1.8 0.3
16 4.9 0.3 2.1 0.3 3.2 0.5
50 8.3 2.1 4.0 0.6 7.0 0.6
Micronucleus induction (Fold change)
mAMSA (nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Conc. Sig. p -value Conc. Sig. p -value Conc. Sig. p -value
8 WT vs. B-/- * 0.0283 0 WT vs. B-/- * 0.0410 8 WT vs. B-/- * 0.001
16 WT vs. B-/- *** 0.0003 0 vs. 8 WT *** 0.0005 8 WT vs. A+/- * 0.0196
16 WT vs. A+/- *** 0.0003 0 vs. 16 WT *** <0.0001 16 WT vs. B-/- *** 0.0004
50 WT vs. B-/- *** 0.0002 0 vs. 8 B-/- * 0.0342 16 WT vs. A+/- ** 0.0088
50 WT vs. A+/- ** 0.0032 0 vs. 16 B-/- * 0.0273 50 B-/- vs. A+/- * 0.0145
50 B-/- vs. A+/- ** 0.0033 0 vs. 8 A+/- * 0.0226 8 vs 16 WT vs. B-/- * 0.0495
0 vs. 16 A+/- *** 0.0005
mAMSA (nM)
Relative survival Average micronuclei (%) Micronucleus induction               
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Figure 6.4  Micronucleus assay data showing the cytotoxic and genotoxic effect of 
mAMSA on Nalm-6 cell lines. 
Nalm-6 WT, Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells were treated with 0 nM, 8 nM, 16 nM and 50 nM 
mAMSA for 48 hours followed by micronucleus assay.   (A) relative survival (%), (B) average 
micronuclei (%) and (C) micronuclei induced over untreated control cells (fold change).   
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6.4 Anthracyclines 
Effect of anthracyclines (Dox) on Nalm-6 cell line growth 
Dox is an anthracycline derivative of Dau (Arcamone et al., 1969a; 
Arcamone et al., 1969b).  It has cardiotoxic side effects.  Knocking out 
TOP2B in cardiomyocytes’ prevents cardiotoxicity  (Capranico et al., 1992; 
Zhang et al., 2012; Vejpongsa and Yeh, 2014).  
Nalm-6 cell lines with reduced amounts of TOP2A (Nalm-6TOP2A+/-) or 
lacking TOP2B (Nalm-6TOP2B-/-) were treated with a range of Dox 
concentrations for 120 hours.  The growth inhibitory effect of Dox was 
determined by XTT assay.  The results show that both Nalm-6TOP2A+/- cells 
and Nalm-6TOP2B-/- cells tolerate higher doses of Dox than wild type cells, 
suggesting both TOP2A and TOP2B are targeted by Dox. The IC50 of Dox 
was 23.3 nM in Nalm-6TOP2A+/- cells and 13.5 nM in Nalm-6TOP2B-/- cells, 
compared to 9.4 nM in Nalm-6 WT cells ( 
Figure 6.5).  Nalm-6TOP2A+/- cells were significantly more resistant to Dox 
than Nalm-6TOP2B-/- cells (p=0.0220), suggesting the growth inhibitory 
effects of Dox may be largely due to targeting of TOP2A. 
Nalm-6 cell lines were treated with Dox for 48 hours followed by 
cytotoxicity estimation by RICC and relative survival.  A summary of this 
data is shown in table 6.5B and C.  The relative survival of Nalm-6TOP2A+/- 
cells in response to 6 nM Dox was slightly higher than Nalm-6TOP2B-/- 
(p=0.42) and Nalm-6 WT cells (p=0.0214).  However, by RICC, the 
cytotoxicity of Dox was similar in all three cell lines ( 
Figure 6.5C).   
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Table 6.5  Summary of relative survival after Dox treatment. 
Determined by (A) XTT, (B) RICC, and (C) FACS in Nalm-6 WT, Nalm-6TOP2A+/- and Nalm-6TOP2B-/- 
cell lines after 48 hours of Dox treatment
Dox (nM) Mean SEM Mean SEM Mean SEM
0.0 100.0 0.0 100.0 0.0 100.0 0.0
5.0 92.0 2.9 96.8 4.8 94.6 4.5
10.0 42.5 6.4 71.8 4.8 92.2 4.0
15.0 14.7 2.7 41.2 1.7 86.9 1.4
17.5 8.3 0.8 26.4 3.0 81.6 7.8
20.0 4.0 0.7 16.8 1.2 60.7 7.5
25.0 1.5 0.4 5.3 0.6 36.2 9.2
27.5 0.9 0.4 2.6 0.5 30.9 10.8
30.0 1.4 0.4 2.3 0.9 26.7 9.7
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
Growth inhibition (XTT)
Dox (nM) Mean SEM Mean SEM Mean SEM
0.0 100.0 0.0 100.0 0.0 100.0 0.0
3.0 86.3 7.6 89.2 7.1 89.5 11.5
6.0 56.5 6.4 65.8 3.0 67.2 9.8
9.5 37.5 4.3 47.5 4.8 43.9 1.0
12.0 - - 48.9 0.0 51.7 5.3
20.0 - - 16.1 6.3 - -
RICC (%)
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
Dox (nM) Mean SEM Mean SEM Mean SEM
0.0 100.0 0.0 100.0 0.0 100.0 0.0
3.0 92.3 3.9 98.0 6.4 100.0 10.9
6.0 61.6 2.8 76.2 4.7 87.8 12.0
9.5 35.0 6.1 53.1 1.6 58.8 7.2
12.0 - - 47.1 0.0 49.2 0.5
20.0 - - 21.1 0.6 - -
Relative survival (%) (FACS)
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
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Figure 6.5  Dox-induced growth inhibition and cytotoxicity in Nalm-6 WT, Nalm-6TOP2A+/- 
and Nalm-6TOP2B-/- cells. 
(A) Cells were treated with increasing concentrations of Dox for 120 hours and growth inhibition 
determined by XTT assay (where % is inhibition of growth in relation to untreated controls). (B & C) 
Cells were treated with increasing concentrations of Dox for 48 hours followed by the estimation of 
(B) relative increase in cell count (RICC) and (C) relative survival by FACS.  The value of untreated 
cells was set as 100% and all values normalised to it.  Dose-response curves were plotted to obtain 
the IC50 of Dox in each cell line.  Error bars represent the mean ± SEM of at least 3 separate 
experiments. 
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Genotoxicity of anthracyclines (Dox) on Nalm6 cell lines 
Cells were treated with 0 nM, 3 nM, 6 nM and 9.5 nM Dox for 48 hours.  
Genotoxicity data from flow cytometry analysis is shown as average 
micronucleus (%) and micronuclei induced over untreated control (fold 
change).  In untreated Nalm-6 WT cells the average micronucleus level 
was 1.3%.  This increased significantly after treatment with Dox.  At 3 nM, 
6 nM and 9.5 nM, micronucleus levels were 2.4% (p=0.01), 6.6% 
(p=0.0002) and 16% (p<0.0001), respectively (Figure 6.6B).  Dox 
induced micronuclei to two-fold over untreated control at 3 nM, (Figure 
6.6C).  Therefore, Dox is genotoxic to Nalm-6 WT cells.   
Average micronucleus levels in untreated Nalm-6TOP2B-/- cells was 1.9%.  
Micronucleus induction by Dox was dose-related.  The average 
percentages of micronuclei  were significantly higher than untreated 
control at 6 nM (4.5%; p=0.0018) and 9.5 nM (8.2%; p<0.0001).  
Micronuclei induction over control at 3 nM was 1.7.  This increased to 2.8 
fold at 6 nM, confirming that Dox is genotoxic to Nalm-6TOP2B-/- cells.  As 
TOP2B is absent in Nalm-6TOP2B-/- cells, this indicates that Dox can induce 
micronuclei in cells only expressing TOP2A.  
The micronuclei level in untreated Nalm-6TOP2A+/- cells was 1.7%.  Dox 
induced micronuclei in Nalm-6TOP2A+/- cells in a dose-dependent manner.  
This was significantly higher than untreated control (1.7%) from 6 nM 
(3.9%; p=0.0245) and 9.5 nM (5.9%; p=0.0105) (Figure 6.6B).  
According to the fold change data, Dox induced more than two-fold 
induction at 6 nM.    
When comparing micronuclei levels between each cell line, Nalm-6TOP2B-/- 
cells contained a higher level of micronuclei than Nalm-6 WT cells at 0 nM. 
However, after treatment with 6 nM or 9.5 nM Dox, Nalm-6 WT cells had 
higher levels of micronuclei than Nalm-6TOP2A+/- or Nalm-6TOP2B-/- cells 
(Figure 6.6C).  This observation is more apparent when presented as fold 
change.  At 6 nM and 9.5 nM the fold change of Nalm-6 WT was 5.1 and 
10.7, respectively.  This was significantly higher Nalm-6TOP2B-/- cells at 2.8-
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fold (p=0.031) and 4.5-fold (p=0.001), respectively.  Therefore, Dox is 
genotoxic to all three Nalm-6 cell lines tested, but is most genotoxic to 
Nalm-6 WT cells.  Although the levels of micronuclei in Nalm-6TOP2A+/- cells 
were slightly lower than in Nalm-6TOP2B-/- cells, this difference was not 
statistically significant. 
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Table 6.6  Summary of micronucleus assay data after Dox treatment. 
(A) Mean of relative survival, (B) average percentage of micronuclei, (C) micronucleus induction by 
fold change and (D) p-values by unpaired t-test in Nalm-6 cell lines after 48 hours of Dox 
treatment.    
% ±SEM % ±SEM % ±SEM
0 100.0 0.0 100.0 0.0 100.0 0.0
3 92.3 3.9 98.0 6.4 100.0 10.9
6 61.6 2.8 76.2 4.7 87.8 12.0
9.5 35.0 6.1 53.1 1.6 58.8 7.2
Doxorubicin 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Relative survival
% ±SEM % ±SEM % ±SEM
0 1.3 0.1 1.9 0.2 1.7 0.3
3 2.4 0.4 2.8 0.5 2.1 0.2
6 6.6 0.9 4.5 0.6 3.9 0.8
9.5 16.0 1.6 8.2 0.7 5.9 1.2
Doxorubicin 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Average micronuclei (%)
Fold ±SEM Fold ±SEM Fold ±SEM
3 2.0 0.4 1.7 0.3 1.2 0.1
6 5.1 0.6 2.8 0.4 2.2 0.0
9.5 10.7 1.2 4.5 0.5 3.3 0.1
Doxorubicin 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Micronucleus induction (Fold change)
Conc. Sig. p -value Conc. Sig. p -value Conc. Sig. p -value
6 WT vs. B-/- * 0.0241 9.5 WT vs. B-/- ** 0.0022 6 WT vs. B-/- * 0.031
6 WT vs. A+/- * 0.0214 9.5 B-/- vs. A+/- ** 0.0074 6 WT vs. A+/- ** 0.0098
9.5 WT vs. B-/- * 0.0104 0 vs. 3 WT ** 0.0100 9.5 WT vs. B-/- ** 0.001
0 vs. 6 WT *** 0.0002 9.5 WT vs. A+/- ** 0.0031
0 vs. 9.5 WT *** <0.0001
0 vs. 6 B-/- ** 0.0018
0 vs. 9.5 B-/- *** <0.0001
0 vs. 6 A+/- * 0.0245
0 vs. 9.5 A+/- * 0.0105
Doxorubicin (nM)
Relative survival Average micronuclei (%) Micronucleus induction               
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Figure 6.6  Micronucleus assay data showing cytotoxicity and genotoxicity of Dox in 
Nalm-6 cell lines. 
Nalm-6 WT, Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells were treated with 0 nM, 3 nM, 6 nM and 9.5 nM 
Dox for 48 hours followed by micronucleus assay by FACS (A) relative survival (%), (B) average 
micronuclei (%) and (C) micronuclei induced over untreated control cells (fold change).   
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Effect of anthracyclines (Epi) on Nalm-6 cell line growth 
Epi is a 4’-epi-isomer of Dox.  Nalm-6 cell lines were treated with 
increasing concentrations of Epi for 120 hours.  The growth inhibitory 
effect was determined by XTT assay.  Epi inhibited growth both in the 
absence of TOP2B (in Nalm-6TOP2B-/- cells) and in cells with reduced levels 
of TOP2A (Nalm-6TOP2A+/- cells).  The growth inhibitory effect of Epi in all 
three cell lines was similar, with an IC50 of 12 nM and 12.8 nM in Nalm-6 
WT and Nalm-6TOP2B-/-, and 16 nM in Nalm-6TOP2A+/- cells.  According to the 
IC50, Nalm-6
TOP2A+/- cells are slightly more tolerant to Epi than Nalm-6 WT 
(p=0.0156) (Figure 6.7A).   
Nalm-6 cell lines were treated with Epi for 48 hours followed by 
cytotoxicity estimation by RICC and relative survival.  The relative survival 
of Nalm-6TOP2A+/- cells in response to Epi was slightly higher than Nalm-
6TOP2B-/- and Nalm-6 WT cells.  The difference in relative survival between 
Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells was not significant.  The trends of 
relative survival and RICC are very similar.    
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Table 6.7  Summary of relative survival after Epi treatment. 
Determined by (A) XTT, (B) RICC, and (C) FACS in Nalm-6 WT, Nalm-6TOP2A+/- and Nalm-6TOP2B-/- 
cell lines after 48 hours of Epi treatment. 
Epi (nM) Mean SEM Mean SEM Mean SEM
0.0 100.0 0.0 100.0 0.0 100.0 0.0
5.0 95.9 4.6 87.5 4.1 102.1 4.6
10.0 77.8 3.0 63.5 4.8 94.2 5.5
15.0 26.7 2.3 31.3 2.9 55.1 4.9
17.5 13.8 1.0 17.3 2.0 39.8 6.3
20.0 9.5 0.4 12.5 1.9 24.4 2.8
25.0 5.3 0.7 4.5 0.6 14.2 1.8
30.0 3.0 0.2 2.0 0.4 7.4 1.1
50.0 2.7 0.4 0.5 0.3 1.6 0.4
Growth inhibition (XTT)
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
Epi (nM) Mean SEM Mean SEM Mean SEM
0.0 100.0 0.0 100.0 0.0 100.0 0.0
3.0 74.3 6.8 80.7 4.7 91.7 4.9
6.0 52.8 6.5 68.2 2.0 73.8 3.4
9.5 34.0 3.7 51.6 1.0 55.8 2.7
12.0 - - 29.7 3.9 54.7 2.7
13.0 20.3 0.9 - - - -
20.0 - - 5.9 0.0 - -
RICC (%)
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
Epi (nM) Mean SEM Mean SEM Mean SEM
0.0 100.0 0.0 100.0 0.0 100.0 0.0
3.0 82.2 4.4 96.3 5.6 102.5 8.7
6.0 58.5 3.6 76.7 13.5 84.2 11.7
9.5 31.8 5.9 57.4 3.6 65.5 14.1
12.0 - - 38.3 2.9 47.3 2.0
13.0 17.8 0.2 - - - -
20.0 - - 11.2 0.0 - -
Relative survival (%) (FACS)
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
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Figure 6.7  Epi-induced growth inhibition and cytotoxicity in Nalm-6 WT, Nalm-6TOP2A+/- 
and Nalm-6TOP2B-/- cells. 
(A) Cells were treated with increasing concentrations of Epi for 120 hours and growth inhibition 
determined by XTT assay (where % is inhibition of growth in relation to untreated controls). (B & C) 
Cells were treated with increasing concentrations of Epi for 48 hours followed by the estimation of 
(B) relative increase in cell count (RICC) and (C) relative survival by FACS.  The value of untreated 
cells was set as 100% and all values normalised to it.   
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Genotoxicity of anthracyclines (Epi) on Nalm6 cell lines 
Cells were treated with 0 nM, 3 nM, 6 nM or 9.5 nM Epi for 48 hours.  
Data from flow cytometry analysis is shown as relative survival, average 
micronucleus (%) and micronuclei induced over untreated (fold change).  
Before treatment with Epi, the average micronucleus level in Nalm-6 WT 
cells was 1.3%. This increased to 2.2% and 4.7% at 3 nM and 6 nM Epi, 
respectively.  These increases were significant compared to untreated 
control, with p-values of 0.0107 and 0.0002, respectively (Figure 6.8B).  
Epi induced micronuclei 1.8-fold or 4.0-fold over untreated cells at 3 nM or 
6 nM, with relative survival levels of 82% and 59% (Figure 6.8A) 
respectively.  Epi is genotoxic to Nalm-6 WT cells.  The fold change at 6 
nM is 3.9. 
Epi induced micronuclei in Nalm-6TOP2B-/- cells in a dose-dependent manner.  
At 6 nM the percentage micronuclei of Nalm-6TOP2B-/- was 4.1%, 
significantly higher than the untreated control (p=0.0027).  The relative 
survival was 77%.  Micronuclei were induced more than two-fold at 6 nM 
(Figure 6.8C).  Therefore, Epi is genotoxic to Nalm-6TOP2B-/- cells at 6 nM 
and above.  Epi induced micronuclei in Nalm-6TOP2A+/- cells in a dose-
dependent manner.  The micronucleus levels were significantly higher 
than background at 6 nM and 9.5 nM Epi, with p-values of 0.0151 and 
0.0041, respectively.  The relative survival at 6 nM and 9.5 nM was 
around 85% and 65%.  Micronuclei fold changes were 1.4 and 1.8 at 3 nM 
and 6 nM, respectively.  The dose required to induce greater than two-fold 
over control is higher than 6 nM.  At 9.5 nM the fold change was 4. 
Figure 6.8B shows that micronuclei levels in each Nalm-6 cell line were 
very similar at 3 nM Epi.  At 6 nM, the average micronucleus level was 
higher in Nalm-6 WT cells, but this was not statistically significant.  This is 
more apparent when comparing fold changes.  At 6 nM Epi, the fold 
change was significantly higher in Nalm-6 WT cells compared to Nalm-
6TOP2B-/- (p=0.0445) or Nalm-6TOP2A+/- (p=0.0108).  Overall, Nalm-6TOP2B-/- 
cells and Nalm-6TOP2A+/- cells had lower levels of micronuclei than Nalm-6 
WT after exposure to the same concentration of Epi, confirming that 
144 
 
micronuclei formation is reduced when there is less TOP2.  There are no 
significant differences between Nalm-6TOP2B-/- and Nalm-6TOP2A+/- cells.  
This suggests that Epi-induced micronucleus formation is mediated via 
both TOP2 isoforms.   
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Table 6.8  Summary of micronucleus assay results after Epi treatment. 
(A) Mean of relative survival, (B) average percentage of micronuclei, (C) micronucleus induction by 
fold change and (D) p-values by unpaired t-test in Nalm-6 cell lines after 48 hours of Epi treatment.    
% ±SEM % ±SEM % ±SEM
0 100.0 0.0 100.0 0.0 100.0 0.0
3 82.2 4.4 96.3 5.6 102.5 8.7
6 58.5 3.6 76.7 13.5 84.2 11.7
9.5 31.8 5.9 57.4 3.6 65.5 14.1
Epirubicin 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Relative survival
% ±SEM % ±SEM % ±SEM
0 1.3 0.1 1.9 0.2 1.7 0.3
3 2.2 0.3 2.3 0.2 2.4 0.3
6 4.7 0.6 4.1 0.5 3.2 0.3
9.5 15.4 4.6 7.0 0.4 7.1 1.3
Epirubicin 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Average micronuclei (%)
Fold ±SEM Fold ±SEM Fold ±SEM
3 1.8 0.2 1.4 0.2 1.4 0.2
6 3.9 0.4 2.5 0.4 1.8 0.2
9.5 10.2 3.0 3.9 0.4 4.0 0.3
Epirubicin 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Micronucleus induction (Fold change)
Conc. Sig. p -value Conc. Sig. p -value Conc. Sig. p -value
9.5 WT vs. B-/- ** 0.0073 0 WT vs. B-/- ** 0.0088 6 WT vs. B-/- * 0.045
9.5 WT vs. B-/- * 0.0495 6 WT vs. A+/- * 0.0108
0 vs. 3 WT * 0.0107 9.5 WT vs. B-/- * 0.015
0 vs. 6 WT *** 0.0002
0 vs. 9.5 WT ** 0.0022
0 vs. 6 B-/- ** 0.0027
0 vs. 9.5 B-/- *** <0.0001
0 vs. 6 A+/- * 0.0151
0 vs. 9.5 A+/- ** 0.0041
Epirubicin (nM)
Relative survival Average micronuclei (%) Micronucleus induction               
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Figure 6.8  Micronucleus assay data showing the cytotoxic and genotoxic effect of Epi in 
Nalm-6 cell lines. 
Nalm-6 WT, Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells were treated with 0 nM, 3 nM, 6 nM or 9.5 nM 
Epi for 48 hours followed by micronucleus assay by FACS.  (A) Relative survival (%), (B) average 
micronuclei (%) and (C) micronuclei induced over untreated control cells (fold change).   
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6.5 VM26 
Effect of VM26 on Nalm6 cell line growth 
VM26 is a TOP2 poison which targets both isoforms of TOP2. To study the role of each 
TOP2 isoform on the growth inhibitory effect of VM26, Nalm-6 cells were treated with 
increasing concentrations of VM26 for 120 hours.  Growth inhibition was detected by XTT 
assay.    The results are plotted on  
figure 6.9A.  A summary of the data is shown on table 6.9. The IC50 of 
VM26 is higher in Nalm-6TOP2A+/- (20 nM) and Nalm-6TOP2B-/- (18 nM) cells 
compared to Nalm-6 WT (10 nM) cells.  The IC50 difference between Nalm-
6TOP2A+/- and Nalm-6TOP2B-/- cells is not significant. 
Cytotoxicity estimation (relative survival and RICC) was used to determine 
an appropriate dose range of VM26 in Nalm-6 cell lines for use in 
micronuclei assays.  Nalm-6 cells were treated with VM26 for 48 hours 
followed by cytotoxicity estimation.  A summary of relative survival data 
determined by FACS and RICC are shown on table 6.9B and C.  Relative 
survival data shows that Nalm-6TOP2A+/- cells were more tolerant to VM26 
than Nalm-6 WT and Nalm-6TOP2B-/- cells.  At 4 nM the relative survival of 
Nalm-6TOP2A+/- (95.5%) was significantly higher Nalm-6 WT (55.1%; 
p=0.0002) and Nalm-6TOP2B-/- (61.7%; p=0.0072), respectively.  The RICC 
differences between Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells at 2 nM, 4 nM 
and 10 nM were not significant. 
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Table 6.9  Summary of relative survival after VM26 treatment. 
Determined by (A) XTT, (B) RICC, and (C) FACS in Nalm-6 WT, Nalm-6TOP2A+/- and Nalm-6TOP2B-/- 
cell lines after 48 hours of VM26 treatment. 
VM26 (nM) Mean SEM Mean SEM Mean SEM
0.0 100.0 0.0 100.0 0.0 100.0 0.0
10.0 49.2 3.8 72.1 2.9 76.8 6.3
15.0 33.9 2.5 57.1 2.9 64.4 4.3
20.0 20.1 0.6 44.1 2.4 54.0 12.3
25.0 12.0 0.3 29.6 0.6 38.9 4.8
30.0 7.8 0.1 22.3 1.1 25.8 3.8
50.0 2.2 0.2 7.3 0.5 9.0 2.1
70.0 1.0 0.2 4.0 0.2 3.7 0.4
100.0 0.8 0.2 3.2 0.5 2.4 0.3
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
Growth inhibition (XTT)
VM26 (nM) Mean SEM Mean SEM Mean SEM
0.0 100.0 0.0 100.0 0.0 100.0 0.0
2.0 74.1 7.1 101.8 15.7 84.1 8.6
4.0 46.0 3.3 67.5 2.7 75.5 12.8
10.0 20.0 1.1 43.8 4.3 36.8 0.8
12.0 - - 31.4 3.2 - -
16.0 - - - - 37.7 3.7
RICC (%)
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
VM26 (nM) Mean SEM Mean SEM Mean SEM
0.0 100.0 0.0 100.0 0.0 100.0 0.0
2.0 80.8 4.5 93.4 1.9 111.8 3.1
4.0 55.1 3.0 61.7 4.5 95.5 4.9
10.0 26.3 5.5 31.1 1.1 67.4 6.3
12.0 - - 25.0 0.9 - -
16.0 - - - - 38.2 3.1
Relative survival (%) (FACS)
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
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Figure 6.9  VM26-induced growth inhibition and cytotoxicity in Nalm-6 WT, Nalm-
6TOP2A+/- and Nalm-6TOP2B-/- cells.   
(A) Cells were treated with increasing concentrations of VM26 for 120 hours and growth inhibition 
determined by XTT assay (where % is inhibition of growth in relation to untreated controls). (B & C) 
Cells were treated with increasing concentrations of VM26 for 48 hours followed by the estimation 
of (B) relative increase in cell count (RICC) and (C) relative survival by FACS.  The value of 
untreated cells was set as 100% and all values normalised to it.  Dose-response curves were 
plotted to obtain the IC50 of VM26 in each cell line.  Error bars represent the mean ± SEM of at 
least 3 separate experiments. 
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Genotoxicity of VM26 in Nalm-6 cell lines 
Cells were treated with 0 nM, 2 nM, 4 nM and 10 nM VM26 for 48 hours.  
Data from flow cytometry analysis are presented as relative survival, 
average micronucleus (%) and micronuclei induced over untreated control 
(fold change).  VM26 induced micronuclei in Nalm-6 WT cells in a dose-
related manner.  It significantly induced micronuclei above untreated 
control (1.9%) at 2 nM (3.8%; p=0.0139) and 4 nM (6.7%; p=0.0007) 
with a relative survival of approximately 80% and 55%, respectively 
(Figure 6.10).  At 2 nM, VM26 induced micronuclei 2.5-fold over 
background.  Thus VM26 is genotoxic to Nalm-6 WT cells.   
In Nalm-6TOP2B-/- cells 2 nM VM26 induced a low level of micronuclei 
(3.3%).  The induction rose significantly above background (2.6%) at 4 
nM (4.9%; p=0.0488) with relative survival around 60%.  The induction 
was more significant at 10 nM (10.3%; p=0.0010), when the relative 
survival dropped to 30%.  In fold changes, cells treated with 2 nM or 4 nM, 
had 1.2-fold and 1.8-fold increase in micronuclei (Figure 6.10C), 
respectively.  Therefore, VM26 is genotoxic to Nalm-6TOP2B-/- cells, inducing 
micronuclei significantly above background at 4 nM or higher.  
VM26 induced micronuclei in Nalm-6TOP2A+/- cells in a dose-dependent 
manner.  At 2 nM, the average micronuclei level was 1.3%.  The induction 
became statistically significant from 4 nM (4.4%; p=0.0061), while 
relative survival remained high at 96%. Micronuclei were induced 2.9-fold 
over control at 10 nM VM26.  Therefore, VM26 is genotoxic to Nalm-
6TOP2A+/- cells. 
Levels of micronuclei induced by VM26 in each cell line were similar at 2 
nM and 4 nM.  However, at 10 nM VM26 Nalm-6TOP2A+/- cells had 
significantly lower levels of micronuclei than Nalm-6 WT (average 
percentage of micronuclei; p=0.0044).  VM26 formed similar levels of 
micronuclei in Nalm-6TOP2B-/- and Nalm-6TOP2A+/- cells.  Fold change levels 
of micronuclei were higher in Nalm-6 WT cells than in Nalm-6TOP2B-/- or 
Nalm-6TOP2A+/- cells at 4 nM (p=0.0026) or 10 nM (p=0.0464) (Figure 
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6.10C and Table 6.10D), respectively.  Reduced TOP2 levels in cells can 
increase tolerance to VM26 and reduce micronuclei formation compared to 
wild type cells. 
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Table 6.10  Summary of micronucleus assay results after VM26 treatment. 
(A) Mean of relative survival, (B) average percentage of micronuclei, (C) micronucleus induction by 
fold change and (D) p-values by unpaired t-test in Nalm-6 cell lines after 48 hours of VM26 
treatment.    
% ±SEM % ±SEM % ±SEM
0 100.0 0.0 100.0 0.0 100.0 0.0
2 80.8 4.5 93.4 1.9 111.8 3.1
4 55.1 3.0 61.7 4.5 95.5 4.9
10 26.3 5.5 31.1 1.1 67.4 6.3
Teniposide 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Relative survival
% ±SEM % ±SEM % ±SEM
0 1.9 0.2 2.6 0.2 2.4 0.2
2 3.8 0.6 3.3 0.2 3.8 0.7
4 6.7 1.1 4.9 1.3 4.4 0.4
10 12.6 0.5 10.3 1.5 6.8 0.6
Teniposide 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Average micronuclei (%)
Fold ±SEM Fold ±SEM Fold ±SEM
2 2.5 0.3 1.2 0.1 1.5 0.2
4 3.5 0.3 1.8 0.3 1.8 0.1
10 5.8 0.9 4.0 0.5 2.9 0.5
Teniposide 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Micronucleus induction (Fold change)
Conc. Sig. p -value Conc. Sig. p -value Conc. Sig. p -value
2 WT vs. A+/- ** 0.0036 10 WT vs. A+/- ** 0.0440 2 WT vs. B-/- * 0.016
2 B-/- vs. A+/- ** 0.0072 0 vs 2 WT * 0.0139 4 WT vs. B-/- ** 0.0026
4 WT vs. A+/- *** 0.0002 0 vs 4 WT *** 0.0007 4 WT vs. A+/- ** 0.0021
4 B-/- vs. A+/- ** 0.0072 0 vs 4 B-/- * 0.0488 10 WT vs. B-/- * 0.0486
10 WT vs. A+/- ** 0.0080 0 vs 10 B-/- ** 0.0010 10 WT vs. A+/- * 0.0464
10 B-/- vs. A+/- *** 0.0003 0 vs 4 A+/- ** 0.0061
0 vs 10 A+/- *** 0.0007
Relative survival Average micronuclei (%) Micronucleus induction               
Teniposide (nM)
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Figure 6.10  Micronucleus assay data showing the cytotoxicity and genotoxicity of VM26 
in Nalm-6 cell lines. 
Nalm-6 WT, Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells were treated with 0 nM, 2 nM, 4 nM and 10 nM 
VM26 for 48 hours followed by micronucleus assay.  The results of (A) relative survival (%), (B) 
average micronuclei (%) and (C) micronuclei induced over untreated control cells (fold change) 
were plotted on graphs.   
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6.6 VP16 
Effect of VP16 on Nalm6 cell line growth 
VP16 is a TOP2 poison (epipodophyllotoxin) which targets both isoforms of 
TOP2 stabilising both TOP2A- and TOP2B- DNA complexes in cells.  This is 
reported in human and murine cells (Willmore et al., 1998; Errington et 
al., 2004; Lee et al., 2016).  Studies suggest that TOP2A rather than 
TOP2B is important in VP16 cytotoxicity (Errington et al., 1999; Toyoda et 
al., 2008).  Nalm-6 cell lines were treated with a range of VP16 
concentrations for 120 hours, and growth inhibition was determined by 
XTT assay.  The data is shown in table 6.11A.  The results show sensitivity 
to VP16 was reduced with lower levels of TOP2A or TOP2B, suggesting 
that VP16 targets both isoforms of TOP2 (in support of previous studies).  
Tolerance to VP16 in Nalm-6 cell lines is ranked Nalm-6TOP2A+/- > Nalm-
6TOP2B-/- > Nalm-6 WT.  IC50 values were approximately 86 nM, 157 nM 
and 264 nM for Nalm-6 WT, Nalm-6TOP2B-/- and Nalm-6TOP2A+/-, respectively.  
This suggests TOP2A is particularly important in VP16-induced growth 
inhibition.  
Nalm-6 cells were treated with VP16 for 48 hours.  Cytotoxicity estimation 
by relative survival and RICC are displayed on Figure 6.11 B and C.  The 
mean and standard error of results are summarised and displayed in Table 
6.11B (RICC) and C (relative survival).  The relative survival results show 
that Nalm-6TOP2A+/- cells are more tolerant to VP16 than Nalm-6 WT and 
Nalm-6TOP2B-/- cells.  At 85 nM relative survival of Nalm-6TOP2A+/-, Nalm-
6TOP2B-/- and Nalm-6 WT were 71%, 44% (p=0.0025), and 37% 
(p=0.0056), respectively; the differences were significant.  The RICC 
results show that VP16 cytotoxicity in Nalm-6TOP2A+/- and Nalm-6TOP2B-/- 
cells is similar at dose range 0 nM – 40 nM, but Nalm-6TOP2A+/- cells 
became more tolerant at dose range 80 nM – 120 nM (Figure 6.11B).  At 
85 nM RICC of Nalm-6TOP2B-/- (41%) was significantly lower than Nalm-
6TOP2A+/- (58%; p=0.0413).   
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The data suggest TOP2A is important in VP16 cytotoxicity which is 
consistent with previous studies and XTT results (Errington et al., 1999; 
Onda et al., 2008).  
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Table 6.11  Summary of relative survival after VP16 treatment. 
Determined by (A) XTT, (B) RICC, and (C) FACS in Nalm-6 WT, Nalm-6TOP2A+/- and Nalm-6TOP2B-/- 
cell lines after 48 hours of VP16 treatment. 
VP16 (nM) Mean SEM Mean SEM Mean SEM
0.0 100.0 0.0 100.0 0.0 100.0 0.0
75.0 65.6 7.2 85.4 10.2 87.8 2.5
100.0 36.7 2.7 80.3 12.9 96.8 5.2
125.0 18.8 1.2 69.0 13.3 86.9 2.8
150.0 10.5 1.3 57.4 12.0 82.4 8.4
200.0 3.1 0.6 37.0 9.4 73.8 4.8
300.0 0.8 0.3 12.3 1.2 36.9 2.5
400.0 0.1 0.2 5.2 1.1 14.5 1.2
500.0 1.1 0.3 2.9 0.9 6.0 1.3
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
Growth inhibition (XTT)
VP16 (nM) Mean SEM Mean SEM Mean SEM
0.0 100.0 0.0 100.0 0.0 100.0 0.0
22.5 69.2 1.8 88.5 2.4 82.5 8.3
45.0 47.2 4.3 70.1 7.8 72.5 3.5
85.0 22.5 1.7 41.0 3.1 57.8 6.9
90.0 - - 40.0 2.8 - -
110.0 - - 39.1 0.0 67.6 2.5
RICC (%)
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
VP16 (nM) Mean SEM Mean SEM Mean SEM
0.0 100.0 0.0 100.0 0.0 100.0 0.0
22.5 82.9 4.9 83.8 7.0 103.7 3.5
45.0 57.4 2.6 66.2 3.5 83.3 3.2
85.0 36.5 4.7 43.9 3.3 70.5 4.2
90.0 - - 40.7 0.6 - -
110.0 - - 35.5 0.0 54.3 3.0
Relative survival (%) (FACS)
Nalm-6 WT Nalm-6TOP2B-/- Nalm-6TOP2A+/-
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Figure 6.11  VP16-induced growth inhibition and cytotoxicity in Nalm-6 WT, Nalm-
6TOP2A+/- and Nalm-6TOP2B-/- cells. 
(A) Cells were treated with increasing concentrations of VP16 for 120 hours and growth inhibition 
determined by XTT assay (where % is inhibition of growth in relation to untreated controls).  Cells 
were treated with increasing concentrations of VP16 for 48 hours followed by the estimation of (B) 
relative increase in cell count (RICC) and (C) relative survival by FACS.  The value of untreated 
cells was set as 100% and all values normalised to it.  Dose-response curves were plotted to obtain 
the IC50 of VP16 in each cell line.  Error bars represent the mean ± SEM of at least 3 separate 
experiments. 
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Genotoxicity of VP16 in Nalm6 cell lines 
Cells were treated with VP16 for 48 hours followed by the micronucleus 
assay.  The flow cytometric analysis results are presented as relative 
survival, average micronuclei (%) and micronuclei induction over 
untreated control (fold change).  
VP16 induced micronuclei in Nalm-6 WT cells significantly above 
background (1.9%) at 22.5 nM (3.4%; p=0.0285) and 45 nM (6.8%; 
p=0.0001).  The relative survival at these two doses remained above 50%.  
This observation was similar with in fold change. The induction was dose-
dependent.  22.5 nM induced micronuclei higher than two-fold above 
untreated cells (Figure 6.12C). 
VP16 induced micronuclei in Nalm-6TOP2B-/- cells.  The induction was VP16 
dose-dependent.  For average micronuclei, induction by VP16 was 
statistically significant compared to untreated control (2.6%) at 22.5 nM 
(5.1%; p=0.0159) and 45 nM (6.5%; p=0.0057).  At these doses, relative 
survival were 84% and 66%, respectively (Table 6.12).  At 22.5 nM, VP16 
increased micronuclei nearly two-fold (1.9) over control (Figure 6.12C).  
This was 2.4-fold and 3.3-fold at 45 nM and 85 nM, respectively.  VP16 is 
genotoxic to Nalm-6TOP2B-/- cells.   
VP16 increased micronucleus formation in Nalm-6TOP2A+/- cells.  The 
micronuclei levels in Nalm-6TOP2A+/- cells was induced significantly above 
background level (2.4%) at 45 nM (4.1%; p=0.0051) and 85 nM VP16 
(p=0.0012).  Relative survival was 83% and 70%, respectively (Figure 
6.12A and B).  45 nM VP16 induced micronuclei more than two-fold over 
control (Figure 6.12C), thus VP16 is genotoxic to Nalm-6TOP2A+/- cells.   
The average micronuclei induced by 85 nM VP16 in Nalm-6 WT cells were 
significantly higher than in Nalm-6TOP2A+/- cells (p=0.0115) (Figure 6.12B 
and Table 6.12D).  The difference in micronuclei levels between Nalm-6 
WT and Nalm-6TOP2A+/- cells was clearer when presented as fold change 
over untreated control.  The difference was significant at both 45 nM 
(p=0.0462) and 85 nM (p=0.0383) (Figure 6.12C and Table 6.12D).  VP16 
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induced slightly higher levels of micronuclei in Nalm-6TOP2B-/- than Nalm-
6TOP2A+/- cells.  However, according to unpaired t-test, the difference was 
not significant (Figure 6.12B and C).  Overall, reduced TOP2 levels can 
reduce micronucleus formation in response to VP16.     
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Table 6.12  Summary of micronucleus assay results after VP16 treatment. 
(A) Mean of relative survival, (B) average percentage of micronuclei, (C) micronucleus induction by 
fold change and (D) p-values by unpaired t-test in Nalm-6 cell lines after 48 hours of VP16 
treatment.    
% ±SEM % ±SEM % ±SEM
0 100.0 0.0 100.0 0.0 100.0 0.0
22.5 82.9 4.9 83.8 7.0 103.7 3.5
45 57.4 2.6 66.2 3.5 83.3 3.2
85 36.5 4.7 43.9 3.3 70.5 4.2
Etoposide 
(nM)
Relative survival
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
% ±SEM % ±SEM % ±SEM
0 1.9 0.2 2.6 0.2 2.4 0.2
22.5 3.4 0.6 5.1 1.0 4.1 0.9
45 6.8 0.8 6.5 1.2 5.0 0.6
85 11.5 1.1 8.5 0.8 6.2 0.6
Average micronuclei (%)
Etoposide 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Fold ±SEM Fold ±SEM Fold ±SEM
22.5 2.3 0.4 1.9 0.2 1.7 0.4
45 3.7 0.4 2.4 0.2 2.1 0.3
85 5.3 0.9 3.3 0.4 2.6 0.1
Etoposide 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Micronucleus induction (Fold change)
Conc. Sig. p -value Conc. Sig. p -value Conc. Sig. p -value
22.5 WT vs. A+/- * 0.0244 0 WT vs. B-/- * 0.0410 45 WT vs. A+/- * 0.0462
45 WT vs. A+/- *** 0.0006 85 WT vs. A+/- * 0.0115 85 WT vs. B-/- * 0.049
45 B-/- vs. A+/- * 0.0234 0 vs. 22.5 WT * 0.0285 85 WT vs. A+/- * 0.0383
85 WT vs. A+/- ** 0.0056 0 vs. 45 WT *** 0.0001
85 B-/- vs. A+/- ** 0.0025 0 vs. 85 WT *** <0.0001
0 vs. 22.5 B-/- * 0.0159
0 vs. 45 B-/- ** 0.0057
0 vs. 85 B-/- *** 0.0001
0 vs. 45 A+/- ** 0.0051
0 vs. 85 A+/- ** 0.0012
B-/- vs. A+/- 
(RICC)
* 0.0413
Etoposide (nM)
Relative survival Average micronuclei (%) Micronucleus induction               
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Figure 6.12  Micronucleus assay data showing the cytotoxicity and genotoxicity of VP16 
in Nalm-6 cell lines. 
Nalm-6 WT, Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells were treated with 0 nM, 22.5 nM, 45 nM or 85 
nM VP16 for 48 hours followed by micronucleus assay.  The results of (A) relative survival (%), (B) 
average micronuclei (%) and (C) micronuclei induced over untreated control cells (fold change) 
were plotted on graphs.   
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6.7 Conclusion and discussion 
The aim of this chapter was to determine the role of both TOP2 isoforms 
in growth inhibition, cytotoxicity and genotoxicity.  
The results of growth inhibition (XTT) and cytotoxicity studies (RICC and 
relative survival by FACS) show that all of the TOP2 poisons tested target 
both isoforms of TOP2.  With 48 hours of continuous exposure, drug 
cytotoxicity was lower in Nalm-6TOP2B-/- and Nalm-6TOP2A+/- cells than in 
Nalm-6 WT cells.  The pattern of growth inhibition and cytotoxicity varied 
according to the TOP2 poison tested.  Two main patterns emerged. The 
first pattern, where the Nalm-6TOP2B-/- was most resistant (MTX and 
mAMSA) and the second pattern, where the Nalm-6TOP2A+/- was most 
resistant (Epi, Dox, VP16 and VM26).  The pattern of Nalm-6 cell line 
resistance towards MTX and mAMSA were similar (Nalm-6TOP2B-/- > Nalm-
6TOP2A+/-> Nalm-6 WT).  The results were consistent between XTT, RICC 
and relative survival.  The patterns of Dox and Epi were similar to each 
other.  Growth inhibition assay results show Nalm-6TOP2A+/- cells were most 
resistant to Dox and Epi.  The cytotoxicity assay (RICC and relative 
survival) showed that both Nalm-6TOP2A+/- and Nalm-6TOP2B-/- cells were 
more resistant than wild type cells, but there was no significant difference 
between Nalm-6TOP2A+/-and Nalm-6TOP2B-/-.  The XTT and relative survival 
results showed that the Nalm-6TOP2A+/- cells were most resistant to VP16 
and VM26.  This confirms that growth inhibition and cytotoxicity of TOP2 
poisons are dependent on TOP2.  This is consistent with previous studies 
(Errington et al., 1999; Toyoda et al., 2008).  
Six TOP2 poisons were tested with the XTT, RICC, relative survival and in 
vitro micronucleus assay in three Nalm-6 cell lines.  For 48 hours of 
continuous exposure, all the agents tested had generated micronuclei 
above background levels.  The induction of micronuclei was TOP2 poison 
dose-dependent.  This finding confirms that TOP2 poisons are genotoxic. 
Three different Nalm-6 cell lines were treated with the same dose of TOP2 
poison to determine the levels of micronuclei.  The Nalm-6TOP2B-/- and 
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Nalm-6TOP2A+/- cells had lower levels of micronuclei than Nalm-6 WT cells, 
presumably because they have less target protein.    
The patterns of micronucleus induction varied between different TOP2 
poisons.  Micronucleus induction data is presented in two ways.  The 
percentage of cells with micronuclei (average micronuclei %) and fold 
increase over control levels.   
For the six drugs analysed in the three cell lines the wild type cells in all 
cases displayed significantly more micronuclei than either Nalm-6TOP2A+/- 
or Nalm-6TOP2B-/-, when measured by fold change.  There were no 
significant differences between Nalm-6TOP2B-/- and Nalm-6TOP2A+/-, except 
with MTX when measured by percentage of micronuclei.   
 
 
164 
 
A 
 
B 
 
Table 6.13  Summary tables of micronucleus assay data (A) MTX and (B) mAMSA. 
  
nM % SEM % SEM Fold SEM % SEM % SEM Fold SEM % SEM % SEM Fold SEM
0.0 100.0 0.0 1.3 0.1 1.0 0.0 100.0 0.0 1.9 0.2 1.0 0.0 100.0 0.0 1.7 0.3 1.0 0.0
0.8 68.7 2.6 3.8 0.2 3.2 0.4 98.6 6.9 2.2 0.1 1.4 0.1 90.5 15.4 3.3 0.1 1.9 0.3
1.5 39.3 4.7 8.3 0.9 7.0 0.8 84.1 9.5 3.8 0.2 2.3 0.2 63.6 8.6 4.8 0.1 2.8 0.4
3.0 16.2 4.2 16.0 2.5 10.7 1.7 55.0 3.4 5.9 0.6 3.2 0.4 37.8 4.1 8.4 0.4 5.0 0.8
4.5 8.4 2.8 11.1 1.7 7.5 1.0 - - - - - - - - - - - -
6.0 - - - - - - 29.7 0.7 9.8 0.9 4.5 0.6 14.3 0.6 17.2 1.1 13.0 0.8
12.0 - - - - - - 19.5 0.0 12.0 0.0 5.0 0.0 - - - - - -
MTX
Nalm-6 WT Nalm-6TO P2B-/- Nalm-6TO P2A +/-
Average 
micronuclei
Micronucleus 
induction 
Average 
micronuclei
Micronucleus 
induction 
Relative survival Relative survival Relative survival
Average 
micronuclei
Micronucleus 
induction 
nM % SEM % SEM Fold SEM % SEM % SEM Fold SEM % SEM % SEM Fold SEM
0.0 100.0 0.0 1.9 0.2 1.0 0.0 100.0 0.0 2.6 0.2 1.0 0.0 100.0 0.0 2.4 0.2 1.0 0.0
8.0 67.7 4.1 5.0 0.6 3.3 0.3 84.0 2.6 4.6 1.0 1.7 0.3 86.3 8.3 4.3 0.6 1.8 0.3
16.0 42.7 2.3 9.1 0.8 4.9 0.3 67.5 2.4 5.8 1.5 2.1 0.3 66.4 2.0 7.5 0.7 3.2 0.5
33.0 - - - - - - - - - - - - 37.8 0.6 12.1 0.2 5.1 0.1
50.0 10.3 1.2 17.4 1.6 8.3 2.1 36.5 2.2 10.8 2.3 4.0 0.6 21.8 1.3 16.5 0.7 7.0 0.6
64.0 - - - - - - 28.3 1.5 13.3 1.2 5.6 0.6 - - - - - -
100.0 - - - - - - 15.9 0.3 19.6 0.3 8.1 0.4 - - - - - -
mAMSA
Relative survival
Average 
micronuclei
Micronucleus 
induction 
Relative survival
Average 
micronuclei
Micronucleus 
induction 
Relative survival
Average 
micronuclei
Micronucleus 
induction 
Nalm-6 WT Nalm-6TO P2B-/- Nalm-6TO P2A +/-
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A 
 
B 
 
Table 6.14  Summary tables of micronucleus assay data (A) Dox and (B) Epi. 
 
 
 
Relative survival
nM % SEM % SEM Fold SEM % SEM % SEM Fold SEM % SEM % SEM Fold SEM
0.0 100.0 0.0 1.3 0.1 1.0 0.0 100.0 0.0 1.9 0.2 1.0 0.0 100.0 0.0 1.7 0.3 1.0 0.0
3.0 92.3 3.9 2.4 0.4 2.0 0.4 98.0 6.4 2.8 0.5 1.7 0.3 100.0 10.9 2.1 0.2 1.2 0.1
6.0 61.6 2.8 6.6 0.9 5.1 0.6 76.2 4.7 4.5 0.6 2.8 0.4 87.8 12.0 3.9 0.8 2.2 0.0
9.5 35.0 6.1 16.0 1.6 10.7 1.2 53.1 1.6 8.2 0.7 4.5 0.5 58.8 7.2 5.9 1.2 3.3 0.1
12.0 - - - - - - 47.1 0.0 10.6 0.0 4.4 0.0 49.2 0.5 9.1 0.3 6.8 0.2
20.0 - - - - - - 21.1 0.6 19.8 0.2 9.1 0.4 - - - - - -
Dox
Micronucleus 
induction 
Micronucleus 
induction Relative survival
Average 
micronuclei
Average 
micronuclei
Micronucleus 
induction 
Relative survival
Average 
micronuclei
Nalm-6 WT Nalm-6TO P2B-/- Nalm-6TO P2A +/-
nM % SEM % SEM Fold SEM % SEM % SEM Fold SEM % SEM % SEM Fold SEM
0.0 100.0 0.0 1.3 0.1 1.0 0.0 100.0 0.0 1.9 0.2 1.0 0.0 100.0 0.0 1.7 0.3 1.0 0.0
3.0 82.2 4.4 2.2 0.3 1.8 0.2 96.3 5.6 2.3 0.2 1.4 0.2 102.5 8.7 2.4 0.3 1.4 0.2
6.0 58.5 3.6 4.7 0.6 3.9 0.4 76.7 13.5 4.1 0.5 2.5 0.4 84.2 11.7 3.2 0.3 1.8 0.2
9.5 31.8 5.9 15.4 4.6 10.2 3.0 57.4 3.6 7.0 0.4 3.9 0.4 65.5 14.1 7.1 1.3 4.0 0.3
12.0 - - - - - - 38.3 2.9 12.5 0.1 5.7 0.2 47.3 2.0 8.4 0.6 6.3 0.5
13.0 17.8 0.2 24.8 4.8 16.7 2.9 - - - - - - - - - - - -
20.0 - - - - - - 11.2 0.0 27.5 0.0 11.5 0.0 - - - - - -
Epi
Relative survival
Average 
micronuclei
Micronucleus 
induction 
Relative survival
Average 
micronuclei
Micronucleus 
induction 
Relative survival
Average 
micronuclei
Micronucleus 
induction 
Nalm-6 WT Nalm-6TO P2B-/- Nalm-6TO P2A +/-
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A 
 
B 
 
Table 6.15  Summary tables of micronucleus assay data (A) VM26 and (B) VP16.   
nM % SEM % SEM Fold SEM % SEM % SEM Fold SEM % SEM % SEM Fold SEM
0.0 100.0 0.0 1.9 0.2 1.0 0.0 100.0 0.0 2.6 0.2 1.0 0.0 100.0 0.0 2.4 0.2 1.0 0.0
2.0 80.8 4.5 3.8 0.6 2.5 0.3 93.4 1.9 3.3 0.2 1.2 0.1 111.8 3.1 3.8 0.7 1.5 0.2
4.0 55.1 3.0 6.7 1.1 3.5 0.3 61.7 4.5 4.9 1.3 1.8 0.3 95.5 4.9 4.4 0.4 1.8 0.1
10.0 26.3 5.5 12.6 0.5 5.8 0.9 31.1 1.1 10.3 1.5 4.0 0.5 67.4 6.3 6.8 0.6 2.9 0.5
12.0 - - - - - - 25.0 0.9 11.9 0.8 4.9 0.4 - - - - - -
16.0 - - - - - - - - - - - - 38.2 3.1 10.5 0.7 4.4 0.3
VM26
Relative survival
Average 
micronuclei
Micronucleus 
induction 
Relative survival
Average 
micronuclei
Micronucleus 
induction 
Relative survival
Average 
micronuclei
Micronucleus 
induction 
Nalm-6 WT Nalm-6TO P2B-/- Nalm-6TO P2A +/-
nM % SEM % SEM Fold SEM % SEM % SEM Fold SEM % SEM % SEM Fold SEM
0.0 100.0 0.0 1.9 0.2 1.0 0.0 100.0 0.0 2.6 0.2 1.0 0.0 100.0 0.0 2.4 0.2 1.0 0.0
22.5 82.9 4.9 3.4 0.6 2.3 0.4 83.8 7.0 5.1 1.0 1.9 0.2 103.7 3.5 4.1 0.9 1.7 0.4
45.0 57.4 2.6 6.8 0.8 3.7 0.4 66.2 3.5 6.5 1.2 2.4 0.2 83.3 3.2 5.0 0.6 2.1 0.3
85.0 36.5 4.7 11.5 1.1 5.3 0.9 43.9 3.3 8.5 0.8 3.3 0.4 70.5 4.2 6.2 0.6 2.6 0.1
90.0 - - - - - - 40.7 0.6 9.2 0.8 3.8 0.4 - - - - - -
110.0 - - - - - - 35.5 0.0 12.1 0.0 5.2 0.0 54.3 3.0 7.9 0.1 3.3 0.0
VP16
Relative survival
Average 
micronuclei
Micronucleus 
induction 
Relative survival
Average 
micronuclei
Micronucleus 
induction 
Relative survival
Average 
micronuclei
Micronucleus 
induction 
Nalm-6 WT Nalm-6TO P2B-/- Nalm-6TO P2A +/-
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Chapter 7. Conclusions and Overview 
 
Chapter 3 presents data demonstrating that proteasome inhibitors can 
potentiate the growth-inhibitory effects of TOP2 poisons in a K562 cell line.  
Two proteasome inhibitors were used: MG132, an investigational drug,  
and PS341-a clinically-important proteasome inhibitor (Trade names 
Velcade or Bortezomib)- which has Food and Drug Administration (FDA) 
approval for use in multiple myeloma and mantle cell lymphoma and 
which is being studied in other chemotherapy regimens (Sterz et al., 
2008).  These agents were used at a fixed concentration (that alone 
produced 20% cell growth inhibition) in combination with increasing 
concentrations of various TOP2 poisons.  The greatest potentiation for 
both agents was seen with mitoxantrone, with a Pf50 of 4.58 for MG132 
and PF50 2.95 for PS341.  PS341 significantly potentiated the growth 
inhibition of three TOP2 poisons in K562 cells: mitoxantrone, mAMSA and 
epirubicin, while MG132 potentiated all six TOP2 poisons.  Both MG132 
and PS341 target the same protease component within the proteasome, 
namely the β5 subunit (Lightcap et al., 2000; Kisselev and Goldberg, 
2001), so it is not entirely clear why the potentiation effects differ.  We 
found that a 120-hour exposure to PS341 increased the intracellular 
protein level of TOP2A, however, MG132 did not.  This drug-specific 
increase in TOP2A target level may contribute to the observed differences 
in potentiation.  Previous reports have suggested that PS341 increases the 
sensitivity of cells to anti-topoisomerase II drugs by increasing levels of 
TOP2 drug target in the cell (Ogiso et al., 2000; Congdon et al., 2008).  
It is possible the MG132 potentiation of anti-topoisomerase II drugs is 
mediated by multiple mechanisms.  Proteasome inhibition will cause the 
accumulation of ubiquitin conjugates and reduce free ubiquitin (Xu et al., 
2004).  Ubiquitination plays a key role in the cellular response to DNA 
damage. MG132 has been shown to inhibit focus formation involving DNA 
damage signalling proteins and DNA repair proteins, such as BRCA1, 
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53BP1 and Rad51, after exposure to IR and cisplatin (Jacquemont and 
Taniguchi, 2007).  Therefore, as well as reducing the processivity of the 
proteasome, MG132 and PS341 may potentiate the growth inhibitory 
effects of anti-topoisomerase II drugs by reducing the repair of double-
strand breaks once TOP2-DNA complexes have been processed.  
The levels of TOP2-DNA complexes in the presence and absence of MG132 
were measured using the TARDIS assay.  This experimental approach 
required higher levels of both the TOP2 drug and MG132.  Inhibition of the 
proteasome increased the levels of TOP2 complexes seen with etoposide 
but not with mAMSA, consistent with the idea that there are multiple 
possible mechanisms by which proteasomal inhibition affects TOP2 drug 
effects.   
Drug stabilised DNA-TOP2 complexes can be removed by a number of 
mechanisms (Figure 7.1).  For example, proteasomal proteases may 
degrade TOP2 protein bound to DNA, leaving a 5’ phosphotyrosyl-adduct 
on a DSB or a SSB, to be removed by TDP2 or FEN1, respectively 
(Salmena et al., 2001; Cortes Ledesma et al., 2009; Schellenberg et al., 
2012; Gao et al., 2014a; Kametani et al., 2016).  Moreover, a number of 
nucleases such as MRE11 and DNA2, or AP lyases such as KU70/80 and 
APE1 can remove stabilised TOP2 complexes to facilitate DSB repair 
(Ayene et al., 2005; Roberts et al., 2010; Lee, 2012; Lee et al., 2012; 
Tammaro et al., 2016).  Different mechanism(s) or a combination of 
mechanisms may be involved in the removal of TOP2 complexes stabilised 
by different TOP2 poisons. This may explain the differences observed with 
mAMSA and etoposide stabilised complexes in response to proteasomal 
inhibition with MG132. 
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Figure 7.1 Schematic summary of the different processes involved in the removal of 
TOP2 complexes.  The various stabilising compounds may affect different pathways.  
 
Clinically, targeting the ubiquitin proteasome system in combination with 
existing therapies may allow treatment intensification.  For example, a low 
dose of PS341 in combination with a TOP2 drug such as mitoxantrone may 
significantly increase the effectiveness without increasing toxicity.  
One type of toxicity investigated in this study is genotoxicity, for which a 
standard measure is to determine the percentage of micronuclei formed 
following exposure to drugs.  In Chapter 4, the effects of combinations of 
proteasome inhibitors and the TOP2 poison mitoxantrone on the 
generation of micronuclei were examined in vitro.  Two methods of 
assessment were used: a slide-based manual counting method and an 
automated method using FACS.  For the slide-based method, at least 
2000 cells were counted per drug condition, whereas for the FACS-based 
method around 30,000 cells were analysed.  However, the experimental 
protocol for the FACS-based method involves cell lysis of the cells which 
can lead to background problems if high levels of cell debris are present 
following exposure to high drug doses. The increased background signal 
can result in misleadingly high levels of micronuclei-sized particles.  These 
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experiments showed that low levels of a proteasome inhibitor can actually 
reduce the level of micronuclei without reducing cytotoxicity.  Further 
studies will be required to determine if these combinations also reduce 
other types of cellular toxicity.   
Type II DNA topoisomerases can be ubiquitinated via a series of 
enzymatic steps.  Ubiquitin is activated by an E1 activation enzyme, then 
transferred to an E2 ubiquitin-conjugating enzyme, and both the E2 and 
the target protein are then bound to an E3 ligase.  Cells possess more 
than 600 E3 ligases exhibiting different substrate specificities.  Two E3 
ligases-Bmi1/Ring1A and HDM2-have been reported to interact with 
TOP2A (Nayak et al., 2007; Kitagaki et al., 2008; Alchanati et al., 2009; 
Conradt et al., 2013).  Small molecule inhibitors for these two E3 ligases 
such as PRT4165 and HLI373 have been described in the literature and 
are commercially available.  Experiments in Chapter 5 showed that both of 
these compounds can potentiate the growth inhibition by some TOP2 
poisons.  Further work will be required to work out the mechanism(s) 
underlying the potentiation.  
Anthracycline therapy is in wide use in the clinic; however the dose that 
can be used is limited by toxicity such as cardiotoxicity.  A murine model 
system showed that TOP2B removal from cardiomyocytes reduced the 
cardiac damage induced by doxorubicin (Zhang et al., 2012).  This 
observation led to the suggestion that drugs targeting only TOP2A would 
be of clinical value in reducing cardiotoxicity. To investigate the effect of 
the two isoforms on genotoxicity, studies in Chapter 6 measured 
micronuclei in three Nalm-6 cells lines with differing levels of TOP2A and 
TOP2B (Nalm-6 WT, Nalm-6TOP2A+/-, and Nalm-6TOP2B-/-).  All six TOP2 
poisons examined were found to generate micronuclei in a dose-
dependent manner.  Further work will be required to investigate the 
contribution of TOP2 isoforms to genotoxicity and cardiotoxicity. 
In conclusion, studies described in this thesis have investigated the role of 
the proteasome in the processing of stabilised TOP2-DNA complexes.  
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Proteasomal inhibition potentiated the growth inhibition of TOP2 poisons.  
Potentiation is possibly mediated by prolonging the stabilisation of TOP2-
DNA complexes.  The association of proteasome and other DNA signalling 
protein and DNA repair proteins, such as BRCA1, 53BP1 and Rad51, may 
also contribute to the potentiation.  Co-inhibition of proteasome and TOP2 
has the potential to reduce the genotoxicity of TOP2 poisons during 
treatment.  Further work will be required to understand the mechanism of 
by which stabilised TOP2-DNA complexes are removed.  Thus, the work 
described here offers a potentially important approach to improving 
current cancer treatment.  
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Appendix table 1  Summary tables of appendix figure 1. 
(A) Relative survival, (B) average percentage of micronuclei and (C) Micronucleus induction (fold 
change)  
 
% ±SEM % ±SEM % ±SEM
0 100.0 0.0 100.0 0.0 100.0 0.0
0.75 68.7 2.6 98.6 6.9 90.5 15.4
1.5 39.3 4.7 84.1 9.5 63.6 8.6
3 16.2 4.2 55.0 3.4 37.8 4.1
4.5 8.4 2.8 - - - -
6 - - 29.7 0.7 14.3 0.6
12 - - 19.5 0.0 - -
Relative survival
Mitoxantrone     
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
% ±SEM % ±SEM % ±SEM
0 1.3 0.1 1.9 0.2 1.7 0.3
0.75 3.8 0.2 2.2 0.1 3.3 0.1
1.5 8.3 0.9 3.8 0.2 4.8 0.1
3 16.0 2.5 5.9 0.6 8.4 0.4
4.5 11.1 1.7 - - - -
6 - - 9.8 0.9 17.2 1.1
12 - - 12.0 0.0 - -
Average micronuclei (%)
Mitoxantrone     
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Fold ±SEM Fold ±SEM Fold ±SEM
0 1.0 0.0 1.0 0.0 1.0 0.0
0.75 3.2 0.4 1.4 0.1 1.9 0.3
1.5 7.0 0.8 2.3 0.2 2.8 0.4
3 10.7 1.7 3.2 0.4 5.0 0.8
4.5 7.5 1.0 - - - -
6 - - 4.5 0.6 13.0 0.8
12 - - 5.0 0.0 - -
Micronucleus induction (Fold change)
Mitoxantrone     
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
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Appendix table 2  Summary tables of appendix figure 2. 
(A) Relative survival, (B) average percentage of micronuclei and (C) Micronucleus induction (fold 
change) 
% ±SEM % ±SEM % ±SEM
0 100.0 0.0 100.0 0.0 100.0 0.0
8 67.7 4.1 84.0 2.6 86.3 8.3
16 42.7 2.3 67.5 2.4 66.4 2.0
33 - - - - 37.8 0.6
50 10.3 1.2 36.5 2.2 21.8 1.3
64 - - 28.3 1.5 - -
100 - - 15.9 0.3 - -
Relative survival
mAMSA (nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
% ±SEM % ±SEM % ±SEM
0 1.9 0.2 2.6 0.2 2.4 0.2
8 5.0 0.6 4.6 1.0 4.3 0.6
16 9.1 0.8 5.8 1.5 7.5 0.7
33 - - - - 12.1 0.2
50 17.4 1.6 10.8 2.3 16.5 0.7
64 - - 13.3 1.2 - -
100 - - 19.6 0.3 - -
Average micronuclei (%)
mAMSA (nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Fold ±SEM Fold ±SEM Fold ±SEM
0 1.0 0.0 1.0 0.0 1.0 0.0
8 3.3 0.3 1.7 0.3 1.8 0.3
16 4.9 0.3 2.1 0.3 3.2 0.5
33 - - - - 5.1 0.1
50 8.3 2.1 4.0 0.6 7.0 0.6
64 - - 5.6 0.6 - -
100 - - 8.1 0.4 - -
Micronucleus induction (Fold change)
mAMSA (nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
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Appendix table 3  Summary tables of appendix figure 3. 
(A) Relative survival, (B) average percentage of micronuclei and (C) Micronucleus induction (fold 
change) 
% ±SEM % ±SEM % ±SEM
0 100.0 0.0 100.0 0.0 100.0 0.0
3 92.3 3.9 98.0 6.4 100.0 10.9
6 61.6 2.8 76.2 4.7 87.8 12.0
9.5 35.0 6.1 53.1 1.6 58.8 7.2
12 - - 47.1 0.0 49.2 0.5
20 - - 21.1 0.6 - -
Relative survival
Doxorubicin 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
% ±SEM % ±SEM % ±SEM
0 1.3 0.1 1.9 0.2 1.7 0.3
3 2.4 0.4 2.8 0.5 2.1 0.2
6 6.6 0.9 4.5 0.6 3.9 0.8
9.5 16.0 1.6 8.2 0.7 5.9 1.2
12 - - 10.6 0.0 9.1 0.3
20 - - 19.8 0.2 - -
Average micronuclei (%)
Doxorubicin 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Fold ±SEM Fold ±SEM Fold ±SEM
0 1.0 0.0 1.0 0.0 1.0 0.0
3 2.0 0.4 1.7 0.3 1.2 0.1
6 5.1 0.6 2.8 0.4 2.2 0.0
9.5 10.7 1.2 4.5 0.5 3.3 0.1
12 - - 4.4 0.0 6.8 0.2
20 - - 9.1 0.4 - -
Micronucleus induction (Fold change)
Doxorubicin 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
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Appendix table 4  Summary tables of appendix figure 4. 
(A) Relative survival, (B) average percentage of micronuclei and (C) Micronucleus induction (fold 
change)  
% ±SEM % ±SEM % ±SEM
0 100.0 0.0 100.0 0.0 100.0 0.0
3 82.2 4.4 96.3 5.6 102.5 8.7
6 58.5 3.6 76.7 13.5 84.2 11.7
9.5 31.8 5.9 57.4 3.6 65.5 14.1
12 - - 38.3 2.9 47.3 2.0
13 17.8 0.2 - - - -
20 - - 11.2 0.0 - -
Relative survival
Epirubicin 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
% ±SEM % ±SEM % ±SEM
0 1.3 0.1 1.9 0.2 1.7 0.3
3 2.2 0.3 2.3 0.2 2.4 0.3
6 4.7 0.6 4.1 0.5 3.2 0.3
9.5 15.4 4.6 7.0 0.4 7.1 1.3
12 - - 12.5 0.1 8.4 0.6
13 24.8 4.8 - - - -
20 - - 27.5 0.0 - -
Average micronuclei (%)
Epirubicin 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Fold ±SEM Fold ±SEM Fold ±SEM
0 1.0 0.0 1.0 0.0 1.0 0.0
3 1.8 0.2 1.4 0.2 1.4 0.2
6 3.9 0.4 2.5 0.4 1.8 0.2
9.5 10.2 3.0 3.9 0.4 4.0 0.3
12 - - 5.7 0.2 6.3 0.5
13 16.7 2.9 - - - -
20 - - 11.5 0.0 - -
Micronucleus induction (Fold change)
Epirubicin 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
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Appendix table 5  Summary tables of appendix figure 5. 
(A) Relative survival, (B) average percentage of micronuclei and (C) Micronucleus induction (fold 
change)  
% ±SEM % ±SEM % ±SEM
0.0 100.0 0.0 100.0 0.0 100.0 0.0
2.0 80.8 4.5 93.4 1.9 111.8 3.1
4.0 55.1 3.0 61.7 4.5 95.5 4.9
10.0 26.3 5.5 31.1 1.1 67.4 6.3
12.0 - - 25.0 0.9 - -
16.0 - - - - 38.2 3.1
Relative survival
Teniposide 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
% ±SEM % ±SEM % ±SEM
0 1.9 0.2 2.6 0.2 2.4 0.2
2 3.8 0.6 3.3 0.2 3.8 0.7
4 6.7 1.1 4.9 1.3 4.4 0.4
10 12.6 0.5 10.3 1.5 6.8 0.6
12 - - 11.9 0.8 - -
16 - - - - 10.5 0.7
Average micronuclei (%)
Teniposide 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Fold ±SEM Fold ±SEM Fold ±SEM
0 1.0 0.0 1.0 0.0 1.0 0.0
2 2.5 0.3 1.2 0.1 1.5 0.2
4 3.5 0.3 1.8 0.3 1.8 0.1
10 5.8 0.9 4.0 0.5 2.9 0.5
12 - - 4.9 0.4 - -
16 - - - - 4.4 0.3
Micronucleus induction (Fold change)
Teniposide 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
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Appendix table 6  Summary tables of appendix figure 6. 
(A) Relative survival, (B) average percentage of micronuclei and (C) Micronucleus induction (fold 
change)  
% ±SEM % ±SEM % ±SEM
0 100.0 0.0 100.0 0.0 100.0 0.0
22.5 82.9 4.9 83.8 7.0 103.7 3.5
45 57.4 2.6 66.2 3.5 83.3 3.2
85 36.5 4.7 43.9 3.3 70.5 4.2
90 - - 40.7 0.6 - -
110 - - 35.5 0.0 54.3 3.0
Relative survival
Etoposide 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
% ±SEM % ±SEM % ±SEM
0 1.9 0.2 2.6 0.2 2.4 0.2
22.5 3.4 0.6 5.1 1.0 4.1 0.9
45 6.8 0.8 6.5 1.2 5.0 0.6
85 11.5 1.1 8.5 0.8 6.2 0.6
90 - - 9.2 0.8 - -
110 - - 12.1 0.0 7.9 0.1
Average micronuclei (%)
Etoposide 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
Fold ±SEM Fold ±SEM Fold ±SEM
0 1.0 0.0 1.0 0.0 1.0 0.0
22.5 2.3 0.4 1.9 0.2 1.7 0.4
45 3.7 0.4 2.4 0.2 2.1 0.3
85 5.3 0.9 3.3 0.4 2.6 0.1
90 - - 3.8 0.4 - -
110 - - 5.2 0.0 3.3 0.0
Micronucleus induction (Fold change)
Etoposide 
(nM)
Nalm-6 WT Nalm-6
TOP2B-/-
Nalm-6
TOP2A+/-
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